Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders

The invention relates to certain compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders that are, at least partially, mediated by TSPO activity.

The translocator protein (18 kDa) (TSPO), also known as peripherial-type benzodiazepine receptor, peripheral BZD receptor or mitochondrial benzodiazepine receptor, is a five transmembrane domain protein that is localized primarily in the outer mitochondrial membrane and expressed predominantly in steroid-synthesizing tissues, including the brain. TSPO is involved in the translocation of cholesterol from the outer to the inner mitochondrial membrane, which is the rate-limiting step in the synthesis of steroids and one of the most well-characterized functions of this protein.

Radiolabeled TSPO ligands are used as neuroimaging agents and are known as important diagnostic tools. TSPO also seems to be a sensitive biomarker of brain damage and neurodegeneration. The binding of labeled TSPO ligands can be visualized and quantified by in vivo imaging techniques such as positron emission tomography (PET) and single photon emission computed tomography (SPECT).

Altered TSPO expression has been shown in numerous neurological and psychiatric disorders.

Therefore, the modulation of the activity of this protein provides an option for treatment of diseases related to disturbed cholesterol metabolism and steroidogenesis, but also aptotosis and cell proliferation. Furthermore, its potential use for neuroprotection, limiting immunological disorders, inflammatory diseases including neuroinflammation and arthritis, encephalomyelitis, irritable bowel syndrome, promoting regeneration, and treating dysfunctions of the nervous system has been envisaged (Rupprecht et al., Nature Reviews, 2010, Vol. 9, 971). TSPO ligands also provide therapeutic potential in neuroregeneration, and anxiety, particularity for the treatment of neurodegenerative disorders such as Alzheimer's disease, head trauma, frontotemporal dementia, multiple sclerosis, Huntington ^' s disease, amyotrophic lateral sclerosis, Morbus Parkinson, cerebrovascular disorders, cerebral ischemia, stroke, tumours including brain tumours, and neurodegenerative diseases related to peripheral nervous system lesions and neuropathologies.

Various TSPO ligands have been shown to exert acute anxiolytic/anticonflict activity in rodents and humans. Therefore, the modulation of TSPO activity additionally offers treatment options for psychiatric disorders such as anxiety disoders including panic attacks, stress disorders including posttraumatic stress disorder, depression including major depressive disorders, dysthymia, angina pectoris (Rupprecht et al., Nature Reviews, 2010, Vol. 9, 971). It was therefore an object of the invention to provide compounds having advantages over the compounds known for TSPO activity. These compounds should be suitable in particular as pharmacological active ingredients in pharmaceutical compositions, preferably in pharmaceutical compositions for the treatment and/or prophylaxis of disorders and/or diseases which are, at least partially, mediated by TPSO activity.

That object is achieved by the subject-matter of the patent claims. It has been found, surprisingly, that compounds of the general formula (I) given below are suitable for the use in the treatment and/or prophylaxis of disorders and/or diseases which are, at least partially, mediated by TPSO activity.

Compounds according to general formula (I) are known and have been described for their activity on KCNQ2/3 ⁺ channels (WO 2010/102809 A1 ; WO 2010/102811 A1 ; WO 2012/025236 A1 ; WO

2012/025237 A1 ; WO 2012/025238 A1 ; WO 2012/025239 A1 ; WO 2012/0052167 A1).

No hint for modulation of TSPO activity and the treatment and/or prophylaxis of disorders and/or diseases, which are, at least partially, mediated by TPSO activity, however, is provided in the prior art.

The first aspect of the present invention therefore relates to a compound of general formula (I),

for the use in the treatment and/or prophylaxis of disorders and/or diseases which are mediated, at least in part, by TSPO (translocator protein 18 kDa), wherein

represents N(R ⁵ )-C(=0) or N(R ⁵ )-C(=S) or N=C(R ⁶ ) represents a d.io-aliphatic residue, unsubstituted or mono- or polysubstituted; a C3.10- cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; represents H; F; CI; Br; I; CN; CF ₃ ; C(=0)H; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C^-aliphatic residue, a C(=0)- C^ aliphatic residue, a C(=0)-0-C ₁ . ₄ aliphatic residue, a C(=0)-NH-C ₁ . ₄ aliphatic residue, a C(=0)-N(C _1-4 aliphatic residue) ₂ , wherein the C^ aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a 0-C _1-4 -aliphatic residue, a 0-C(=0)-C ₁ _ ₄ -aliphatic residue, a S-C - -aliphatic residue, a S(=0) ₂ -C ₁ . ₄ -aliphatic residue, a S(=0) ₂ -0-Ci^-aliphatic residue, wherein the C- aliphatic residue may in each case be unsubstituted or mono- or polysubstituted; a C^-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

R ³ represents H; F; CI; Br; I; CN; CF ₃ ; SCF ₃ ; N0 ₂ ; OCF ₃ ; a d. -aliphatic residue, a O-C^-aliphatic residue, a S-C _1-4 -aliphatic residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C3_ ₆ -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

R ⁴ represents H; F; CI; Br; I; CN; CF ₃ ; SCF ₃ ; N0 ₂ ; OCF ₃ ; a C^-aliphatic residue, a O-C^-aliphatic residue, a S-Ci. ₄ -aliphatic residue, wherein the Ci_4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a Cs-e-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

or represents N(R ⁷ )(R ⁸ ),

wherein

R ⁷ represents a C^o-aliphatic residue, unsubstituted or mono- or polysubstituted; a C^o- cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a Ci_ ₈ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

on the condition that if R ⁷ denotes a 3 to 10 membered heterocycloaliphatic residue or a heteroaryl, the 3 to 10 membered heterocycloaliphatic residue or the heteroaryl is linked via a carbon atom;

R ⁸ denotes H or a C^o-aliphatic residue, unsubstituted or mono- or polysubstituted;

or

R ⁷ and R ⁸ form together with the nitrogen atom connecting them a 3 to 10 membered

heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted; or R ³ and R ⁴ represent CH=CH-CH=CH,

wherein one or more H-Atoms independently of one another may be replaced by one a radical selected from the group consisting of F; CI; Br; I; CN; CF ₃ ; C(=0)H; C(=0)-OH; C(=0)-NH ₂ ; SCF ₃ S(=0) ₂ -OH; N0 ₂ ; OCF ₃ ; a C _1-4 -aliphatic residue, a C^C -C^ aliphatic residue, a C(=0)-0-C _1-4 aliphatic residue, a C(=0)-NH-C ₁ . ₄ aliphatic residue, a C(=0)-N(d. ₄ aliphatic residue) ₂ , wherein the C- aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a O- C^-aliphatic residue, a 0-C(=0)-C ₁ . ₄ -aliphatic residue, a S-C^-aliphatic residue, a S(=0) ₂ -C _1-4 - aliphatic residue, a S(=0) ₂ -0-C ₁ . ₄ -aliphatic residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a NH(C _1-4 aliphatic residue), a N(C _1-4 aliphatic residue) ₂ , a NH-C(=0)-C . ₄ aliphatic residue, a NH-S(=0) ₂ -C _lJ( -aliphatic residue, a N C^ aliphatic residue)-C(=0)-C ₁ . ₄ aliphatic residue, or a N(C _-4 aliphatic residue)-S(=0) ₂ -C - ₄ aliphatic residue, wherein the C- aliphatic residue may in each case be unsubstituted or mono- or polysubstituted; a C^e-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _! _ ₄ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

R ⁵ represents a C- o-aliphatic residue, unsubstituted or mono- or polysubstituted; a C3.10- cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a 0 _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

on the condition that if R ⁵ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,

R ⁶ represents a C ₂ . ₁₀ -aliphatic residue or a C ₂ . ₁₀ -heteroaliphatic residue, in each case unsubstituted or mono- or polysubstituted; a Cj. ₁₀ -cycloaliphatic residue or a 3 to 10 membered

heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a Ci. ₈ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

or

denotes S-R ¹¹ , O-R ¹² or N(R ⁹ R ¹⁰ ),

wherein

R ¹¹ and R ¹² in each case represent a C^o-aliphatic residue, unsubstituted or mono- or polysubstituted; a Cj o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C-|. ₈ aliphatic group or a C ₂ . ₈ -heteroaliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

on the condition that if R ¹¹ or R ¹² denotes a 3 to 10 membered

heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,

R ⁹ represents a C^o-aliphatic residue, unsubstituted or mono- or

polysubstituted; a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

on the condition that if R ⁹ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom; R ¹⁰ denotes a d. ₁₀ -aliphatic residue, unsubstituted or mono- or polysubstituted; or

R ⁹ and R ¹⁰ form together with the nitrogen atom connecting them a 3 to 10

membered heterocycloaliphatic residue, unsubstituted or mono- or

polysubstituted;

in the form of the free compounds, the racemate, the enantiomers, diastereomers, mixtures of the enantiomers or diastereomers in any mixing ratio, or of an individual enantiomer or diastereomer, or in the form of the salts of physiologically acceptable acids or bases.

The term "mono- or polysubstituted" with respect to an "aliphatic group" and an "aliphatic residue", "alkyl group", "alkyl residue", "heteroaliphatic group", "heteroalipahtic residue", "heteroalkyl group", "heteroalkyl residue", "heterocyloaliphatic group", "heterocycloalipahtic residue", "heterocycloalkyl group",

"heterocycloalkyl residue", "cycloalipahtic residue" and "cycloalkyl" within the scope of the present invention is the substitution of one or more hydrogen atoms, in each case independently of one another, by F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; =0; C _-8 -alkyl; C ₂ - ₈ -heteroalkyl; aryl; heteroaryl; Cuo-cycloalkyl;

heterocyclyl; C _1-8 -alkyl- or C ₂ . ₈ -heteroalkyl-bridged aryl, heteroaryl, C ₃ . ₁₀ -cycloalkyl or heterocyclyl; CHO; C(=0)C _1-8 -alkyl; C(=0)aryl; C(=0)heteroaryl; C0 ₂ H; C(=0)0-C ₁ . ₈ -alkyl; C(=0)0-aryl; C(=0)0-heteroaryl; CONH ₂ ; C(=0)NH-C _1-8 -alkyl; C(=0)N(C _1-8 -alkyl) ₂ ; C(=0)NH-aryl; C(=0)N(aryl) ₂ ; C(=0)NH-heteroaryl; C(=0)N(heteroaryl) ₂ ; C(=0)N(C ₁ . ₈ -alkyl)(aryl); C(=0)N(C _1-8 -alkyl)(heteroaryl); C(=0)N(heteroaryl)(aryl); OH; 0-C _1-8 -alkyl; OCF ₃ ; 0-(d. ₈ -alkyl)-OH; 0-(d. ₈ -alkyl)-0-d- ₈ -alkyl; O-benzyl; O-aryl; O-heteroaryl; O- C(=0)C ₁ . ₈ -alkyl; 0-C(=0)aryl; 0-C(=0)heteroaryl; NH ₂ ; NH-d_ ₈ -alkyl; N(d. ₈ -alkyl) ₂ ; NH-C(=0)C _1-8 -alkyl; N(C ₁ . ₈ -alkyl)-C(=0)C ₁ . ₈ -alkyl; N(C(=0)C _1-8 -alkyl) ₂ ; NH-C(=0)-aryl; NH-C(=0)-heteroaryl; NH-S(=0) ₂ -C ₁ . ₈ - alkyl; NH-S(=0) ₂ -aryl; NH-S(=0) ₂ -heteroaryl; SH; S-d. ₈ -alkyl; SCF ₃ ; S-benzyl; S-aryl; S-heteroaryl; S(=0) ₂ C _1-8 -alkyl; S(=0) ₂ aryl; S(=0) ₂ heteroaryl; S(=0) ₂ OH; S(=0) ₂ 0-C ₁ . ₈ -alkyl; S(=0) ₂ 0-aryl; S(=0) ₂ 0- heteroaryl; S(=0) ₂ -NH-C ₁ . ₈ -alkyl; S(=0) ₂ -NH-aryl; and S(=0) ₂ -NH-C ₁ . ₈ -heteroaryl.

The term "mono- or polysubstituted" with respect to "aryl" and a "heteroaryl" within the scope of the present invention is the substitution of one or more hydrogen atoms, in each case independently of one another, by F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; d. ₈ -alkyl; C ₂ . ₈ -heteroalkyl; aryl; heteroaryl; C^o-cycloalkyl;

heterocyclyl; d_ ₈ -alkyl- or C ₂ . ₈ -heteroalkyl-bridged aryl, heteroaryl, C ₃ . ₁₀ -cycloalkyl or heterocyclyl; CHO;

C(=0)C ₁ . ₈ -alkyl; C(=0)aryl; C(=0)heteroaryl; C0 ₂ H; C(=0)0-C ₁ _ ₈ -alkyl; C(=0)0-aryl; C(=0)0-heteroaryl;

CONH ₂ ; C(=0)NH-C _1-8 -alkyl; C(=0)N(C ₁ . ₈ -alkyl) ₂ ; C(=0)NH-aryl; C(=0)N(aryl) ₂ ; C(=0)NH-heteroaryl;

C(=0)N(heteroaryl) ₂ ; C(=0)N(C ₁ . ₈ -alkyl)(aryl); C(=0)N(C ₁ . ₈ -alkyl)(heteroaryl); C(=0)N(heteroaryl)(aryl); OH; 0-d_ ₈ -alkyl; OCF ₃ ; 0-(d. ₈ -alkyl)-OH; 0-(d-8-alkyl)-0-d. ₈ -alkyl; O-benzyl; O-aryl; O-heteroaryl; O-

C(=0)d. ₈ -alkyl; 0-C(=0)aryl; 0-C(=0)heteroaryl; NH _{2 ;} NH-d_ ₈ -alkyl; N(d. ₈ -alkyl) ₂ ; NH-C(=0)d. ₈ -alkyl;

N(d. ₈ -alkyl)-C(=0)C _1-8 -alkyl; N(C(=0)C _1-8 -alkyl) ₂ ; NH-C(=0)-aryl; NH-C(=0)-heteroaryl; SH; S-d. ₈ -alkyl;

SCF ₃ ; S-benzyl; S-aryl; S-heteroaryl; S(=0) ₂ C _1-8 -alkyl; S(=0) ₂ aryl; S(=0) ₂ heteroaryl; S(=0) ₂ OH; S(=0) ₂ 0-

C _1-8 -alkyl; S(=0) ₂ 0-aryl; S(=0) ₂ 0-heteroaryl; S(=0) ₂ -NH-d. ₈ -alkyl; S(=0) ₂ -NH-aryl; S(=0) ₂ -NH- C _1-8 -heteroaryl; $ ^' 0 , ?~0 , , Within the scope of this invention, the terms "alkyl" and "aliphatic residue" or "aliphatic group" or ' _{1- 0} - alkyl", "C^-alkyrVC^-alkyl", "C^-alkyl", "C^-alkyl" and "C ₂ -6-alkyl" include acyclic saturated or unsaturated aliphatic hydrocarbon radicals, which can be branched or unbranched as well as unsubstituted or mono- or poly-substituted, having from 1 to 10 or from 1 to 8 or from 1 to 6 or from 1 to 4 or from 1 to 2 or from 2 to 6 carbon atoms, that is to say Ci. ₁₀ -alkanyls, C ₂ . ₁₀ -alkenyls and C ₂ -io-alkynyls or Ci. ₈ -alkanyls, C ₂ -8-alkenyls and C ₂ . ₈ -alkynyls or Ci. ₆ -alkanyls, C ₂ . ₆ -alkenyls and C ₂ -6-alkynyls or C _-4 - alkanyls, C ₂ _4-alkenyls and C ₂ . ₄ -alkynyls or C^-alkanyls, C ₂ -alkenyls and C ₂ -alkynyls or C ₂ . ₆ -alkanyls, C ₂ . ₆ -alkenyls and C ₂ .6-alkynyls. Alkenyls contain at least one C-C double bond and alkynyls contain at least one C-C triple bond. Alkyl is preferably selected from the group comprising methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, n- nonyl, n-decyl, ethenyl (vinyl), ethynyl, propenyl (-CH ₂ CH=CH ₂ , -CH=CH-CH ₃ , -C(=CH ₂ )-CH ₃ ), propynyl (-CH-C≡CH, -C≡C-CH ₃ ), butenyl, butynyl, pentenyl, pentynyl, hexenyl and hexynyl, heptenyl, heptynyl, octenyl, octynyl, nonenyl, nonynyl, decenyl and decynyl. Within the scope of this invention, the terms "heteroalkyl" or "C ₂ . ₁₀ -heteroalkyl" and "C ₂ . ₈ -heteroalkyl" or "heteroaliphatic" or "C ₂ _i ₀ - heteroaliphatic" and "C ₂ _ ₈ - heteroaliphatic" include acyclic aliphatic saturated or unsaturated hydrocarbon radicals having from 2 to 10 carbon atoms, that is to say C ₂ . ₀ -heteroalkanyls, C ₂ . ₁₀ -heteroalkenyls and C ₂ . ₁₀ -heteroalkynyls, or having from 2 to 8 carbon atoms, that is to say C ₂ . ₈ - heteroalkanyls, C ₂ . ₈ -heteroalkenyls and C ₂ . ₈ -heteroalkynyls, which in each case can be branched or unbranched as well as unsubstituted or mono- or poly-substituted and in which at least one carbon atom, optionally also two or three carbon atoms, have been replaced by a heteroatom or heteroatom group in each case selected independently of one another from the group consisting of O, N, NH and N(d. ₈ -alkyl), preferably N(CH ₃ ), wherein the initial carbon atom of a C ₂ . ₁₀ -heteroalkyl or of a C ₂ _ ₈ -heteroalkyl, via which the C ₂ . ₁₀ -heteroalkyl or C ₂ . ₈ -heteroalkyl is bonded to the respective general structure of higher order, cannot be replaced by a heteroatom or heteroatom group and adjacent carbon atoms cannot simultaneously be replaced by a heteroatom or heteroatom group. The heteroatom groups NH and Ν(^_ 8-alkyl) of the heteroalkyl can optionally be mono- or poly-substituted. C ₂ . ₁₀ -Heteroalkenyls and C ₂ . ₈ - heteroalkenyls contain at least one C-C or C-N double bond and C ₂ . ₀ -heteroalkynyls and C ₂ _ ₈ - heteroalkynyls contain at least one C-C triple bond. Heteroalkyl is preferably selected from the group comprising -CH ₂ -0-CH ₃ , -CH ₂ -CH ₂ -0-CH ₃ , -CH ₂ -CH ₂ -0-CH ₂ -CH ₃ , -CH ₂ -CH ₂ -0-CH ₂ -CH ₂ -0-CH ₃ , -

CH=CH-0-CH ₃ , -CH=CH-0-CH ₂ -CH ₃ , =CH-0-CH ₃ , =CH-0-CH ₂ -CH ₃ , =CH-CH ₂ -0-CH ₂ -CH ₃ , =CH-CH ₂ -0- CH ₃ , -CH ₂ -NH-CH ₃ , -CH ₂ -CH ₂ -NH-CH ₃ , -CH ₂ -CH ₂ -NH-CH ₂ -CH ₃ , -CH ₂ -CH ₂ -NH-CH ₂ -CH ₂ -NH-CH ₃ , - CH=CH-NH-CH ₃ , -CH=CH-NH-CH ₂ -CH ₃ , -CH=CH-N(CH ₃ )-CH ₂ -CH ₃ , =CH-NH-CH ₃ , =CH-NH-CH ₂ -CH ₃ , =CH-CH ₂ -NH-CH ₂ -CH ₃ , =CH-CH ₂ -NH-CH ₃ , -CH ₂ -N(CH ₃ )-CH ₃ , -CH ₂ -CH ₂ -N(CH ₃ )-CH ₃ , -CH ₂ -CH ₂ -N(CH ₃ )- CH ₂ -CH ₃ , -CH ₂ -CH ₂ -N(CH ₃ )-CH ₂ -CH ₂ -N(CH ₃ )-CH ₃ , CH ₂ -CH ₂ -NH-CH ₂ -CH ₂ -0-CH ₃ , CH ₂ -CH ₂ -0-CH ₂ -CH ₂ - NH-CH ₃ , CH ₂ -CH ₂ -N(CH ₃ )-CH ₂ -CH ₂ -0-CH ₃ , CH ₂ -CH ₂ -0-CH ₂ -CH ₂ -N(CH ₃ )-CH ₃ , CH ₂ -NH-CH ₂ -0-CH ₃ , CH ₂ -0-CH ₂ -NH-CH ₃ , CH ₂ -N(CH ₃ )-CH ₂ -0-CH ₃ , CH ₂ -0-CH ₂ -N(CH ₃ )-CH ₃ , -CH=CH-N(CH ₃ )-CH ₃ , =CH- N(CH ₃ )-CH ₃ , =CH-N(CH ₃ )-CH ₂ -CH ₃ , =CH-CH ₂ -N(CH ₃ )-CH ₂ -CH ₃ , =CHCH ₂ -N(CH ₃ )-CH ₃ , -CH ₂ CH ₂ =N(CH ₃ ) and -CH ₂ =N(CH ₃ ).

For the purposes of this invention, the terms "cycloalkyl" or "C ₃ . ₁₀ -cycloalkyl", "C ₃ . ₇ -cycloalkyl" and "C^e- cycloalkyl'Or "cycloaliphatic" denote cyclic aliphatic hydrocarbons having 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms or having 3, 4, 5, 6 or 7 carbon atoms or having 3, 4, 5, 6, 7 or 8 carbon atoms, wherein the hydrocarbons can be saturated or unsaturated (but not aromatic), unsubstituted or mono- or poly- substituted. The bonding of the cycloalkyi to the general structure of higher order can take place via any desired and possible ring member of the cycloalkyi radical. The cycloalkyi radicals can also be fused with further saturated, (partially) unsaturated, (hetero)cyclic, aromatic or heteroaromatic ring systems, that is to say with cycloalkyi, heterocyclyl, aryl or heteroaryl, which can themselves be unsubstituted or mono- or poly-substituted. The cycloalkyi radicals can further be bridged one or more times, as, for example, in the case of adamantyl, bicyclo[2.2.1 ]heptyl or bicyclo[2.2.2]octyl. Cycloalkyi is preferably selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, adamantyl,

, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl.

The term "heterocyclyl" or "heterocycloalkyl" or "heterocycloaliphatic" includes aliphatic saturated or unsaturated (but not aromatic) cycloalkyls having from three to ten, that is to say 3, 4, 5, 6, 7, 8, 9 or 10, ring members, in which at least one carbon atom, optionally also two or three carbon atoms, has been replaced by a heteroatom or heteroatom group in each case selected independently of one another from the group consisting of O, S, N, NH and N(Ci_ ₈ -alkyl), preferably N(CH ₃ ), wherein the ring members can be unsubstituted or mono- or poly-substituted. The bonding of the heterocyclyl to the general structure of higher order can take place via any desired and possible ring member of the heterocyclyl radical. The heterocyclyl radicals can also be fused with further saturated, (partially) unsaturated (hetero)cyclic or aromatic or heteroaromatic ring systems, that is to say with cycloalkyi, heterocyclyl, aryl or heteroaryl, which can themselves be unsubstituted or mono- or poly-substituted. Heterocyclyl radicals are preferably selected from the group comprising azetidinyl, aziridinyl, azepanyl, azocanyl, diazepanyl, dithiolanyl, dihydroquinolinyl, dihydropyrrolyl, dioxanyl, dioxolanyl, dihydroindenyl, dihydropyridinyl, dihydrofuranyl, dihydroisoquinolinyl, dihydroindolinyl, dihydroisoindolyl, imidazolidinyl, isoxazolidinyl, morpholinyl, oxiranyl, oxetanyl, pyrrolidinyl, piperazinyl, piperidinyl, pyrazolidinyl, pyranyl, tetrahydropyrrolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, tetrahydroindolinyl, tetrahydrofuranyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrahydropyridoindolyl, tetrahydronaphthyl,

tetrahydrocarbolinyl, tetrahydroisoxazolopyridinyl, thiazolidinyl and thiomorpholinyl.

Within the scope of this invention, the term "aryl" denotes aromatic hydrocarbons having up to 14 ring members, inter alia phenyls and naphthyls. Each aryl radical can be unsubstituted or mono- or poly- substituted, it being possible for the aryl substituents to be identical or different and to be in any desired and possible position of the aryl. The aryl can be bonded to the general structure of higher order via any desired and possible ring member of the aryl radical. The aryl radicals can also be fused with further saturated, (partially) unsaturated, (hetero)cyclic, aromatic or heteroaromatic ring systems, that is to say with cycloalkyi, heterocyclyl, aryl or heteroaryl, which can themselves be unsubstituted or mono- or poly- substituted. Examples of fused aryl radicals are benzodioxolanyl and benzodioxanyl. Aryl is preferably selected from the group containing phenyl, 1-naphthyl and 2-naphthyl, each of which can be

unsubstituted or mono- or poly-substituted. A particularly preferred aryl is phenyl, unsubstituted or mono- or poly-substituted.

The term "heteroaryl" denotes a 5- or 6-membered cyclic aromatic radical which contains at least 1 heteroatom, optionally also 2, 3, 4 or 5 heteroatoms, wherein the heteroatoms are in each case selected independently of one another from the group S, N and O and the heteroaryl radical can be unsubstituted or mono- or poly-substituted; in the case of substitution on the heteroaryl, the substituents can be identical or different and can be in any desired and possible position of the heteroaryl. Bonding to the general structure of higher order can take place via any desired and possible ring member of the heteroaryl radical. The heteroaryl can also be part of a bi- or poly-cyclic system having up to 14 ring members, wherein the ring system can be formed with further saturated, (partially) unsaturated,

(hetero)cyclic or aromatic or heteroaromatic rings, that is to say with cycloalkyi, heterocyclyl, aryl or heteroaryl, which can themselves be unsubstituted or mono- or poly-substituted. It is preferred for the heteroaryl radical to be selected from the group comprising benzofuranyl, benzoimidazolyl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzotriazolyl, benzooxazolyl, benzooxadiazolyl, quinazolinyl, quinoxalinyl, carbazolyl, quinolinyl, dibenzofuranyl, dibenzothienyl, furyl (furanyl), imidazolyl,

imidazothiazolyl, indazolyl, indolizinyl, indolyl, isoquinolinyl, isoxazolyl, isothiazolyl, indolyl, naphthyridinyl, oxazolyl, oxadiazolyl, phenazinyl, phenolthiazinyl, phthalazinyl, pyrazolyl, pyridyl (2-pyridyl, 3-pyridyl, 4- pyridyl), pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, purinyl, phenazinyl, thienyl (thiophenyl), triazolyl, tetrazolyl, thiazolyl, thiadiazolyl and triazinyl. Furyl, pyridyl and thienyl are particularly preferred.

Within the scope of the invention, the expressions "C^-alkyl- or C^s-alkyl-bridged aryl, heteroaryl, heterocyclyl or cycloalkyi" mean that C _1-4 -alkyl or C _1-8 -alkyl and aryl or heteroaryl or heterocyclyl or cycloalkyi have the meanings defined above and the aryl or heteroaryl or heterocyclyl or cycloalkyi radical is bonded to the general structure of higher order via a C^-alkyl or C _1-a -alkyl group. The alkyl chain can in all cases be saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly- substituted. C _1-4 -Alkyl or C _1-8 -alkyl is preferably selected from the group

comprising -CH ₂ -, -CH ₂ CH ₂ -, -CH(CH ₃ )-, -CH ₂ CH ₂ CH ₂ -, -CH(CH ₃ )-CH ₂ -, -CH(CH ₂ CH ₃ )-, -CH ₂ -(CH ₂ ) ₂ -

CH ₂ -, -CH(CH ₃ )-CH ₂ -CH ₂ -, -CH ₂ -CH(CH ₃ )-CH ₂ - , -CH(CH ₃ )-CH(CH ₃ )-, -CH(CH ₂ CH ₃ )-CH ₂ -, -C(CH ₃ ) ₂ -CH ₂ - , -CH(CH ₂ CH ₂ CH ₃ )-, -C(CH ₃ )(CH ₂ CH ₃ )-, -CH ₂ -(CH ₂ ) ₃ -CH ₂ -, -CH(CH ₃ )-CH ₂ -CH ₂ -CH ₂ -, -CH ₂ -CH(CH ₃ )-CH ₂ - CH ₂ -, -CH(CH ₃ )-CH ₂ -CH(CH ₃ )-, -CH(CH ₃ )-CH(CH ₃ )-CH ₂ -, -C(CH ₃ ) ₂ -CH ₂ -CH ₂ -, -CH ₂ -C(CH ₃ ) ₂ -CH ₂ - , -CH(CH ₂ CH ₃ )-CH ₂ -CH ₂ -, -CH ₂ -CH(CH ₂ CH ₃ )-CH ₂ -, -C(CH ₃ ) ₂ -CH(CH ₃ )-, -CH(CH ₂ CH ₃ )-CH(CH ₃ )- , -C(CH ₃ )(CH ₂ CH ₃ )-CH ₂ -, -CH(CH ₂ CH ₂ CH ₃ )-CH ₂ -, -C(CH ₂ CH ₂ CH ₃ )-CH ₂ -, -CH(CH ₂ CH ₂ CH ₂ CH ₃ )-, - C(CH ₃ )(CH ₂ CH ₂ CH ₃ )-, -C(CH ₂ CH ₃ ) ₂ -, -CH ₂ -(CH ₂ ) ₄ -CH ₂ -, -CH=CH-, -CH=CH-CH ₂ -, -C(CH ₃ )=CH ₂ - , -CH=CH-CH ₂ -CH ₂ -, -CH ₂ -CH=CH-CH ₂ -, -CH=CH-CH=CH-, -C(CH ₃ )=CH-CH ₂ -, -CH=C(CH ₃ )-CH ₂ -, - C(CH ₃ )=C(CH ₃ )-, -C(CH ₂ CH ₃ )=CH-, -CH=CH-CH ₂ -CH ₂ -CH ₂ -, -CH ₂ -CH=CH ₂ -CH ₂ -CH ₂ -, -CH=CH=CH- CH ₂ -CH ₂ -, -CH=CH ₂ -CH-CH=CH ₂ -, -C≡C-, -C≡C-CH ₂ -, -C≡C-CH ₂ -CH ₂ - -C≡C-CH(CH ₃ )-, -CH ₂ -C≡C- CH ₂ -, -C≡C-C≡C-, -C≡C-C(CH ₃ ) ₂ -, -C≡C-CH ₂ -CH ₂ -CH ₂ -, -CH ₂ -C≡C-CH ₂ -CH ₂ -, -C≡C-C≡C-CH ₂ - and - C≡C-CH ₂ -C≡C-. Within the scope of the invention, the expressions "C ₂ -8-heteroalkyl-bridged aryl, heteroaryl, heterocyclyl or cycloalkyl" mean that C ₂ . ₈ -heteroalkyl and aryl or heteroaryl or heterocyclyl or cycloalkyl have the meanings defined above and the aryl or heteroaryl or heterocyclyl or cycloalkyl radical is bonded to the general structure of higher order via a C ₂ -8-heteroalkyl group. The heteroalkyl chain can in all cases be saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted. If a terminal carbon atom of the C ₂ -8-heteroalkyl group has been replaced by a heteroatom or heteroatom group, then the bonding of a heteroaryl or heterocyclyl to the heteroatom or heteroatom group of the C ₂ . ₈ - heteroalkyl always takes place via a carbon atom of the heteroaryl or heterocyclyl. The terminal carbon atom is understood as being the carbon atom within the C ₂ . ₈ -heteroalkyl that is furthest in the chain from the general structure of higher order. If the terminal carbon atom of a C ₂ . ₈ -heteroalkyl has been replaced, for example, by an N(CH ₃ ) group, that group is located within the C ₂ . ₈ -heteroalkyl furthest from the general structure of higher order and is bonded to the aryl or heteroaryl or heterocyclyl or cycloalkyl radical. C ₂ . ₈ -Heteroalkyl is preferably selected from the group comprising -CH ₂ -NH-, -CH ₂ -N(CH ₃ )-, -CH ₂ - 0-, -CH ₂ -CH ₂ -NH-, -CH ₂ -CH ₂ -N(CH ₃ )-, -CH ₂ -CH ₂ -0-, -CH ₂ -CH ₂ -CH ₂ -NH-, -CH ₂ -CH ₂ -CH ₂ -N(CH ₃ )-, -CH ₂ - CH ₂ -CH ₂ -0-, -CH ₂ -0-CH ₂ -, -CH ₂ -CH ₂ -0-CH ₂ -, -CH ₂ -CH ₂ -0-CH ₂ -CH ₂ -, -CH ₂ -CH ₂ -0-CH ₂ -CH ₂ -0-CH ₂ -, - CH=CH-0-CH ₂ - -CH=CH-0-CH ₂ -CH ₂ -, =CH-0-CH ₂ -, =CH-0-CH ₂ -CH ₂ -, =CH-CH ₂ -0-CH ₂ -CH ₂ -, =CH-CH ₂ -0-CH ₂ -, -CH ₂ -NH-CH ₂ -, -CH ₂ -CH ₂ -NH-CH ₂ -, -CH ₂ -CH ₂ -NH-CH ₂ -CH ₂ - -CH ₂ -CH ₂ -NH-CH ₂ -CH ₂ - NH-CH ₂ , -CH=CH-NH-CH ₂ -, -CH=CH-NH-CH ₂ -CH ₂ -, -CH=CH-N(CH ₃ )-CH ₂ -CH ₂ -, =CH-NH-CH ₂ -, =CH- NH-CH ₂ -CH ₂ -, =CH-CH ₂ -NH-CH ₂ -CH ₂ -, =CH-CH ₂ -NH-CH ₂ -, -CH ₂ -N(CH ₃ )-CH ₂ -, -CH ₂ -CH ₂ -N(CH ₃ )-CH ₂ - , -CH ₂ -CH ₂ -N(CH ₃ )-CH ₂ -CH ₂ -, -CH ₂ -CH ₂ -N(CH ₃ )-CH ₂ -CH ₂ -N(CH ₃ )-CH ₂ -, CH ₂ -CH ₂ -NH-CH ₂ -CH ₂ -0-CH ₂ -, CH ₂ -CH ₂ -0-CH ₂ -CH ₂ -NH-CH ₂ -, CH ₂ -CH ₂ -N(CH ₃ )-CH ₂ -CH ₂ -0-CH ₂ -, CH ₂ -CH ₂ -0-CH ₂ -CH ₂ -N(CH ₃ )-CH ₂ -, CH ₂ -NH-CH ₂ -0-CH ₂ -, CH ₂ -0-CH ₂ -NH-CH ₂ -, CH ₂ -N(CH ₃ )-CH ₂ -0-CH ₂ - CH ₂ -0-CH ₂ -N(CH ₃ )-CH ₂ -, - CH=CH-N(CH ₃ )-CH ₂ -, =CH-N(CH ₃ )-CH ₂ -, =CH-N(CH ₃ )-CH ₂ -CH ₂ -, =CH-CH ₂ -N(CH ₃ )-CH ₂ -CH ₂ - and =CH-CH ₂ -N(CH ₃ )-CH ₂ -.

In connection with "alkyl", "heteroalkyl", "heterocyclyl" and "cycloalkyl", the expression "mono- or poly- substituted" is understood as meaning within the scope of this invention the substitution of one or more hydrogen atoms one or more times, for example two, three or four times, in each case independently of one another, by substituents selected from the group comprising F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; =0; C^e-alkyl; C ₂ . ₈ -heteroalkyl; aryl; heteroaryl; Cs-io-cycloalkyl; heterocyclyl; d-e-alkyl- or C ₂ . ₈ -heteroalkyl-bridged aryl, heteroaryl, C^o-cycloalkyl or heterocyclyl; CHO; C(=0)C ₁ . ₈ -alkyl; C(=0)aryl; C(=0)heteroaryl; C0 ₂ H; C(=0)0-C _1-8 -alkyl; C(=0)0-aryl; C(=0)0-heteroaryl; CONH ₂ ; C(=0)NH-C _1-8 -alkyl; C(=0)N(C ₁ . ₈ -alkyl) ₂ ; C(=0)NH-aryl; C(=0)N(aryl) ₂ ; C(=0)NH-heteroaryl; C(=0)N(heteroaryl) ₂ ; C(=0)N(C ₁ . ₈ -alkyl)(aryl);

C(=0)N(C ₁ . ₈ -alkyl)(heteroaryl); C(=0)N(heteroaryl)(aryl); OH; O-d-e-alkyl; OCF ₃ ; 0-(d- ₈ -alkyl)-OH; O-iC _t -e-alky -O-C^e-alkyl; O-benzyl; O-aryl; O-heteroaryl; 0-C(=0)C,_ ₈ -alkyl; 0-C(=0)aryl; O-

C(=0)heteroaryl; NH _{2 ;} NH-d-a-alkyl; N(d-s-alkyl) ₂ ; NH-C(=0)d. ₈ -alkyl; N(C ₁ . ₈ -alkyl)-C(=0)C ₁ . ₈ -alkyl; N(C(=0)C _1-8 -alkyl) ₂ ; NH-C(=0)-aryl; NH-C(=0)-heteroaryl; SH; S-d. ₈ -alkyl; SCF ₃ ; S-benzyl; S-aryl; S-heteroaryl; S(=0) ₂ C ₁ . ₈ -alkyl; S(=0) ₂ aryl; S(=0) ₂ heteroaryl; S(=0) ₂ OH; S(=0) ₂ 0-C ₁ _ ₈ -alkyl; S(=0) ₂ 0- aryl; S(=0) ₂ 0-heteroaryl; S(=0) ₂ -NH-d_ ₈ -alkyl; S(=0) ₂ -NH-aryl; and S(=0) ₂ -NH-C ₁ . ₈ -heteroaryl; wherein polysubstituted radicals are to be understood as being radicals that are substituted several times, for example two, three or four times, either on different atoms or on the same atom, for example three times on the same carbon atom, as in the case of CF ₃ or CH ₂ CF ₃ , or at different places, as in the case of CH(OH)-CH=CH-CHCI ₂ . A substituent can itself optionally be mono- or poly-substituted. Polysubstitution can take place with the same or with different substituents.

Preferred "alkyl", "heteroalkyl", "heterocyclyl" and "cycloalkyl" substituents are selected from the group comprising F; CI; Br; I; N0 ₂ ; CH ₂ CF ₃ ; CF ₃ ; CN; d. ₈ -alkyl; C ₂ - ₈ -heteroalkyl; phenyl; naphthyl; pyridyl; thienyl; furyl; C^o-cycloalkyl; heterocyclyl; C _1-8 -alkyl- or C ₂ . ₈ -heteroalkyl-bridged phenyl, naphthyl, pyridyl, thienyl, furyl, C^o-cycloalkyl or heterocyclyl; CHO; C(=0)C ₁ . ₈ -alkyl; C0 ₂ H; C(=0)0-C ₁ _ ₈ -alkyl; CONH ₂ ; C(=0)NH-C ₁ . ₈ -alkyl; C(=0)N(C ₁ _ ₈ -alkyl) ₂ ; OH; =0; 0-d_ ₈ -alkyl; OCF ₃ ; 0-(d. ₈ -alkyl)-OH; 0-(d. ₈ -alkyl)-0- d. ₈ -alkyl; O-benzyl; O-phenyl; O-heteroaryl; 0-C(=0)C ₁ . ₈ -alkyl; NH _{2 ;} NH-C _1-8 -alkyl; N(d. ₈ -alkyl) ₂ ;

NH-C(=0)C ₁ . ₈ -alkyl; N(C ₁ _ ₈ -alkyl)-C(=0)C ₁ . ₈ -alkyl; SH; S-d_ ₈ -alkyl; SCF ₃ ; S-benzyl; S-phenyl; S-heteroaryl; S(=0) ₂ C ₁ . ₈ -alkyl; S(=0) ₂ OH; S(=0) ₂ 0-C ₁ . ₈ -alkyl; S(=0) ₂ -NH-C ₁ . ₈ -alkyl.

In connection with "aryl" and "heteroaryl", "mono- or poly-substituted" is understood within the scope of this invention as meaning the substitution of one or more hydrogen atoms of the ring system one or more times, for example two, three or four times, in each case independently of one another, by substituents selected from the group comprising F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; C ₁ . ₈ -alkyl; C ₂ - ₈ -heteroalkyl; aryl; heteroaryl; heterocyclyl; C _1-8 -alkyl- or C _2-8 -heteroalkyl-bridged aryl, heteroaryl, C ₃ . ₁₀ -cycloalkyl or heterocyclyl; CHO; C(=0)C _1-8 -alkyl; C(=0)aryl; C(=0)heteroaryl; C0 ₂ H; C(=0)0-C _1-8 -alkyl; C(=0)0-aryl;

C(=0)0-heteroaryl; CONH ₂ ; C(=0)NH-d. ₈ -alkyl; C(=0)N(C ₁ . ₈ -alkyl) ₂ ; C(=0)NH-aryl; C(=0)N(aryl) ₂ ; C(=0)NH-heteroaryl; C(=0)N(heteroaryl) ₂ ; C(=0)N(C ₁ _ ₈ -alkyl)(aryl); C(=0)N(C ₁ . ₈ -alkyl)(heteroaryl);

C(=0)N(heteroaryl)(aryl); OH; 0-d. ₈ -alkyl; OCF ₃ ; 0-(C _1-8 -alkyl)-OH; 0-(d. ₈ -alkyl)-0-d. ₈ -alkyl; O-benzyl;

O-aryl; O-heteroaryl; 0-C(=0)C _1-8 -alkyl; 0-C(=0)aryl; 0-C(=0)heteroaryl; NH _{2 ;} NH-d. ₈ -alkyl;

N(d. ₈ -alkyl) ₂ ; NH-C(=0)d_ ₈ -alkyl; N(d. ₈ -alkyl)-C(=0)d. ₈ -alkyl; N(C(=0)d. ₈ -alkyl) ₂ ; NH-C(=0)-aryl;

NH-C(=0)-heteroaryl; SH; S-d. ₈ -alkyl; SCF ₃ ; S-benzyl; S-aryl; S-heteroaryl; S(=0) ₂ C ₁ . ₈ -alkyl; S(=0) ₂ aryl; S(=0) ₂ heteroaryl; S(=0) ₂ OH; S(=0) ₂ 0-C ₁ . ₈ -alkyl; S(=0) ₂ 0-aryl; S(=0) ₂ 0-heteroaryl; S(=0) ₂ -NH- d_ ₈ -alkyl; S(=0) ₂ -NH-aryl; S(=0) ₂ -NH-C ₁ . ₈ -heteroaryl; on one atom or optionally on different atoms, wherein a substituent can itself optionally be mono- or poly-substituted. Polysubstitution is carried out with the same or with different substituents. Preferred "aryl" and "heteroaryl" substituents are F; CI; Br; I; N0 ₂ ; CH ₂ CF ₃ ; CF ₃ ; CN; C _1-8 -alkyl; C ₂ . ₈ - heteroalkyl; phenyl; naphthyl; pyridyl; thienyl; furyl; C ₃ . ₁₀ -cycloalkyl; heterocyclyl; C _1-8 -alkyl- or C ₂ . ₈ - heteroalkyl-bridged phenyl, naphthyl, pyridyl, thienyl, furyl, Cs-io-cycloalkyl or heterocyclyl; CHO; C(=0)C ₁ . ₈ -alkyl; C0 ₂ H; C(=0)0-d_ ₈ -alkyl; CONH ₂ ; C(=0)NH-d. ₈ -alkyl; C(=0)N(d. ₈ -alkyl) ₂ ; OH; 0-d. ₈ -alkyl; OCF ₃ ; 0-(d. ₈ -alkyl)-OH; 0-(d. ₈ -alkyl)-0-d. ₈ -alkyl; O-benzyl; O-phenyl; O-heteroaryl; 0-C(=0)C _1-8 -alkyl; NH _{2 ;} NH-C _1-8 -alkyl; N(d. ₈ -alkyl) ₂ ; NH-C(=0)d. ₈ -alkyl; N(d. ₈ -alkyl)-C(=0)d. ₈ -alkyl; N(C(=0)C _1-8 -alkyl) ₂ ; SH; S-Ci. ₈ -alkyl; SCF ₃ ; S-benzyl; S-phenyl; S-heteroaryl; S(=0) ₂ d. ₈ -alkyl; S(=0) ₂ 0H; S(=0) ₂ 0-d. ₈ -alkyl; S(=0) ₂ -NH-d. ₈ -alkyl.

The compounds according to the invention are defined by substituents, for example by R ¹ , R ² and R ³ (1st generation substituents), which are themselves optionally substituted (2nd generation substituents).

Depending on the definition, these substituents of the substituents can in turn themselves be substituted (3rd generation substituents). If, for example, R ¹ = aryl (1st generation substituent), aryl can itself be substituted, for example by C^-alkyl (2nd generation substituent). This yields the functional group aryl- C _1-8 -alkyl. C^-Alkyl can then in turn itself be substituted, for example by CI (3rd generation substituent). Overall, this then yields the functional group aryl-C^s-alkyl-CI. In a preferred embodiment, however, the 3rd generation substituents cannot themselves be substituted, that is to say there are no 4th generation substituents.

In another preferred embodiment, the 2nd generation substituents cannot themselves be substituted, that is to say there are not even any 3rd generation substituents. In other words, in this embodiment, for example in the case of the general formula (1 ), the functional groups for R ¹ to R ¹³ can in each case optionally be substituted, but the substituents in each case cannot themselves be substituted.

In some cases, the compounds according to the invention are defined by substituents which are or carry an aryl or heteroaryl radical, in each case unsubstituted or mono- or poly-substituted, or which, together with the carbon atom(s) or heteroatom(s) joining them as ring member(s), form a ring, for example an aryl or heteroaryl, in each case unsubstituted or mono- or poly-substituted. Both these aryl or heteroaryl radicals and the aromatic ring systems so formed can optionally be fused with C^o-cycloalkyl or heterocyclyl, in each case saturated or unsaturated, that is to say with a C ₃ . ₁₀ -cycloalkyl such as cyclopentyl or with a heterocyclyl such as morpholinyl, it being possible for the C^o-cycloalkyl or heterocyclyl radicals so fused to be unsubstituted or mono- or poly-substituted.

In some cases, the compounds according to the invention are defined by substituents which are or carry a or heterocyclyl radical, in each case unsubstituted or mono- or poly-substituted, or which, together with the carbon atom(s) or heteroatom(s) joining them as ring member(s), form a ring, for example a C^o-cycloalkyl or heterocyclyl, in each case unsubstituted or mono- or poly-substituted. Both these C3_io-cycloalkyl or heterocyclyl radicals and the aliphatic ring systems formed can optionally be fused with aryl or heteroaryl, that is to say with an aryl such as phenyl or with a heteroaryl such as pyridyl, it being possible for the aryl or heteroaryl radicals so fused to be unsubstituted or mono- or poly- substituted.

The expression "salt formed with a physiologically acceptable acid" is understood within the scope of this invention as meaning salts of the active ingredient in question with inorganic or organic acids that are physiologically acceptable - in particular when used in humans and/or mammals. The hydrochloride is particularly preferred. Examples of physiologically acceptable acids are: hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, maleic acid, lactic acid, citric acid, glutamic acid, saccharinic acid, monomethylsebacic acid, 5-oxo-proline, hexane-1 -sulfonic acid, nicotinic acid, 2-, 3- or 4-aminobenzoic acid, 2,4,6-trimethyl-benzoic acid, a-liponic acid, acetylglycine, hippuric acid, phosphoric acid and/or aspartic acid. Citric acid and hydrochloric acid are particularly preferred.

Physiologically acceptable salts with cations or bases are salts of the compound in question - in the form of the anion with at least one, preferably inorganic cation - that are physiologically acceptable - in particular when used in humans and/or mammals. Particular preference is given to the salts of the alkali and alkaline earth metals but also to ammonium salts, but in particular to (mono-) or (di-)sodium, (mono-) or (di-)potassium, magnesium or calcium salts. The first aspcet of the present invention relates to a compound according the general formula (I) for the treatment and/or the prophylaxis of disorders and/or diseases which are mediated, at least in part, by TSPO (translocator protein 18 kDa).

Hence, the compounds according to the present invention are useful for the treatment and/or the prophylaxis of disorders and/or diseases which are mediated, at least in part, by TSPO activity.

Disorders and/or diseases, which are mediated, at least in part, by TSPO activity, include

- neurological and neurodegenerative disorders,

- psychiatric disorders,

- brain tumours,

- immunological disorders

and inflammatory diseases.

Neurological and neurodegenerative disorders include

Ischaemic stroke, Alzheimer's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis, diabetic peripheral neuropathy, chemotherapy- induced peripheral neuropathy, amyotrophic lateral sclerosis, exictotoxic brain injury, traumatic brain injury, ischaemic brain damage, cerebrovascular disorders and cerebral ischemia. Psychiatric disorders include

anxiety disorders, particularily panic disorders, post traumatic stress disorder,

panic and adult separation disorder, social anxiety, major depression with adult separation anxiety disorder and bipolar disorder with adult separation anxiety disorder, dysthymia, angina pectoris, suicidality and schizophrenia.

Immunological disorders and inflammatory diseases include

neuroinflammation and arthritis, encephalomyelitis and irritable bowel syndrome.

Another embodiment of the present invention therefore relates to a compound according to general formula (I) for the treatment and/or the prophylaxis of disorders and/or diseases,

wherein the disorder and/or the disease is selected from the group consisting of

(i) neurological and neurodegenerative disorders, including

Ischaemic stroke, Alzheimer's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis, diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, amyotrophic lateral sclerosis, exictotoxic brain injury, traumatic brain injury, ischaemic brain damage, cerebrovascular disorders and cerebral ischemia;

(ii) psychiatric disorders, including anxiety disorders, particularity panic disorders, post traumatic stress disorder,

panic and adult separation disorder, social anxiety, major depression with adult separation anxiety disorder and bipolar disorder with adult separation anxiety disorder, dysthymia, angina pectoris, suicidality and schizophrenia;

(iii) brain tumours;

(iv) immunological disorders and inflammatory diseases, including

neuroinflammation and arthritis, encephalomyelitis and irritable bowel syndrome.

A preferred embodiment of the present invention relates to a compound according to general formula (I) for the treatment and/or the prophylaxis of

(i) neurological and neurodegenerative disorders, including

ischaemic stroke, Alzheimer's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis, diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, amyotrophic lateral sclerosis, exictotoxic brain injury, traumatic brain injury, ischaemic brain damage, cerebrovascular disorders and cerebral ischemia;

(ii) psychiatric disorders, including

anxiety disorders, particularily panic disorders, post traumatic stress disorder, panic and adult separation disorder, social anxiety, major depression with adult separation anxiety disorder and bipolar disorder with adult separation anxiety disorder, dysthymia, angina pectoris, suicidality and schizophrenia;

(iii) brain tumours;

(iv) immunological disorders and inflammatory diseases, including

neuroinflammation and arthritis, encephalomyelitis and irritable bowel syndrome. Another preferred embodiment of the present invention relates to a compound according to general formula (I) for the treatment and/or the prophylaxis of neurological and neurodegenerative disorders, including ischaemic stroke, Alzheimer's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis, diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, amyotrophic lateral sclerosis, exictotoxic brain injury, traumatic brain injury, ischaemic brain damage, cerebrovascular disorders and cerebral ischemia.

Another preferred embodiment of the present invention relates to a compound according to general formula (I) for the treatment and/or the prophylaxis of psychiatric disorders,

including anxiety disorders, particularily panic disorders, post traumatic stress disorder, panic and adult separation disorder, social anxiety, major depression with adult separation anxiety disorder and bipolar disorder with adult separation anxiety disorder, dysthymia, angina pectoris, suicidality and schizophrenia.

Yet another preferred embodiment of the present invention relates to a compound according to general formula (I) for the treatment and/or the prophylaxis of brain tumours. Yet another preferred embodiment of the present invention relates to a compound according to general formula (I) for the treatment and/or the prophylaxis of immunological disorders and inflammatory diseases,

including neuroinflammation and arthritis, encephalomyelitis and irritable bowel syndrome.

One embodiment of the present invention relates to a compound of general formula (I), wherein the compound is selected from a compound according to general formula (1-1).

wherein

A ¹⁰¹ represents CR ⁰ R ¹¹¹ or S;

A ¹⁰² represents CR ¹¹² R ¹¹³ , C(=0), O, S, S(=0) or S(=0) ₂ ; R ¹⁰¹ represents C _1-10 -alkyl or C ₂ -i ₀ -heteroalkyl, in each case saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted; C^o-cycloalkyl or heterocyclyl, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted; aryl or heteroaryl, in each case unsubstituted or mono- or poly-substituted; C^s-alkyl- or C _2-8 -heteroalkyl-bridged C^o-cycloalkyl or heterocyclyl, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted, wherein the alkyl or heteroalkyi chain can in each case be branched or unbranched, saturated or unsaturated, unsubstituted or mono- or poly-substituted; or C _1-8 -alkyl- or C ₂ - ₈ -heteroalkyl-bhdged aryl or heteroaryl, in each case unsubstituted or mono- or poly-substituted, wherein the alkyl or heteroalkyi chain can in each case be branched or unbranched, saturated or unsaturated, unsubstituted or mono- or poly-substituted; R , R and R each independently of the others represents H; F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; OH; OCF ₃ ; SH; SCF ₃ ; methyl; CH ₂ -0-methyl; CH ₂ -OH; C ₂ . ₆ -alkyl, 0-d.e-alkyl, S-d-e-alkyl, in each case saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted; C ₃ . ₇ -cycloalkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted; NR ^1a R ^1b , wherein R ^1a and R ^1b each independently of the other represents H or C^-alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted, or R ^1a and R ^1b , together with the nitrogen atom joining them, form a heterocyclyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted;

_R io5 _R io8 _R io7 _R io8 _R io9 _R i ii _R i i2 _{gnd R} i i3 _egch j _ndepenclent | _y of the others represents H; F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; OH; OCF ₃ ; SH; SCF ₃ ; C _1-10 -alkyl, C _2-10 -heteroalkyl, O-Ci.i ₀ -alkyl or S-C _1-10 -alkyl, in each case saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted; C ₃ _ ₁₀ -cycloalkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly- substituted; with the proviso that when R ¹⁰⁵ , R ¹⁰⁶ , R ¹⁰⁷ and R ¹⁰⁸ each denotes H and A ¹ represents S, A ² may not denote S, S(=0) or S(=0) ₂ ; or R ¹⁰⁵ and R ¹⁰⁶ or R ¹⁰⁷ and R ¹⁰⁸ or R ¹¹⁰ and R ¹¹¹ or R ¹¹² and R ^m or R ¹⁰⁵ and R ¹¹¹ or R ¹⁰⁵ and R ¹⁰⁷ or R ¹⁰⁵ and R ¹¹³ or R ¹⁰⁷ and R ¹¹³ or R ⁰⁷ and R ¹¹¹ or R ¹¹¹ and R ¹¹³ , together with the carbon atom(s) joining them, form a C ₃ . ₈ -cycloalkyl or a heterocyclyl having from three to eight ring members, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted; wherein the remaining substituents R ¹⁰⁵ , R ⁰⁶ ,

_R 107 _R 108 _R 11 _{0j R} 111 _{f R} 112 ^ _R 113 _{jn each case have} ^ _meanjng gj _{ven above;}

R ¹⁰⁹ represents C ₃ .i ₀ -cycloalkyl or heterocyclyl, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted; aryl or heteroaryl, in each case unsubstituted or mono- or poly-substituted; or represents CR ^1c R ^1d , wherein R ^1c and R ^d each independently of the other denotes C _1-4 -alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted; with the proviso that when A ¹⁰² represents O or S and R ¹⁰⁹ represents heterocyclyl, saturated or unsaturated, unsubstituted or mono- or poly-substituted; or heteroaryl, unsubstituted or mono- or poly- substituted, the bonding of the heteroaryl or heterocyclyl takes place via a carbon atom of the heteroaryl or heterocyclyl; wherein "alkyl substituted", "heteroalkyl substituted", "heterocyclyl substituted" and "cycloalkyl substituted" denote the substitution of one or more hydrogen atoms, in each case independently of one another, by F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; =0; C _1-8 -alkyl; C ₂ - ₈ -heteroalkyl; aryl; heteroaryl; C ₃ . ₁₀ -cycloalkyl; heterocyclyl; d. ₈ -alkyl- or C ₂ . ₈ -heteroalkyl-bridged aryl, heteroaryl, C _3-10 -cycloalkyl or heterocyclyl; CHO;

C(=0)C _1-8 -alkyl; C(=0)aryl; C(=0)heteroaryl; C0 ₂ H; C(=0)0-C _1-8 -alkyl; C(=0)0-aryl; C(=0)0-heteroaryl;

CONH ₂ ; C(=0)NH-C _1-8 -alkyl; C(=0)N(C ₁ . ₈ -alkyl) ₂ ; C(=0)NH-aryl; C(=0)N(aryl) ₂ ; C(=0)NH-heteroaryl; C(=0)N(heteroaryl) ₂ ; C(=0)N(C ₁ . ₈ -alkyl)(aryl); C(=0)N(C ₁ . ₈ -alkyl)(heteroaryl); C(=0)N(heteroaryl)(aryl);

OH; O-d-8-alkyl; OCF ₃ ; 0-(d. ₈ -alkyl)-OH; 0-(d. ₈ -alkyl)-0-d. ₈ -alkyl; O-benzyl; O-aryl; O-heteroaryl; O-

C(=0)C ₁ . ₈ -alkyl; 0-C(=0)aryl; 0-C(=0)heteroaryl; NH _{2 ;} NH-d. ₈ -alkyl; N(d. ₈ -alkyl) ₂ ; NH-C(=0)d. ₈ -alkyl;

N(C ₁ _ ₈ -alkyl)-C(=0)C ₁ -8-alkyl; N(C(=0)C ₁ . ₈ -alkyl) ₂ ; NH-C(=0)-aryl; NH-C(=0)-heteroaryl; SH; S-C _1-8 -alkyl;

SCF ₃ ; S-benzyl; S-aryl; S-heteroaryl; S(=0) ₂ C _1-8 -alkyl; S(=0) ₂ aryl; S(=0) ₂ heteroaryl; S(=0) ₂ OH; S(=0) ₂ 0- C _1-8 -alkyl; S(=0) ₂ 0-aryl; S(=0) ₂ 0-heteroaryl; S(=0) ₂ -NH-d. ₈ -alkyl; S(=0) ₂ -NH-aryl; and S(=0) ₂ -NH- d. ₈ -heteroaryl; wherein "aryl substituted" and "heteroaryl substituted" denote the substitution of one or more hydrogen atoms, in each case independently of one another, by F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; C _-8 -alkyl; C ₂ . ₈ - heteroalkyl; aryl; heteroaryl; C^o-cycloalkyl; heterocyclyl; C _1-8 -alkyl- or C ₂ . ₈ -heteroalkyl-bridged aryl, heteroaryl, C ₃ .i ₀ -cycloalkyl or heterocyclyl; CHO; C(=0)d. ₈ -alkyl; C(=0)aryl; C(=0)heteroaryl; C0 ₂ H; C(=0)0-d_ ₈ -alkyl; C(=0)0-aryl; C(=0)0-heteroaryl; CONH ₂ ; C(=0)NH-d_ ₈ -alkyl; C(=0)N(d_ ₈ -alkyl) ₂ ; C(=0)NH-aryl; C(=0)N(aryl) ₂ ; C(=0)NH-heteroaryl; C(=0)N(heteroaryl) ₂ ; C(=0)N(C ₁ . ₈ -alkyl)(aryl); C(=0)N(C ₁ . ₈ -alkyl)(heteroaryl); C(=0)N(heteroaryl)(aryl); OH; 0-d.e-aikyl; OCF ₃ ; O-iCLs-alky -OH; O-benzyl; O-aryl; O-heteroaryl; 0-C(=0)C ₁ . ₈ -alkyl; 0-C(=0)aryl; O- C(=0)heteroaryl; NH ₂ ; NH-CLa-alkyl; N(C _1-8 -alkyl) ₂ ; NH-C(=0)C ₁ . ₈ -alkyl; N(C _1-8 -alkyl)-C(=0)C ₁ . ₈ -alkyl; N(C(=0)C ₁ . ₈ -alkyl) ₂ ; NH-C(=0)-aryl; NH-C(=0)-heteroaryl; SH; S-d. ₈ -alkyl; SCF ₃ ; S-benzyl; S-aryl; S-heteroaryl; S(=0) ₂ C _1-8 -alkyl; S(=0) ₂ aryl; S(=0) ₂ heteroaryl; S(=0) ₂ OH; S(=O) ₂ 0-C ₁ . ₈ -alkyl; S(=0) ₂ 0- aryl; S(=0) ₂ 0-heteroaryl; S(=0) ₂ -NH-C _1-8 -alkyl; S(=0) ₂ -NH-aryl; S(=0) ₂ -NH-C ₁ _ ₈ -heteroaryl.

The compounds according to general formula (1-1) are known from WO 2010/102809 A1 , which is fully included by reference.

In preferred embodiments of the compounds of the general formula (1-1) according to the invention A ¹⁰¹ represents S and

A ¹⁰² represents CR ² R ¹¹³ , O, S or S(=0) ₂ , preferably CR ¹¹² R ¹¹³ , S or S(=0) ₂ , particular preferably CR ^{1 2} R ¹¹³ .

Further preferred embodiments of the compounds of the general formula (1-1) according to the invention

Compounds of the general formulae (1-l-a), (1-l-b) and (1-l-c) are most particularly preferred. Compounds of the general formula (1-1a) are especially preferred.

In a further preferred embodiment the radical R ¹⁰ represents

C^o-alkyl or C ₂ -io-heteroalkyl, in each case saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CF ₃ , CN, OH, =0, C(=0)-OH, OCF ₃ , NH ₂ , S(=0) ₂ OH, SH, SCF ₃ , C _1-8 -alkyl, 0-d. ₈ -alkyl, S^-alky!, NH-d. ₈ -alkyl, N(C ₁ . ₈ -alkyl) ₂ , C^^-cycloalkyl and heterocyclyl, wherein the above alkyl radicals can in each case be saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, 0-Ci _-8 -alkyl, OH and OCF ₃ , and wherein d-io-cycloalkyl or heterocyclyl can in each case be saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, Ci. ₈ -alkyl, OH, =0, 0-C _1-8 -alkyl, OCF ₃ , NH ₂ , NH-d-e-alkyl and N(C _1-8 -alkyl) ₂ ;

or C^o-cycloalkyl or heterocyclyl, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, 0-C _1-8 -alkyl, OCF ₃ , C _1-8 -alkyl, C(=0)-OH, CF ₃ , NH ₂ , NH(C _1-8 -alkyl), N(d. ₈ -alkyl) ₂ , SH, S-d. ₈ -alkyl, SCF ₃ , S(=0) ₂ OH, benzyl, phenyl, pyridyl and thienyl, wherein benzyl, phenyl, pyridyl, thienyl can in each case be unsubstituted or mono- or poly-substituted by one or more substituents selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, 0-C _1-8 -alkyl, OCF ₃ , d. ₈ -alkyl, C(=0)-OH, CF ₃ , NH ₂ , NH(d. ₈ -alkyl), N(C _1-8 -alkyl) ₂ , SH, S-C _1-8 -alkyl, SCF ₃ and S(=0) ₂ OH;

or aryl or heteroaryl, in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, 0-d.e-alkyl, OCF ₃ , d. ₈ -alkyl, C(=0)-OH, CF ₃ , NH ₂ , NH(d. ₈ -alkyl), N(d. ₈ -alkyl) ₂ , SH, S-Cvs-alkyl, SCF ₃ , S(=0) ₂ OH, benzyl, phenyl, pyridyl and thienyl, wherein benzyl, phenyl, pyridyl, thienyl can in each case be unsubstituted or mono- or poly-substituted by one or more substituents selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, 0-d. ₈ -alkyl, OCF ₃ , C _1-8 -alkyl, C(=0)-OH, CF ₃ , NH ₂ , NH(d. ₈ -alkyl), N(d. ₈ -alkyl) ₂ , SH, S-Ci. ₈ -alkyl, SCF ₃ and S(=0) ₂ OH;

or d_ ₈ -alkyl- or C ₂ . ₈ -heteroalkyl-bridged C^o-cycloalkyl or heterocyclyl, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, 0-d. ₈ -alkyl, OCF ₃ , d. ₈ -alkyl, C(=0)-OH, CF ₃ , NH ₂ , NH(d. ₈ -alkyl), N(d.8-alkyl) ₂ , SH, S-d. ₈ -alkyl, SCF ₃ , S(=0) ₂ OH, benzyl, phenyl, pyridyl and thienyl, wherein benzyl, phenyl, pyridyl, thienyl can in each case be unsubstituted or mono- or poly-substituted by one or more substituents selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, 0-d_ ₈ -alkyl, 0CF ₃ , d. ₈ -alkyl, C(=0)-OH, CF ₃ , NH ₂ , NH(C _1-8 -alkyl), N(d_ ₈ -alkyl) ₂ , SH, S-d. ₈ -alkyl, SCF ₃ and S(=0) ₂ OH;

wherein the alkyl or heteroalkyl chain can in each case be branched or unbranched, saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CF ₃ , CN, OH, =0, C(=0)-OH, OCF ₃ , NH ₂ , S(=0) ₂ OH, SH, SCF ₃ , C^-alky!, 0-Ci. ₈ -alkyl, S-C^s-alkyl, NH-C^s-alkyl, N(C _1-8 -alkyl) ₂ , C ₃ . ₁₀ -cycloalkyl and heterocyclyl, wherein the above alkyl radicals can in each case be saturated or unsaturated , branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, 0- C _1-8 -alkyl, OH and OCF ₃ , and wherein C ₃ . ₁₀ -cycloalkyl or heterocyclyl can in each case be saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, C _1-8 -alkyl, OH, =0, 0-C _1-8 -alkyl, OCF ₃ , NH ₂ , NH-C _1-8 -alkyl and N(C _1-8 -alkyl) ₂ ; or C^e-alkyl- or C ₂ . ₈ -heteroalkyl-bridged aryl or heteroaryl, in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, O'C^-alky!, OCF ₃ , C _1-8 -alkyl, C(=0)-OH, CF ₃ , NH ₂ , SH, S-d-e-alkyl, SCF ₃ , S(=0) ₂ OH, benzyl, phenyl, pyridyl and thienyl, wherein benzyl, phenyl, pyridyl, thienyl can in each case be unsubstituted or mono- or poly-substituted by one or more substituents selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, O'C^-alky!, OCF ₃ , C^-alkyl, C(=0)-OH, CF ₃ , NH ₂ , Hid-e-alkyl), N(C _1-8 -alkyl) ₂ , SH, S-C _1-8 -alkyl, SCF ₃ and S(=0) ₂ OH;

wherein the alkyl or heteroalkyi chain can in each case be branched or unbranched, saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CF ₃ , CN, OH, =0, C(=0)-0H, OCF ₃ , NH ₂ , S(=0) ₂ OH, SH, SCF ₃ , C^-alky!, 0-C _1-8 -alkyl, S-C _1-8 -alkyl, NH-C^e-alkyl, N(Ci_ ₈ -alkyl) ₂ , C ₃ . ₁₀ -cycloalkyl and heterocyclyl, wherein the above alkyl radicals can in each case be saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, 0-Ci. ₈ -alkyl, OH and OCF ₃ , and wherein Cs- _K rcycloalkyl or heterocyclyl can in each case be saturated or unsaturated, unsubstituted or mono- or poly- substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, C^-alky!, OH, =0, O'C^a-alky!, OCF ₃ , NH ₂ , NH-C^-alkyl and

In a further preferred embodiment the substituent R ¹⁰¹ represents the following partial structure (1 -T1 ),

-(CR ^114a R ^114b ) _m1 -(Y ¹ ) _n1 -B ¹ (1-T1 ), wherein

R ^114a and R ^114b each independently of the other represents H; F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; OH; OCF ₃ ; NH ₂ ; C^-alkyl, O-C^-alkyl, NH-Ci_ ₄ -alkyl, NiC^-alkyl^, in each case saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, O-C^-alkyl, OH and OCF ₃ ; C ₃ _i ₀ - cycloalkyl or heterocyclyl, in each case saturated or unsaturated, unsubstituted or mono- or poly- substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, C^-alkyl, OH, =0, 0-d. ₄ -alkyl, OCF ₃ , NH ₂ , NH-d. ₄ -alkyl and N(d. ₄ -alkyl) ₂ ; ml represents 0, 1 , 2 or 3;

Y represents O or NR ¹⁵ ,

wherein R ¹¹⁵ represents H; d_ ₄ -alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, C _1-4 -alkyl, OH, O-d^-alkyl, OCF ₃ , NH ₂ , NH-d„ ₄ -alkyl and N(C-|. ₄ -alkyl) ₂ ; or represents C ₃ . ₁₀ -cycloalkyl, saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, C _1-4 -alkyl, OH, O- d_ ₄ -alkyl, OCF ₃ , NH ₂ , NH-d. ₄ -alkyl and N(d. ₄ -alkyl) ₂ ; n1 represents 0 or 1 ,

B ¹ represents d. ₈ -alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, =0, 0-d. ₄ -alkyl, OCF ₃ , C(=0)-OH, CF ₃ , NH ₂ , NH(C _1-4 -alkyl), N(d. ₄ -alkyl) ₂ , SH, S-C^-alkyl, SCF ₃ and S(=0) ₂ OH; C ₃ -io-cycloalkyl or heterocyclyl, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, 0-C _1-8 -alkyl, OCF ₃ , d. ₈ -alkyl, C(=0)-OH, CF ₃ , NH ₂ , NH(d. ₈ -alkyl), N(d. ₈ -alkyl) ₂ , SH, S-d. ₈ -alkyl, SCF ₃ , S(=0) ₂ OH, benzyl, phenyl, pyridyl and thienyl,

wherein benzyl, phenyl, pyridyl, thienyl can in each case be unsubstituted or mono- or poly-substituted by one or more substituents selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, 0-d. ₈ -alkyl, OCF ₃ , C _1-8 -alkyl, C(=0)- OH, CF ₃ , NH ₂ , NH(d. ₈ -alkyl), N(d. ₈ -alkyl) ₂ , SH, S-C^-alkyl, SCF ₃ and S(=0) ₂ OH; aryl or heteroaryl, in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, 0-d.e-alkyl, OCF ₃ , d. ₈ -alkyl, C(=0)-OH, CF ₃ , NH ₂ , NH(d. ₈ -alkyl), N(d. ₈ -alkyl) ₂ , SH, S-d. ₈ -alkyl, SCF ₃ , S(=0) ₂ OH, benzyl, phenyl, pyridyl and thienyl, wherein benzyl, phenyl, pyridyl, thienyl can in each case be unsubstituted or mono- or poly-substituted by one or more substituents selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, 0-d. ₈ -alkyl, OCF ₃ , d_ ₈ -alkyl, C(=0)-OH, CF ₃ , NH ₂ , NH(d. ₈ -alkyl), N(d. ₈ -alkyl) ₂ , SH, S-d. ₈ -alkyl, SCF ₃ and S(=0) ₂ OH.

Preferably,

R ^114a and R ^114b each independently of the other represents H; F; CI; Br; I; N0 ₂ ; CF ₃ ; CH ₂ CF ₃ ; CN; OH; OCF ₃ , NH ₂ ; d. ₄ -alkyl, 0-d. ₄ -alkyl, 0-d. ₄ -alkyl-OH, 0-d. ₄ -alkyl-OCH ₃ , NH-Ci. ₄ -alkyl, N(d. ₄ -alkyl) ₂ , in each case saturated or unsaturated, branched or unbranched, unsubstituted; C^o-cycloalkyl, saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, C - -alkyl, OH, 0-C _1-4 -alkyl; ml represents 0, 1, 2 or 3;

Y ¹ represents O or NR ¹¹⁵ ;

wherein R ^{1 5} represents H; C _1-4 -alkyl, saturated or unsaturated, unsubstituted; or represents C ₃ _i ₀ - cycloalkyl, saturated or unsaturated, unsubstituted; n1 represents 0 or 1 ;

B ¹ represents d. ₈ -alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, 0-Ci. ₄ -alkyl, OCF ₃ , CF ₃ , NH ₂ , NH(d. ₄ -alkyl), N(C _lJr alkyl) ₂ , SCF ₃ ; Cs-io-cycloalkyl or heterocyclyl, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, 0-d_ ₄ -alkyl, OCF ₃ , C _1-4 -alkyl, CF ₃ , NH ₂ , NH(d. ₄ -alkyl), N(d_ ₄ -alkyl) ₂ , SCF ₃ ; aryl or heteroaryl, in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, 0-Ci. -alkyl, OCF ₃ , d. ₄ -alkyl, C(=0)-OH, CF ₃ , NH ₂ , NH(d_ ₄ -alkyl), N(d. ₄ -alkyl) ₂ , SH, S-C^-alkyl, SCF ₃ , S(=0) ₂ OH, benzyl, phenyl and pyridyl, wherein benzyl, phenyl or pyridyl are in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, 0-C _1- -alkyl, OCF ₃ , Ci. ₄ -alkyl, C(=0)-OH, CF ₃ , NH ₂ , NH(d. ₄ -alkyl), N(d. ₄ -alkyl) ₂ , SH, S-d. ₄ -alkyl, SCF ₃ and S(=0) ₂ OH.

Particularly preferably, R ^114a and R ^114b each independently of the other represents H; F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; methyl; ethyl; n-propyl; isopropyl; cyclopropyl; n-butyl; sec-butyl; tert-butyl; CH ₂ CF ₃ ; OH; O- methyl; O-ethyl; 0-(CH ₂ ) ₂ -0-CH ₃ ; 0-(CH ₂ ) ₂ -OH; OCF ₃ ; NH ₂ ; NH-methyl; N(methyl) ₂ ; NH-ethyl; N(ethyl) ₂ ; or N(methyl)(ethyl); ml represents 0, 1 or 2; n1 represents 0; and

B ¹ represents d^-alkyl, saturated, branched or unbranched, unsubstituted or mono- or poly- substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, OH, 0-d. ₄ -alkyl, OCF ₃ and CF ₃ ; C^o-cycloalkyl, saturated, unsubstituted; phenyl, naphthyl, pyridyl, thienyl, in each case unsubstituted or mono- or di- or tri- substituted by one, two or three substituents each selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, O-C^-alkyl, OCF ₃ , C^-alkyl, C(=0)-OH, CF ₃ , NH ₂ , NHfC alkyl), NfC^-alkyl);,, SH, S-C^-alkyl, SCF ₃ , S(=0) ₂ OH.

Most particularly preferably, R ^14a and R ^{1 4b} each independently of the other represents H; F; CI; Br; I; methyl; ethyl; n-propyl; isopropyl; n-butyl; sec-butyl; tert-butyl; OH; O-methyl; O-ethyl; 0-(CH ₂ )2-0-CH ₃ ; or 0-(CH ₂ ) ₂ -OH; ml represents 0, 1 or 2; n1 represents 0; and

B ¹ represents methyl; ethyl; n-propyl; isopropyl; n-butyl; sec-butyl; tert-butyl; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; cycloheptyl; adamantyl; bicyclo[2.2.1]heptyl; bicyclo[2.2.2]octyl; phenyl, pyridyl, thienyl, in each case unsubstituted or mono-, di- or tri-substituted by one, two or three substituents each selected independently of one another from the group consisting of F, CI, Br, I,

N0 ₂ , CN, OH, O-C^-alkyl, OCF ₃ , C^-alkyl, C(=0)-OH, CF ₃ , NH ₂ , NHiC^-alkyl), N C^-alkyl^, SH, S-C _1-4 -alkyl, SCF ₃ and S(=0) ₂ OH.

For n1 = 0, the partial structure (1-T1) for R ¹⁰¹ yields the partial structure (1-T1-1):

-(CR ^{1 4a} R ^114b ) _m1 -B ¹ (1-T1-1).

In a preferred embodiment for n1 = 0, R ^{11 a} and R ^14b each independently of the other represents H; F; CI; Br; I; methyl; ethyl; n-propyl; isopropyl; n-butyl; sec-butyl; tert-butyl; OH; O-methyl; O-ethyl; 0-(CH ₂ ) ₂ -0- CH ₃ ; or 0-(CH ₂ ) ₂ -OH.

In a preferred embodiment for ml = 0, B ¹ represents phenyl, pyridyl or thienyl, mono- or di- or tri- substituted by one, two or three substituents each selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, O-C^-alkyl, OCF ₃ , C _1-4 -alkyl, C(=0)-OH, CF ₃ , NH ₂ , NH(C _1-4 -alkyl), N(C -alkyl) ₂ , SH, S-C^-alkyl, SCF ₃ , S(=0) ₂ OH.

In a preferred embodiment for ml = 1 or 2, B ¹ represents cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; cycloheptyl; adamantyl; bicyclo[2.2.1]heptyl; bicyclo[2.2.2]octyl. In a preferred embodiment for ml = 0, 1 or 2, B ¹ represents methyl; ethyl; n-propyl; isopropyl; n-butyl; sec-butyl or tert-butyl.

A further particularly preferred embodiment of the compounds of the general formula (1-1) according to the invention has the general formula (1-1-2):

In a further preferred embodiment,

the radicals R ¹⁰² , R ¹⁰³ and R ¹⁰⁴ each independently of the others represent H; F; CI; Br; I; N0 ₂ ; CF ₃ ; CN;

OH; OCF ₃ ; SH; SCF ₃ ; methyl; CH ₂ -0-methyl; CH ₂ -OH; C ₂ - ₆ -alkyl, 0-d. ₆ -alkyl or S-C _1-e -alkyl, in each case saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly- substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, OH, =0 and 0-C _-4 -alkyl; C3_ ₇ -cycloalkyl, saturated or unsaturated, branched or unbranched, unsubstituted; NR ^1a R ^1b ,

wherein R ^1a and R ^1b each independently of the other represents H or C^-alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of OH, =0 and 0-C _-4 -alkyl,

or R ^1a and R ^1b , together with the nitrogen atom joining them, form a heterocyclyl, saturated or unsaturated, unsubstituted or mono- or poly-substituted by C _1-4 -alkyl.

Preferably,

the radicals R ¹⁰² , R ¹⁰³ and R ¹⁰⁴ each independently of the others represent H; F; CI; Br; I; N0 ₂ ; CF ₃ ; CN;

OH; OCF ₃ ; SH; SCF ₃ ; methyl; ethyl; n-propyl; isopropyl; butyl; sec-butyl; tert-butyl; CH ₂ CF ₃ ; O- methyl; O-ethyl; O-n-propyl; O-isopropyl; O-butyl; O-sec-butyl; O-tert-butyl; 0-(CH ₂ ) ₂ -0-methyl; 0-(CH ₂ ) ₂ -OH; 0-(C=0)-methyl; 0-(C=0)-ethyl; S-methyl; S-ethyl; cyclopropyl; cyclobutyl;

NR ^1a R ^1b ,

wherein R ^1a and R ^1b each independently of the other is selected from the group consisting of H, methyl, ethyl, (CH ₂ ) ₂ -0-methyl, (CH ₂ ) ₂ -OH, (C=0)-methyl, (C=0)-ethyl, or R ^1a and R ^1b , together with the nitrogen atom joining them, form a pyrrolidinyl, piperidinyl, 4-methylpiperazinyl or morpholinyl.

Particularly preferably,

the radicals R ⁰² , R ¹⁰³ and R ¹⁰⁴ each independently of the others represent H; F; CI; Br; I; methyl; ethyl; n-propyl, isopropyl; cyclopropyl; CN; CF ₃ ; O-methyl; OCF ₃ ; S-methyl; SCF ₃ , pyrrolidinyl,

N(methyl) ₂ .

Most particularly preferably, the radicals R ¹⁰² , R ¹⁰³ and R ⁰⁴ each independently of the others represent H; F; CI; methyl; ethyl; O-methyl; CF ₃ ; in particular H. In a further preferred embodiment, the radicals R ¹⁰⁵ , R ¹⁰⁶ , R ⁰⁷ , R ¹⁰⁸ , R ^{1 0} , R ¹¹¹ , R ¹¹² and R ¹¹³ each independently of the others represents H; F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; OH; OCF ₃ ; SH; SCF ₃ ; C^-alkyl; 0- C _1-e -alkyl or S-C^-alkyl, in each case saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, OH and O-C^-alkyl; C3_ ₇ -cycloalkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, OH, =0 and O-C^-alkyl; or R ¹⁰⁵ and R ¹⁰⁶ or R ¹⁰⁷ and R ¹⁰⁸ or R ¹¹⁰ and R ¹¹¹ or R ¹¹² and R ¹¹³ or R ¹⁰⁵ and R ¹¹¹ or R ¹⁰⁵ and R ¹⁰⁷ or R ¹⁰ⁱ and R ¹¹³ or R ¹⁰⁷ and R ¹¹³ or R ¹⁰⁷ and R ¹¹¹ or R ^{1 1} and R ^{1 3} together with the carbon atom(s) joining them, form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl or piperidinyl, in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, OH, =0 and O-C^-alkyl; wherein the remaining substituents R ¹⁰⁵ , R ¹⁰⁶ , R ⁰⁷ , R ⁰⁸ , R ¹¹⁰ , R ¹¹¹ , R ^{1 2} and R ¹¹³ in each case have the meaning given above. Preferably, the radicals R ¹⁰⁵ , R ¹⁰⁶ , R ⁰⁷ , R ¹⁰⁸ , R ¹¹⁰ , ¹¹¹ , R ¹¹² and R ^{1 3} each independently of the others represents H; F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; OH; OCF ₃ ; SH; SCF ₃ ; methyl; ethyl; n-propyl; isopropyl; n-butyl; sec-butyl; tert-butyl; O-methyl; O-ethyl; 0-(CH ₂ ) ₂ -0-CH ₃ ; 0-(CH ₂ ) ₂ -OH; S-methyl; S-ethyl; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl;

or R ¹⁰⁵ and R ¹⁰⁶ or R ¹⁰⁷ and R ¹⁰⁸ or R ¹¹⁰ and R ¹¹¹ or R ¹¹² and R ¹¹³ or R ¹⁰⁵ and R ¹¹¹ or R ¹⁰⁵ and R ¹⁰⁷ or R ^10! and R ¹¹³ or R ¹⁰⁷ and R ¹¹³ or R ¹⁰⁷ and R ¹¹ or R ¹¹ and R ¹¹³ together with the carbon atom(s) joining them, form a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in each case unsubstituted; wherein the remaining substituents R ¹⁰⁵ , R ⁰⁶ , R ¹⁰⁷ , R ¹⁰⁸ , R ¹¹⁰ , R ¹¹¹ , R ¹¹² and R ³ in each case have the meaning given above. Particularly preferably, the radicals R ¹⁰⁵ , R ¹⁰⁶ , R ¹⁰⁷ , R ¹⁰⁸ , R ¹¹⁰ , R ¹¹¹ , R ¹¹² and R ¹¹³ each independently of the others represents H; F; CI; Br; I; CN; CF ₃ ; OCF ₃ ; SCF ₃ ; methyl; ethyl; n-propyl, isopropyl; cyclopropyl; O-methyl; S-methyl;

or R ¹⁰⁵ and R ¹⁰⁷ form a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl ring substituted as desired by H, F, CI, Me, Et, OMe, preferably an unsubstituted cyclopentyl or cyclohexyl ring.

Most particularly preferably, the radicals R ¹⁰⁵ , R ¹⁰⁶ , R ¹⁰⁷ , R ¹⁰⁸ , R ¹¹⁰ , R ¹¹¹ , R ¹¹² and R ¹¹³ each

independently of the others represents F; CI; H; methyl; ethyl; n-propyl, isopropyl; cyclopropyl; in particular F; H; methyl; or ethyl. In particular, the radicals R ¹¹² and R ¹¹³ each independently of the other represents H, F or methyl.

In a further preferred embodiment,

the radical R ¹⁰⁹ represents C _3-10 -cycloalkyl or heterocyclyl, in each case saturated or unsaturated,

unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, =0,

O-C^-alkyl, OCF ₃ , C _1-4 -alkyl, CF ₃ , SH, S-d. ₄ -alkyl and SCF ₃ ; aryl or heteroaryl, in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, O-C^-alkyl, OCF ₃ , C^-alkyl, CF ₃ , NH ₂ , NH(C^-alkyl), N(d.4-alkyl) ₂ , SH, S-C^-alkyl and SCF ₃ ;

or represents CR ^1c R ^1d ,

wherein R ^1c and R ^1d each independently of the other denotes Ci. ₄ -alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, OH, O-C^-alkyl, CF ₃ , OCF ₃ and SCF ₃ .

Preferably, R ¹⁰⁹ represents C ₃ . ₇ -cycloalkyl, saturated or unsaturated, pyrrolidinyl, piperazinyl, 4- methylpiperazinyl, piperidinyl, morpholinyl, in each case unsubstituted or mono- or poly- substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, OH, O-C^-alkyl, OCF ₃ , C - -alkyl, CF ₃ , SH, S-C^-alkyl and SCF ₃ ; phenyl, naphthyl, pyridyl or thienyl, in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, O-C^-alkyl, OCF ₃ , C _1-4 -alkyl, CF ₃ , SH, S-C^-alkyl and SCF ₃ ;

or represents CR ^1c R ^d ,

wherein R ^1c and R ^1d each independently of the other denotes C _-4 -alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, OH and O-C^-alkyl.

Particularly preferably, the radical R ¹⁰⁹ is selected from the group consisting of phenyl, pyridyl or thienyl, in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, CN, OH, 0-Ci_ ₄ -alkyl, OCF ₃ , C _1-4 -alkyl, CF ₃ , SH, S-C _1-4 -alkyl and SCF ₃ .

Most particularly preferably, R ¹⁰⁹ represents phenyl, pyridyl and thienyl, unsubstituted or mono- or poly- substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, O-methyl, O- ethyl, O-n-propyl, O-isopropyl, O-butyl, O-sec-butyl, O-tert-butyl, OH, OCF ₃ , CF ₃ , SH, S-C^-alkyl and SCF ₃ .

In particular, R ¹⁰⁹ represents phenyl, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, O-methyl, O-ethyl, OCF ₃ , CF ₃ and SCF ₃ .

In a further, particularly preferred embodiment

A ¹⁰¹ represents S and

A ¹⁰² represents CR ¹¹² R ¹¹³ ;

R ¹⁰ represents the partial structure (1-T1-1)

wherein R ^114a and R ^114b each independently of the other represents H; F; CI; Br; I; methyl; ethyl; n-propyl; isopropyl; n-butyl; sec-butyl; tert-butyl; OH; O-methyl; O-ethyl; 0-(CH ₂ ) ₂ -0-CH ₃ ; or 0-(CH ₂ ) ₂ -OH; ml represents 0, 1 or 2;

B ¹ represents methyl; ethyl; n-propyl; isopropyl; n-butyl; sec-butyl; tert-butyl; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; cycloheptyl; adamantyl; bicyclo[2.2.1]heptyl; bicyclo[2.2.2]octyl; phenyl, pyridyl, thienyl, in each case unsubstituted or mono-, di- or tri-substituted by one, two or three substituents each selected independently of one another from the group consisting of F, CI, Br, I, N0 ₂ , CN, OH, 0-C _1-4 -alkyl, OCF ₃ , Ci. ₄ -alkyl, C(=0)-OH, CF ₃ , NH ₂ , NH(CM-alkyl), N(CM-alkyl) ₂ , SH, S-C^-alkyl, SCF ₃ and

S(=0) ₂ OH;

_R io2 _R io3 _{and R} io4 _each independently ₀ f _tne others represents H; F; CI; methyl; ethyl; CF ₃ or O-methyl; R ¹⁰⁵ , R ¹⁰⁶ , R ¹⁰⁷ , R ¹⁰⁸ , R ¹¹⁰ , R ¹¹¹ , R ¹¹² and R ¹¹³ each independently of the others represents H; F; CI;

methyl; ethyl; n-propyl, isopropyl; cyclopropyl;

R ¹⁰⁹ represents phenyl, pyridyl or thienyl, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, CI, Br, I, CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, O-methyl, O-ethyl, O-n-propyl, O-isopropyl, O-butyl, O-sec-butyl, O-tert-butyl, OH, OCF ₃ , CF ₃ , SH, S-C _1-4 -alkyl and SCF ₃ .

Another embodiment of the present invention relates to a compound of general formula (I), wherein the compound is selected from a compound according to general formula (2-I).

(2-I),

wherein

R ²⁰¹ represents a C^o-aliphatic residue, unsubstituted or mono- or polysubstituted; a C ₃ .-| ₀ - cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C^e aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a Ci _-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R represents H; F; CI; Br; I; CN; CF ₃ ; C(=0)H; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C^-aliphatic residue, a C(=0)- C _1-4 aliphatic residue, a C(=0)-0-C ₁ . ₄ aliphatic residue, a C(=0)-NH-C ₁ . ₄ aliphatic residue, a

aliphatic residue) ₂ , wherein the C aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a O-CM-aliphatic residue, a 0-C(=0)-C ₁ _ ₄ -aliphatic residue, a S-C _1-4 -aliphatic residue, a S(=0) ₂ -C . ₄ -aliphatic residue, a S(=0) ₂ -0-C ₁ . ₄ -aliphatic residue, wherein the C _1J( aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C^e-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a d^ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

_R 203 _R 204 _R 205 _{and R} 206 _egch i _ndependent | _{y of one} another represent H; F; CI; Br; I; CN; CF ₃ ;

C(=0)H; C(=0)-OH; C(=0)-NH ₂ ; SCF ₃ ; S(=0) ₂ -OH; N0 ₂ ; OCF ₃ ; a d. ₄ -aliphatic residue, a C(=0)- C _M aliphatic residue, a aliphatic residue, a C(=0)-N(C _1j aliphatic residue) ₂ , wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a 0-C _-4 -aliphatic residue, a 0-C(=0)-C ₁ ^-aliphatic residue, a S-d. ₄ -aliphatic residue, a

residue, wherein the d_ ₄ aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a NH(d_ ₄ aliphatic residue), a N(C _1-4 aliphatic residue) ₂ , a NH-C(=0)-C ₁ . ₄ aliphatic residue, a NH-S(=0) ₂ -C ₁ . ₄ -aliphatic residue, a N(C ₁₄ aliphatic residue)-C(=0)-d^ aliphatic residue, or a N(d. ₄ aliphatic aliphatic residue, wherein the d-4 aliphatic residue may in each case be unsubstituted or mono- or polysubstituted; a C^- cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a Ci_ ₄ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

R ²⁰⁷ represents a Ci_ ₁₀ -aliphatic residue, unsubstituted or mono- or polysubstituted; a C3.10- cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a d-e aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

on the condition that if R ²⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, in which an "aliphatic group" and "aliphatic residue" can in each case be branched or unbranched, saturated or unsaturated, in which a "cycloaliphatic residue" and a "heterocycloaliphatic residue" can in each case be saturated or unsaturated, in which "mono- or polysubstituted" with respect to an "aliphatic group" and an "aliphatic residue" relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d. ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , a NH-C(=0)-C _1J( aliphatic residue, a NH-S(=0) ₂ -d-4 aliphatic residue, =0, OH, OCF ₃ , a O-C^-aliphatic residue, a 0-C(=0)-C ₁ . ₄ - aliphatic residue, SH, SCF ₃ , a residue, a S(=0) ₂ -0-d. ₄ -aliphatic residue, a S(=0) ₂ -NH-C ₁ . ₄ -aliphatic residue, CN, CF ₃ , CHO, COOH, a C _1-4 - aliphatic residue, a C(=0)-C ₁ _ ₄ -aliphatic residue, a C(=0)-0-d_ ₄ -aliphatic residue, a C ₃ . ₆ -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(=0)-NH ₂ , a C(=0)-NH(C ₁ . ₄ aliphatic residue), and a C(=0)-N(C _-4 aliphatic residue) ₂ ; in which "mono- or polysubstituted" with respect to a "cycloaliphatic residue" and a "heterocycloaliphatic residue" relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , a NH-C^O)-^ aliphatic residue, a NH-S(=0) ₂ -C ₁ _4 aliphatic residue, =0, OH, OCF ₃ , a O-C^-aliphatic residue, a O- C(=0)-C _1-4 -aliphatic residue, SH, SCF ₃ , a S-C^-aliphatic residue, S(=0) ₂ OH, a S(=0) ₂ -C _lJ( -aliphatic residue, a residue, CN, CF ₃ , CHO, COOH, a C- -aliphatic residue, a C(=0)-C ₁ _ ₄ -aliphatic residue, a C(=0)-0-C ₁ _ -aliphatic residue, a C^e- cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(=0)-NH ₂ , a

aliphatic residue), and a 0(=Ο)-Ν(0 _1-4 aliphatic residue) ₂ ; in which "mono- or polysubstituted" with respect to "aryl" and a "heteroaryl" relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one

> another by at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ ,

, an NH(C _lJt aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , an NH-C(=0)-C _1- aliphatic residue, an NH-S(=0) ₂ -C _-4 aliphatic residue, OH, OCF ₃ , a O-C^-aliphatic residue, a 0-C(=0)-C _1-4 - aliphatic residue, SH, SCF ₃ , a S-Ci_ ₄ -aliphatic residue, S(=0) ₂ OH, a S(=0) ₂ -C ₁ . ₄ -aliphatic residue, a S(=0) ₂ -0-C ₁ . ₄ -aliphatic residue, a S(=0) ₂ -NH-C _1-4 -aliphatic residue, CN, CF ₃ , C(=0)H, C(=0)OH, a d. ₄ - aliphatic residue, a C(=0)-C ₁ . ₄ -aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, a C^e-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(=0)-NH ₂ , a C(=0)- ΝΗ(θ _! . ₄ aliphatic residue), and a C(=0)-N(C . ₄ aliphatic residue) ₂ .

The compounds according to general formula (2-I) are known from WO 2012/025236 A1 , which is fully included by reference.

Preferred embodiments of the compound according to general formula (2-I) have general formulae (2-la), (2-lb), (2-lc) or (2-ld):

(2-la)

Another preferred embodiment of present invention is a compound according to general formula (2-1), wherein

R ²⁰ denotes a C^o-aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _-4 aliphatic residue) ₂ , OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, or denotes a C3_ ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, a C ₃ . ₆ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _! . ₄ aliphatic residue) ₂ , OH, =0, an 0-Ci_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-CL ₄ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

and wherein the C ₃ . ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C^s aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an ΝΗ(0^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-CL ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1- aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d- ₄ aliphatic residue), an N(Ci _-4 aliphatic residue) ₂ , OH, an 0-d_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0- residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an aliphatic residue), an N(Ci_4 aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH, SCF ₃ , a S-d^ aliphatic residue, CF ₃ , CN, a d. ₄ -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C^cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci. ₄ aliphatic residue), an N(d_ ₄ aliphatic residue) ₂ , OH, =0, an 0-d. ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a d_ ₄ -aliphatic residue and C(=0)- OH,

and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a d_ ₈ aliphatic group, preferably a C _-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(d_ ₄ aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN and C(=0)-OH, represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S-C _1-4 -aliphatic residue, a O-d^-aliphatic residue,

wherein the d_ ₄ aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted;

a C^e-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent

selected from the group consisting of F, CI, Br, I, =0, OH, a C _1-4 -aliphatic residue and an 0- C _-4 -aliphatic residue,

wherein the d. ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted 0-d. -aliphatic residue,

and wherein the C ₃ - ₆ -cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a Ci _-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, an unsubstituted C _1- -aliphatic residue and an unsubstituted O-C^-aliphatic residue,

_R 203 _R 204 _R 205 _{and R} 206 _egch j _ndependerit | _{y of one} another represent H; F; CI; Br; I; CN; CF ₃ ;

OCF ₃ ; SCF ₃ ; C(=0)H; C(=0)-OH; C(=0)-NH ₂ ; S(=0) ₂ -OH; N0 ₂ ; a C^-aliphatic residue, a C(=0)-C _1- aliphatic residue, a C^OJ-O-C^ aliphatic residue, a C(=0)-NH-C ₁ . ₄ aliphatic residue, a

aliphatic residue, a S-C^-aliphatic residue, a S(=0) ₂ -C ₁ ^-aliphatic residue, a NH(C _1-4 aliphatic residue), a N(C _! _ ₄ aliphatic residue) ₂ , a NH-C(=0)-C _1J( aliphatic residue, and a NH- S(=0) ₂ -C _lJt -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and a O-C^-aliphatic residue; a C^-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C _1-4 -aliphatic residue and a 0-C _1-4 -aliphatic residue, and in each case optionally bridged via an unsubstituted C _1-4 aliphatic group,

preferably on the condition that at least one of R ²⁰³ , R ²⁰⁴ , R ²⁰⁵ and R ²⁰⁶ is≠ H,

R ²⁰⁷ denotes a Ci_ ₁₀ -aliphatic residue, preferably a C-i_ ₈ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an aliphatic residue), an N(Ci_ aliphatic residue) ₂ , OH, =0, an 0-Ci_ ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, CF ₃ , CN, a C _1- -aliphatic residue and C(=0)- OH,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C _1- aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, a C ₃ . ₆ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C ₁ _ ₄ aliphatic residue), an N(C _! _ ₄ aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C1.4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

and wherein the C^^-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an ΝΗ(0·ι_ ₄ aliphatic residue), an N C^ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH,

on the condition that if R ²⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom.

In a preferred embodiment of the compound according to general formula (2-I), the residue

R ²⁰ denotes a C _1-10 -aliphatic residue, preferably a C-i_ ₈ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _ ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C- -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _-4 -aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)- OH,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(Ci. ₄ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, a j-ecycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the C^ecycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _! . ₄ aliphatic residue), an N(C _! _ ₄ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _{1 4} aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

and wherein the C ₃ _i ₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1J( aliphatic residue), an N(C _! . ₄ aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1- aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NI-KC^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C ₃ . ₆ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the Ci. ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI,

Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C^ aliphatic residue), an Ν(0,. aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH,

SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a d. ₄ -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C^e cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _{1 4} -aliphatic residue and C(=0)- OH,

and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a Ci. ₈ aliphatic group, preferably a Ci _-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an Η(0 _Μ aliphatic residue), an N(Ci _-4 aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN and C(=0)-0H. In a further preferred embodiment of the compound according to general formula (2-I), the residue R ²⁰¹ represents the partial structure (2-T1)

_ _{(C R} 208a _R 208b _)m2 _ _R 208c wherein

m2 denotes 0, 1 , 2, 3 or 4, preferably denotes 0, 1 , or 2,

R ^208a and R ^208b each independently of one another represent H, F, CI, Br, I, N0 ₂ , NH ₂ , a NH(C _M aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an 0-Ci_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _-4 aliphatic residue, CF ₃ , CN, a C _1-4 aliphatic residue or C(=0)-OH, or together denote =0, preferably each independently of one another represent H, F, CI, Br, I, NH ₂ , a NhKC^ aliphatic residue), a N(C _1-4 aliphatic residue) ₂ , OH, O-C^ aliphatic residue or a Ci_ ₄ aliphatic residue,

more preferably each independently of one another represent H, F, CI, Br, I, an O-C^ aliphatic residue or a C^ aliphatic residue,

even more preferably each independently of one another represent H, F, an O-C1.4 aliphatic residue or a C^ aliphatic residue, and denotes a C^ aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S- C _1-4 aliphatic residue, CF ₃ , CN, a C _1- -aliphatic residue and C(=0)-OH, or denotes a C3_i ₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, preferably when m2 is≠ 0, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N C^ aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S- C _1-4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, a C^cycloaliphatic residue and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and

wherein the C^cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF3, SH, SCF ₃ , a S-Ci. ₄ aliphatic residue, CF ₃ , CN, a d. -aliphatic residue and C(=0)- OH, or denotes - preferably when m2 is = 0 - an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C ₃ . ₆ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, , benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the Ci_ ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C ₁ _ aliphatic residue), an N(C^ aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0- CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-C _1- aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)- OH.

represents the partial structure (2-T1 ),

wherein

m2 denotes 0, 1 , or 2,

R ^208a and R ^208b each independently of one another represent H, F, CI, Br, I, an 0-C _1-4 aliphatic residue or a C _1-4 aliphatic residue,

preferably each independently of one another represent H, F, a 0-C _1-2 aliphatic residue or a C _1-2 aliphatic residue, and

R ^208c denotes a aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , a C^-aliphatic residue and C(=0)-OH, or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered

heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , a C^-aliphatic residue, C(=0)-OH, a C^ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O- C _-4 -aliphatic residue, and

wherein the C^e cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , a C^-aliphatic residue and C(=0)-OH, or denotes - preferably when m2 is = 0 - an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-Ci. ₄ aliphatic residue, CF ₃ , CN, a d. ₄ -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C _M cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl or oxazolyl,

wherein the Ci_ ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O- C^-aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O- C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ ,

wherein the C;}. ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , CF ₃ , a C^-aliphatic residue and C(=0)-OH.

More preferably,

R ²⁰¹ represents the partial structure (2-T1),

wherein

m2 denotes 0, 1 , or 2,

,208a

R' and R each independently of one another represent H, F, CI, Br, I, an O-C^ aliphatic residue or a Ci.4 aliphatic residue,

preferably each independently of one another represent H, F, a 0-Ci. ₂ aliphatic residue or a C _1-2 aliphatic residue, and

,208c

R' denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, an 0-C _1-4 aliphatic residue, CF ₃ , and a C ₁ _ ₄ -aliphatic residue,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI,

CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes a C ₃ .i ₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an 0-C _1-4 aliphatic residue, CF ₃ , and a C^-aliphatic residue, wherein the C _lJ( -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, CF ₃ and an unsubstituted O-C^-aliphatic residue, or denotes - preferably when m2 is = 0 - an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-CH ₃ , C(=0)- C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C ₃ . ₆ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl,

wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C^-aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ , and

wherein the C^e cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-d.4 aliphatic residue, OCF ₃ , CF ₃ , a C _1-4 -aliphatic residue and C(=0)-OH.

In a further preferred embodiment of the compound according to general formula (2-I), the residue R ²⁰¹ represents the partial structure (2-T1),

wherein

m2 is 0, 1 or 2 and

R ^208a and R ^208b each independently of one another represent H, F, a O-C^ aliphatic residue or a C _1- aliphatic residue; preferably H, F, CH ₃ or OCH ₃ ;

R ^208c denotes a C^ aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, an unsubstituted 0-C _1-4 aliphatic residue, CF ₃ , and an unsubstituted C _-4 -aliphatic residue,

or denotes a residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted O-C^ aliphatic residue, CF ₃ , and an unsubstituted C _1-4 -aliphatic residue,

or

wherein

m2 is 0,

R ^208a and R ^208b each independently of one another represent H, F, a O-C^ aliphatic residue or a C^ aliphatic residue; preferably H, F, CH ₃ or OCH ₃ ; and

R ^208c denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , CN, a C^-aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ , C(=0)-0-C ₂ H ₅ and phenyl,

wherein phenyl may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , CN, a C^-aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ .

Particularly preferred is a compound according to general formula (2-1) which has the following general formula (2-le):

(2-le).

In a preferred embodiment of the compound according to general formula (2-1), the residue

R ²⁰² represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C^-aliphatic residue, a S-C^-aliphatic residue, a 0-C _1-4 -aliphatic residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C;3.6-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted.

Preferably,

R ²⁰² represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C^-aliphatic residue, a S-C _1-4 -aliphatic residue, a 0-C _1- -aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted 0-Ci. -aliphatic residue,

a C^e-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C _1-4 -aliphatic residue and a O-C^-aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted O-C- -aliphatic residue,

and wherein the C^e-cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, an unsubstituted C _-4 -aliphatic residue and an unsubstituted O- C^-aliphatic residue.

More preferably,

R ²⁰² represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C^-aliphatic residue, a S-C _1-4 -aliphatic residue, a 0-C _1- -aliphatic residue, wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted 0-C _1-4 -aliphatic residue,

cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, morpholinyl, or piperidinyl, preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, an unsubstituted C^-aliphatic residue and an unsubstituted O-C^-aliphatic residue,

and wherein cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, 4- methylpiperazinyl, morpholinyl or piperidinyl may in each case be optionally bridged via an Ci_ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, an unsubstituted C^-aliphatic residue and an unsubstituted O-C^-aliphatic residue. Even more preferably,

R ²⁰² represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec-butyl; tert.-butyl; O-methyl; O-ethyl; 0-(CH ₂ ) ₂ -0-CH ₃ ; 0-(CH ₂ ) ₂ -OH; S-Methyl; S-Ethyl; cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Still more preferably,

R ²⁰² is selected from the group consisting of H; F; CI; CF ₃ ; CN; SCF ₃ ; OCF ₃ ; CH ₃ ; C ₂ H ₅ ; n-propyl; iso- propyl; t-butyl; cyclopropyl; 0-CH ₃ and 0-C ₂ H ₅ ;

In particular,

R ²⁰² is selected from the group consisting of H; F; CI; CF ₃ ; CH ₃ ; C ₂ H ₅ , iso-propyl; cyclopropyl; and O- CH ₃ ;

In a particular preferred embodiment of the compound according to general formula (2-1), the residue R ²⁰² is≠ H.

In a preferred embodiment of the compound according to general formula (2-1), the residues

_R 203 _R 204 _R 205 _{and R} 206 _egch j _ndependent | _{y of one ano} ther represent H; F; CI; Br; I; CN; CF ₃ ;

OCF ₃ ; SCF ₃ ; C(=0)H; C(=0)-OH; C(=0)-NH ₂ ; S(=0) ₂ -OH; N0 ₂ ; a C _1-4 -aliphatic residue, a C(=0)-C ₁ . ₄ aliphatic residue, a C(=0)-0-C ₁ . ₄ aliphatic residue, a C(=0)- NH-C^ aliphatic residue, a C(=0)-N(C _1J( aliphatic residue) ₂ , a O-C^-aliphatic residue, a

4-aliphatic residue, a NH(Ci_4 aliphatic residue), a N(Ci. aliphatic residue) ₂ , a NH- C(=0)-C-|. ₄ aliphatic residue, and a NH-S(=0) ₂ -C ₁ _ ₄ -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of

F, CI, Br, I, =0, OH, and a O-C^-aliphatic residue; a C^e-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C _1-4 -aliphatic residue and a O-C^-aliphatic residue, and in each case optionally bridged via an unsubstituted C _1-4 aliphatic group,

preferably on the condition that at least one of R ²⁰³ , R ²⁰⁴ , R ²⁰⁵ and R ²⁰⁶ is≠ H.

Preferably,

_R 203 _R 204 _R 205 _{and R} 206 _egch j _ndependent | _{y of one} another represent H; F; CI; Br; I; CN; CF ₃ ;

OCF ₃ ; SCF ₃ ; C(=0)H; C(=0)-OH; C(=0)-NH ₂ ; S(=0) ₂ -OH; N0 ₂ ; a d. ₄ -aliphatic residue, a C(=0)-C _1-4 aliphatic residue, a C(=0)-0-C _1- aliphatic residue, a O-C^- aliphatic residue, a 0-C(=0)-C ₁ _ ₄ -aliphatic residue, a S-C^-aliphatic residue, a residue, wherein the C ₁ _ ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and a 0-C-i_ ₄ -aliphatic residue; a C ₃ . _e -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C _1-4 - aliphatic residue and a O-C^-aliphatic residue, and in each case optionally bridged via an unsubstituted C _1-4 aliphatic group,

preferably on the condition that at least one of R ²⁰³ , R ²⁰⁴ , R ²⁰⁵ and R ²⁰⁶ is≠ H.

More preferably,

_R 203 _R 204 _R 205 _{and R} 206 _each j _ndependent | _{y of one ano} ther represent H; F; CI; Br; I; CN; CF ₃ ; OCF ₃ ;

SCF ₃ ; C(=0)H; N0 ₂ ; a C _1-4 -aliphatic residue, a aliphatic residue, a aliphatic residue, a 0-C _1-4 -aliphatic residue, a S-Ci. ₄ -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and a O-C^-aliphatic residue; a C^e- cycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a Ci. ₄ - aliphatic residue and a O-C^-aliphatic residue, and in each case optionally bridged via an unsubstituted C _1-4 aliphatic group,

preferably on the condition that at least one of R ²⁰³ , R ²⁰⁴ , R ²⁰⁵ and R ²⁰⁶ is≠ H. In a further preferred embodiment of the present invention

_R 203 _R 204 _R 205 _anc | R ²⁰⁶ _eacn independently of one another are selected from the group consisting of H;

F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; OCF ₃ ; SCF ₃ ; a (C^-C^ aliphatic residue, a C _1- aliphatic residue, O-C^ aliphatic residue, a S- C _1-4 aliphatic residue, wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of

F, CI, and 0-CH ₃ ;

preferably on the condition that at least one of R ²⁰³ , R ²⁰⁴ , R ²⁰⁵ and R ²⁰⁶ is≠ H. Preferably,

R ²⁰³ , R ²⁰⁴ , R ²⁰⁵ and R ²⁰⁶ each independently of one another are selected from the group consisting of H;

F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; OCF ₃ ; SCF ₃ ; methyl; ethyl; n-propyl; iso-propyl; n- butyl; sec-butyl; tert.-butyl; cyclopropyl; C(=0)-methyl; C(=0)-ethyl; (C=0)- isopropyl; (C=0)-t-butyl; O-methyl; O-ethyl; O-isopropyl; O-t-butyl; 0-(CH ₂ ) ₂ -0-

CH ₃ ; S-Methyl; S-Ethyl;

preferably on the condition that at least one of R ²⁰³ , R ²⁰⁴ , R ²⁰⁵ and R ²⁰⁶ is≠ H. In particular,

R ²⁰³ , R ²⁰⁴ , R ²⁰⁵ and R ²⁰⁶ are each independently of one another are selected from the group

consisting of H; F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; (C=0)-methyl; (C=0)-ethyl; (C=0)- isopropyl; (C=0)-t-butyl; methyl; ethyl; isopropyl; t-butyl; O-methyl; O-Ethyl; O- isopropyl; O-t-butyl; OCF ₃ ; S-methyl; S-ethyl; and SCF ₃ ;

preferably on the condition that at least one of R ²⁰³ , R ²⁰⁴ , R ²⁰⁵ and R ²⁰⁶ is≠ H.

More particularly,

_R 203 _R 204 _R 205 _{and R} 206 _{gre egcn} j _nc | _e p _enc | _en tiy ₀ f one another selected from the group

consisting of H; F; CI; Br; CF ₃ ; CN; OCF ₃ and N0 ₂ ;

preferably on the condition that at least one of R ²⁰³ , R ²⁰⁴ , R ²⁰⁵ and R ²⁰⁶ is≠ H.

Most preferred,

_R 203 _R 204 _{and R} 206 _egch j _nc | _e p _enc | _en t|y ₀ f one another are selected from the group consisting of H and F; and

R ²⁰⁵ denotes F; Br; CF ₃ ; OCF ₃ ; CN; or N0 ₂ .

In a particular preferred embodiment of the compound according to general formula (2-1)

at least one of the residues R ²⁰³ , R ²⁰⁴ , R ²⁰⁵ and R ²⁰⁶ is≠ H. In a preferred embodiment of the compound according to general formula (2-1), the residue

R ²⁰⁷ denotes a C^o-aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(Ci_ ₄ aliphatic residue) ₂ , OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, a C(=0)-0- Ci_4-aliphatic residue, and C(=0)-OH,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C- -aliphatic residue,

or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an H(C!_ ₄ aliphatic residue), an N(C _1- aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a Ci _-4 -aliphatic residue, C(=0)-OH, a C(=0)-0-d_ ₄ -aliphatic residue a C ₃ _ ₆ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NhKC^ aliphatic residue), an N(Ci_ ₄ aliphatic residue) ₂ , OH, =0, an O-C1.4 aliphatic residue, OCF3, SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)-

OH,

and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _-8 aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci. ₄ aliphatic residue), an

N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, OCF3, SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)-0H, on the condition that if R ²⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom.

In a further preferred embodiment of the compound according to general formula (2-I), the residue R ²⁰⁷ denotes a C^o-aliphatic residue, preferably a C _-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, a C(=0)-0- C _-4 -aliphatic residue, CF ₃ , CN, and a C _1- -aliphatic residue

wherein the Ci- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-Ci_ ₄ aliphatic residue, a C(=0)-0-C _1- -aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, a C ₃ . ₆ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI,

Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and

wherein the C ₃ . _e cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, and a C _1-4 - aliphatic residue, and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, preferably a aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-C _-4 aliphatic residue, a

aliphatic residue.

on the condition that if R ²⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom. Preferably,

R ²⁰⁷ denotes a C-|. ₈ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , and a C _1-4 - aliphatic residue

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes a residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a C(=0)-0-

C^-aliphatic residue, a S-C^ aliphatic residue, CF ₃ , and a C^-aliphatic residue,

wherein the Ci_ ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF3, CF ₃ and an unsubstituted O-C^-aliphatic residue, and and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _-8 aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C- aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, a C(=0)-0-C _lJr aliphatic residue, CF ₃ , CN, and a C^-aliphatic residue.

on the condition that if R ²⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom.

More preferably,

R ²⁰⁷ denotes a C^e-aliphatic residue, preferably a C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-d. ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, CF ₃ , a C(=0)-0-C _1-4 - aliphatic residue, and a C _1- -aliphatic residue

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI,

Br, I, OH, CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, or denotes a C ₃ . ₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , SCF ₃ , a S-C _1-4 aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , and a C^-aliphatic residue,

wherein the C-|. ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _-4 -aliphatic residue, and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue is bridged via a C _1-8 aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , CN, and a C _-4 -aliphatic residue.

Even more preferably,

R ²⁰⁷ denotes a C _1-8 -aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 -aliphatic residue, a C(=0)-0-C _1-4 - aliphatic residue, CF ₃ , and a Ci. ₄ -aliphatic residue

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes a C3_i ₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , SCF ₃ , a S-Ci_ ₄ aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , and a C-i_ ₄ -aliphatic residue,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue is in each case bridged via a unsubstituted C _1-8 aliphatic group, preferably an unsubstituted C^ aliphatic group.

Still more preferably,

R ²⁰⁷ denotes a C^e-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 -aliphatic residue, a C(=0)-0-C _lJi -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 - aliphatic residue,

wherein the C^-aliphatic residue in each case is unsubstituted,

or denotes a C ₃ . ₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , SCF ₃ , a S-C^ aliphatic residue, a C(=0)-0-C _1-4 -aliphatic residue, CF ₃ , and a Ci _-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with OH or an unsubstituted O-C^-aliphatic residue,

and wherein the C ₃ . ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue is in each case bridged via a unsubstituted aliphatic group.

In particular,

R ²⁰⁷ denotes a C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^-aliphatic residue, a residue, CF ₃ , and a C - - aliphatic residue,

wherein the C^-aliphatic residue in each case is unsubstituted.

Most preferred,

RR ²⁰⁷ ddeennootteess a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CF ₃ , CI, OH, and O-methyl.

Preferred is also a compound according to general formula (2-1), wherein

R ²⁰¹ represents the partial structure (2-T1 ), -(CR ^208A R ^208B ) _M2 -R ^208C (2-T1 ),

wherein

m2 is 0, 1 or 2 and

R ^208A and R ^208B each independently of one another represent H, F, a O-C^ aliphatic residue or a C-i. aliphatic residue; preferably H, F, CH ₃ or OCH ₃ ;

R ^208C denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted O-C^ aliphatic residue, CF ₃ , and an unsubstituted C _1-4 -aliphatic residue,

or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted O-C^ aliphatic residue, CF ₃ , and an unsubstituted C-i_ ₄ -aliphatic residue,

or

wherein

m2 is 0,

R ^208A and R ^208B each independently of one another represent H, F, a O-C^ aliphatic residue or a

C aliphatic residue; preferably H, F, CH ₃ or OCH ₃ ; and

R ^208C denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ , C(=0)-0-C ₂ H ₅ and phenyl,

wherein phenyl may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ ,

R ²⁰² is selected from the group consisting of H; F; CI; CF ₃ ; CH ₃ ; C ₂ H ₅ , iso-propyl; cyclopropyl; and O- CH ₃ ;

R ²⁰³ , R ²⁰⁴ , R ²⁰⁵ and R ²⁰⁶ are each independently of one another selected from the group

consisting of H; F; CI; Br; CF ₃ ; CN; OCF ₃ and N0 ₂ ;

preferably on the condition that at least one of R ²⁰³ , R ²⁰⁴ , R ²⁰⁵ and R ²⁰⁶ is≠ H, denotes a C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-Ci. ₄ -aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, CF ₃ , and a C _1-4 - aliphatic residue

wherein the C _-4 -aliphatic residue in each case is unsubstituted.

Particularly preferred is also a compound according to general formula (2-I), wherein

R ²⁰¹ represents aryl, preferably phenyl, or heteroaryl, preferably pyridyl or thienyl, in each case

unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCH ₃ , OCF ₃ , CF ₃ , CN, and CH ₃ ,

preferably represents phenyl, unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCH ₃ , OCF ₃ , CF ₃ , CN, and CH ₃ ;

R ²⁰² is selected from the group consisting of H, F, CI, CF ₃ , CH ₃ , C ₂ H ₅ , iso-propyl, cyclopropyl, and O- CH ₃ ; preferably is selected from the group consisting of CH ₃ , C ₂ H ₅ , OCH ₃ and CF ₃ ;

R , R and R are each independently of one another selected from the group consisting of H,

F, CI, Br, CF ₃ , CN, OCF ₃ and N0 ₂ ;

preferably on the condition that at least one of R ²⁰³ , R ²⁰⁴ , R ²⁰⁵ and R ²⁰⁶ is≠ H, more preferably on the condition that R ²⁰⁵ is≠ H; denotes a saturated C ₁ . ₄ -aliphatic residue, unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, 0-CH ₃ , OCF ₃ , SCF ₃ , and CF ₃ .

Another embodiment of the present invention therefore relates to a compound of general formula (I), wherein the compound is selected from a compound according to general formula (3-I),

wherein

R ³⁰¹ represents a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C ₃ _ ₁₀ - cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C^e aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; represents H; F; CI; Br; I; CN; CF ₃ ; C(=0)H; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C^-aliphatic residue, a C(=0)- CM aliphatic residue, a C(=0)-0-C . ₄ aliphatic residue, a C(=0)-NH-C _lJt aliphatic residue, a C(=0)-N(C-4 aliphatic residue) ₂ , wherein the CM aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a 0-C _lJ( -aliphatic residue, a 0-C(=0)-C ₁ ^-aliphatic residue, a

residue, wherein the CM aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a Cs-e-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a CM aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

_R 304 _R 305 _{AND R} 3oe _each j _ndependent | _{y of one} another represent H; F; CI; Br; I; CN; CF ₃ ; C(=0)H; C(=0)-OH; C(=0)-NH ₂ ; SCF ₃ ; S(=0) ₂ -OH; N0 ₂ ; OCF ₃ ; a CM-aliphatic residue, a C(=0)-C _1-4 aliphatic residue, a C(=0)-0-CM aliphatic residue, a C(=0)-NH-C ₁ _ ₄ aliphatic residue, a C(=0)- N(CM aliphatic residue) ₂ , wherein the C aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a O-CM-aliphatic residue, a 0-C(=0)-C _1-4 -aliphatic residue, a S-C ₁ - aliphatic residue, a S(=0) ₂ -C ₁ . ₄ -aliphatic residue, a S(=0) ₂ -0-CM-aliphatic residue, wherein the CM aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a NH(C-|. 4 aliphatic residue), a N(C- ₄ aliphatic residue) ₂ , a NH-C(=0)-CM aliphatic residue, a NH-S(=0) ₂ - CM-aliphatic residue, a N(C- ₄ aliphatic residue)-C(=0)-CM aliphatic residue, or a N(CM aliphatic residue)-S(=0) ₂ -C-4 aliphatic residue, wherein the C aliphatic residue may in each case be unsubstituted or mono- or polysubstituted; a Cs-6-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a CM aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

on the condition that at least one of R ³⁰³ , R ³⁰⁴ , R ³⁰⁵ and R ³⁰⁶ is≠ H, represents a Ci.i ₀ -aliphatic residue, unsubstituted or mono- or polysubstituted; a C ₃ . ₁₀ - cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C^s aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

on the condition that if R ³⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the binding is carried out via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue;

R ³⁰⁸ denotes H or a C^o-aliphatic residue, preferably a Ci_ ₄ -aliphatic residue, unsubstituted or mono- or polysubstituted;

or

R ³⁰⁷ and R ³⁰⁸ form together with the nitrogen atom connecting them a 3 to 10 membered

heterocycloaliphatic residue, preferably a 3 to 6 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted; in which an "aliphatic group" and "aliphatic residue" can in each case be branched or unbranched, saturated or unsaturated, in which a "cycloaliphatic residue" and a "heterocycloaliphatic residue" can in each case be saturated or unsaturated, in which "mono- or polysubstituted" with respect to an "aliphatic group" and an "aliphatic residue" relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an aliphatic residue, a NH-S(=0) ₂ -C ₁ . ₄ aliphatic residue, =0, OH, OCF ₃ , a 0-C _1-4 -aliphatic residue, a Ο-0(=Ο)-0 _1-4 - aliphatic residue, SH, SCF ₃ , a S-C^-aliphatic residue, S(=0) ₂ OH, a S(=0) ₂ -C ₁ ^-aliphatic residue, a residue, CN, CF ₃ , CHO, COOH, a C _1-4 - aliphatic residue, a C(=0)-C _1-4 -aliphatic residue, a C(=0)-0-C _-4 -aliphatic residue, a C ₃ . ₆ -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(=0)-NH ₂ , a C(=0)-NH(C _1-4 aliphatic residue), and a C(=0)-N(C _1-4 aliphatic residue) ₂ ; in which "mono- or polysubstituted" with respect to a "cycloaliphatic residue" and a "heterocycloaliphatic residue" relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(d_ ₄ aliphatic residue) ₂ , a NH-C(=0)-C _1-4 aliphatic residue, a NH-S(=0)2-C _1-4 aliphatic residue, =0, OH, OCF ₃ , a O-C^-aliphatic residue, a O- C(=0)-C _1-4 -aliphatic residue, SH, SCF ₃ , a S-C _1-4 -aliphatic residue, S(=0) ₂ OH, a S(=0) ₂ -C _1-4 -aliphatic residue, a S(=0) ₂ -0-C _1-4 -aliphatic residue, a S(=0) ₂ -NH-G. ₄ -aliphatic residue, CN, CF ₃ , CHO, COOH, a C-i_ ₄ -aliphatic residue, a C(=0)-C ₁ ^-aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, a C ₃ . ₆ - cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(=0)-NH ₂ , a C(=0)-NH(C ₁ . ₄ aliphatic residue), and a C(=0)-N(C _1-i aliphatic residue) ₂ ; in which "mono- or polysubstituted" with respect to "aryl" and a "heteroaryl" relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one -O

> another by at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , , f ^' O) _t -/ _t ^ _{t an} NH(Ci. ₄ aliphatic residue), an N(CL ₄ aliphatic residue) ₂ , an NH-C(=0)-C _1-4 aliphatic residue, an NH-S(=0) ₂ -C ₁ . ₄ aliphatic residue, OH, OCF ₃ , a 0-C _1-4 -aliphatic residue, a 0-C(=0)-C ₁ _ ₄ - aliphatic residue, SH, SCF ₃ , a S-Ci_ ₄ -aliphatic residue, S(=0) ₂ OH, a S(=0) ₂ -C _1- -aliphatic residue, a S(=0) ₂ -0-C ₁ _ ₄ -aliphatic residue, a S(=0) ₂ -NH-d. ₄ -aliphatic residue, CN, CF ₃ , C(=0)H, C(=0)0H, a C^- aliphatic residue, a C(=0)-C ₁ . -aliphatic residue, a C(=0)-0-C _1- -aliphatic residue, a C3. ₆ -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(=0)-NH ₂ , a C(=0)- NFKC^ aliphatic residue), and a C(=0)-N(C _J( aliphatic residue) ₂ .

The compounds according to general formula (3-I) are known from WO 2012/025237 A1 , which is fully included by reference.

Preferred embodiments of the compound according to general formula (3-1) have general formulae (3-la), (3-lb), (3-lc) or (3-ld):

Another preferred embodiment of present invention is a compound according to general formula (I), wherein

R ³⁰ denotes a C _1-10 -aliphatic residue, preferably a C^e-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(Ci_ ₄ aliphatic residue) ₂ , OH, =0, an 0-C _-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 -aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)- OH,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-Ci. -aliphatic residue, or denotes a C ₃ _ ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C ₁ _ ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, a C^ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C-|.. ₄ aliphatic residue), an N C^ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1- aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)- OH,

and wherein the C _M o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C^e aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1J( aliphatic residue), an N(d. ₄ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1- -aliphatic residue and C(=0)-OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_ ₄ aliphatic residue), an N(Ci_ ₄ aliphatic residue) ₂ , OH, an 0-Ci_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0- residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1- -aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C- aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C ₁ _ ₄ -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d. ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-CL4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a C _1-8 aliphatic group, preferably a aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _! _ ₄ aliphatic residue), an N(C _ ₄ aliphatic residue) ₂ , OH, =0, an O-C ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN and C(=0)-OH, R 302 represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; 0CF ₃ ; SCF ₃ ; a C^-aliphatic residue, a S-C _1-4 -aliphatic residue, a 0-C _1-4 -aliphatic residue, wherein the Ci. aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C^e-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C^ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted, preferably represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S-C^-aliphatic residue, a 0-Ci_ -aliphatic residue, wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted O-C^-aliphatic residue; a C _3-e -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C^-aliphatic residue and an 0-Ci. ₄ -aliphatic residue, wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted 0-C _1-4 -aliphatic residue, and wherein the Cs-6-cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, an unsubstituted C^- aliphatic residue and an unsubstituted 0-C _1-4 -aliphatic residue, R*", R- ⁵⁰⁴ , R ³⁰⁵ and R ³⁰⁶ each independently of one another represent H; F; CI; Br; I; CN; CF ₃ ;

OCF ₃ ; SCF ₃ ; C(=0)H; C(=0)-OH; C(=0)-NH ₂ ; S(=0) ₂ -OH; N0 ₂ ; a d. ₄ -aliphatic residue, a C(=0)- aliphatic residue, a residue, a S- C^-aliphatic residue, a S(=0) ₂ -C ₁ _ ₄ -aliphatic residue, a ΝΗ(0^ aliphatic residue), a N(C _-4 aliphatic residue) ₂ , a residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and a O- C _1-4 -aliphatic residue; a Cs-e-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a d. ₄ -aliphatic residue and a 0-Ci. ₄ - aliphatic residue, and in each case optionally bridged via an unsubstituted C-i_ aliphatic group, on the condition that at least one of R ³⁰³ , R ³⁰⁴ , R ³⁰⁵ and R ³⁰⁶ is≠ H, R denotes a C _{1- 0} -aliphatic residue, preferably a C _-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_ ₄ aliphatic residue), an N(C†. ₄ aliphatic residue) ₂ , OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _-4 -aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, a C(=0)-0- C _-4 -aliphatic residue, and C(=0)-OH,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF3, CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue,

or denotes a C ₃ _i ₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, a C(=0)-0-C _1-4 -aliphatic residue a C .6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the C^e cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d. ₄ aliphatic residue), an N C^ aliphatic residue) ₂ , OH, =0, an O-C aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

and wherein the C ₃ . ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C^e aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1J( aliphatic residue), an N(C _lJt aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, a C(=0)-0-C _lJt -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH, on the condition that if R ³⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom ,

and

R ³⁰⁸ denotes H or a C^o-aliphatic residue, preferably a C _1-4 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(d_ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a d_ ₄ -aliphatic residue and C(=0)- OH,

wherein the d_ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted' with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-d_ ₄ -aliphatic residue, R ³⁰⁷ and R ³⁰⁸ form together with the nitrogen atom connecting them a 3 to 10 membered

heterocycloaliphatic residue, preferably a 3 to 6 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an Nh^C^ aliphatic residue), an N(Ci-4 aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C^- aliphatic residue, C(=0)-OH, a C^ cycloaliphatic residue, and a 3 to 6 membered

heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(Ci _-4 aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)- OH.

In a preferred embodiment of the compound according to general formula (3-I), the residue

R ³⁰ denotes a C^o-aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C-|. ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an

residue, OCF ₃ , SH, SCF ₃ , a S-Ci_ ₄ -aliphatic residue, CF ₃ , CN, a Ci_ ₄ -aliphatic residue and C(=0)- OH,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH^.,, aliphatic residue), an N(C- aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, a C ₃ . ₆ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and wherein the C _M cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_ ₄ aliphatic residue), an N^.,, aliphatic residue) ₂ , OH, =0, an 0-C-i_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH, and wherein the C ₃ . ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C-|. ₈ aliphatic group, preferably a Ci_ ₄ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1J( aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C ₁ _ ₄ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)-OH,

or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHfC^ aliphatic residue), an N(Ci_ ₄ aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ ,

C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C ₃ . ₆ cycloali residue, a 3 to 6 membered heterocycloaliphatic residue, >~0 , r ^' O , _ _ benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the Ci. -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH, SCF ₃ , a S-C _M aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C ₁ . ₄ -aliphatic residue and C(=0)- OH,

and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a Ci_ ₈ aliphatic group, preferably a Ci. aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(Ci _-4 aliphatic residue) ₂ , OH, =0, an 0-Ci_ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN and C(=0)-0H.

In a further preferred embodiment of the compound according to general formula (I), the residue

R ³⁰¹ represents the partial structure (3-T1)

wherein

m3 denotes 0, 1 , 2, 3 or 4, preferably denotes 0, 1 , or 2 each independently of one another represent H, F, CI, Br, I, N0 ₂ , NH ₂ , a NH(C _1- aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 aliphatic residue or C(=0)-OH, or together denote =0,

preferably each independently of one another represent H, F, CI, Br, I, NH ₂ , a NH(C-|. ₄ aliphatic residue), a N(Ci_ ₄ aliphatic residue) ₂ , OH, 0-C _1-4 aliphatic residue or a C _1-4 aliphatic residue,

more preferably each independently of one another represent H, F, CI, Br, I, an O-C^ aliphatic residue or a C _1-4 aliphatic residue,

even more preferably each independently of one another represent H, F, an O- Ci_4 aliphatic residue or a C _-4 aliphatic residue, and

denotes a C^ ₄ aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d. ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C- aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^- aliphatic residue and C(=0)-OH,

or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered

heterocycloaliphatic residue, preferably when m is≠ 0, in each case

unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-Ο|_ ₄ aliphatic residue, 0CF ₃ , SH, SCF ₃ , a S-Ci_ ₄ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, a C ₃ . ₆ cycloaliphatic residue and a 3 to 6 membered heterocycloaliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O- C^-aliphatic residue, and

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-Ci_4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1- -aliphatic residue and C(=0)-OH,

or denotes - preferably when m3 is = 0 - an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d. ₄ aliphatic residue), an N(C . ₄ aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C ₃ . ₆ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, ,t _t t ,t , benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O- C^-aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_ ₄ aliphatic residue), an N(d. aliphatic residue) ₂ , OH, an O-C1.4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C ₃ _ ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d^ aliphatic residue), an Ν(Ο aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-Ci.4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH.

Preferably,

R ³⁰¹ represents the partial structure (3-T1),

wherein

m3 denotes 0, 1 , or 2,

R ^308a and R ^308b each independently of one another represent H, F, CI, Br, I, an 0-C _1-4 aliphatic residue or a C _1-4 aliphatic residue,

preferably each independently of one another represent H, F, a 0-C _1-2 aliphatic residue or a C _-2 aliphatic residue, and

R ^308c denotes a Ci_ ₄ aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-Ci.4 aliphatic residue, OCF ₃ , CF ₃ , a C _1-4 -aliphatic residue and C(=0)-OH, or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered

heterocycloaliphatic residue, in each case unsubstituted or mono- or

polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , a C _1-4 -aliphatic residue, C(=0)-OH, a C _M cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O- C^-aliphatic residue, and

wherein the C ₃ . _e cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , a C _1-4 -aliphatic residue and C(=0)-0H,

or denotes - preferably when m3 is = 0 - an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ ,

SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C3-6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl or oxazolyl,

wherein the C - -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O- C _1-4 -aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O- C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI,

CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ ,

wherein the C ₃ . _e cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 aliphatic residue,

OCF ₃ , CF ₃ a d^-aliphatic residue and C(=0)-OH.

More preferably,

R ³⁰¹ represents the partial structure (3-T1),

wherein

m3 denotes 0, 1 , or 2,

R ^308a and R ^308b each independently of one another represent H, F, CI, Br, I, an 0-Ci_ ₄ aliphatic residue or a C _1-4 aliphatic residue,

preferably each independently of one another represent H, F, a O-C^ aliphatic residue or a C _1-2 aliphatic residue, and R ^308c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an 0-C _1-4 aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue,

wherein the C-|. ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of

F, CI, CF ₃ and an unsubstituted O-C^-aliphatic residue, or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an O-C^ aliphatic residue, CF ₃ , and a C^-aliphatic residue,

wherein the Ci _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, or denotes - preferably when m3 is = 0 - an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-Ci_ aliphatic residue, OCF ₃ , CF ₃ , CN, a C _-4 -aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C^e cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl,

wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , CN, a C _-4 -aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ ,

CF ₃ and OCF ₃ , and

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , CF ₃ a C^-aliphatic residue and C(=0)-OH.

In a further preferred embodiment of the compound according to general formula (3-I), the residue R ³⁰¹ represents the partial structure (3-T1),

wherein

m3 is 0, 1 or 2 and

R ^308a and R ^308b each independently of one another represent H, F, a O-C1.4 aliphatic residue or a

C1.4 aliphatic residue; preferably H, F, CH ₃ or OCH ₃ ;

R ^308c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted 0-C _1-4 aliphatic residue, CF ₃ , and an unsubstituted C _1-4 -aliphatic residue, or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted O-C^ aliphatic residue, CF ₃ , and an unsubstituted C- -aliphatic residue,

or

wherein

m3 is 0,

R ,308a

and R each independently of one another represent H, F, a O-C^ aliphatic residue or a C^ aliphatic residue; preferably H, F, CH ₃ or OCH ₃ ; and

R ,308c denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ ,

C(=0)-0-CH ₃ , C(=0)-0-C ₂ H ₅ and phenyl,

wherein phenyl may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ .

Particularly preferred is a compound according to general formula (3-I) which has the following general formula (3-le):

(3-le) In a preferred embodiment of the compound according to general formula (3-I), the residue

R ³⁰² represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S-C _1-4 -aliphatic residue, a O-C^-aliphatic residue, wherein the aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C^e-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted.

Preferably,

R ³⁰² represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S-C ₁ . ₄ -aliphatic residue, a O-C^-aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted 0-C _1-4 -aliphatic residue,

a C ₃ _e-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C _-4 -aliphatic residue and a 0-C _1-4 -aliphatic residue,

wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted O-C^-aliphatic residue,

and wherein the C ₃ . ₆ -cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C- aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, an unsubstituted C^-aliphatic residue and an unsubstituted O- C^-aliphatic residue.

More preferably,

R ³⁰² represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C^-aliphatic residue, a S-C^-aliphatic residue, a 0-C _1-4 -aliphatic residue,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted O-C^-aliphatic residue,

cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, morpholinyl, or piperidinyl, preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, an unsubstituted C^-aliphatic residue and an unsubstituted 0-Ci. ₄ -aliphatic residue,

and wherein cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, 4- methylpiperazinyl, morpholinyl or piperidinyl may in each case be optionally bridged via an C _-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, an unsubstituted C^-aliphatic residue and an unsubstituted 0-Ci_ ₄ -aliphatic residue.

Even more preferably,

R ³⁰² represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec-butyl; tert-butyl; O-methyl; O-ethyl; 0-(CH ₂ ) ₂ -0-CH ₃ ; 0-(CH ₂ ) ₂ -OH; S-Methyl; S-Ethyl;

cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

Still more preferably,

R ³⁰² is selected from the group consisting of H; F; CI; Br; CF ₃ ; CN; SCF ₃ ; 0CF ₃ ; CH ₃ ; C ₂ H ₅ ; n-propyl; iso-propyl; t-butyl; cyclopropyl; 0-CH ₃ and 0-C ₂ H ₅ .

In particular, R ³⁰² is selected from the group consisting of H; F; CI; Br; CF ₃ ; CH ₃ ; C ₂ H ₅ , iso-propyl; cyclopropyl; and

In a particular preferred embodiment of the compound according to general formula (3-1), the residue R ³⁰² is≠ H.

In another preferred embodiment of the compound according to general formula (3-1), the residues

R303 _R 304 _R 305 _{and R} 306 _egch j _ndependent |y _{of one} another represent H; F; CI; Br; I; CN; CF ₃ ;

OCF ₃ ; SCF ₃ ; C(=0)H; C(=0)-OH; C(=0)-NH ₂ ; S(=0) ₂ -OH; N0 ₂ ; a C _1-4 -aliphatic residue, a C(=0)- C1.4 aliphatic residue, a C(=0)-0-C ₁ . ₄ aliphatic residue, a C(=0)-NH-C _1J( aliphatic residue, a C(=0)-N(C _1J( aliphatic residue) ₂ , a 0-C _1- -aliphatic residue, a 0-C(=0)-C ₁ . ₄ -aliphatic residue, a S- C _1-4 -aliphatic residue, a S(=0) ₂ -C ₁ . ₄ -aliphatic residue, a NH(C _1- aliphatic residue), a N(d_ ₄ aliphatic residue) ₂ , a NH-C(=0)-C-|. ₄ aliphatic residue, and a NH-S(=0) ₂ -C ₁ . ₄ -aliphatic residue, wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and a O- C _1-4 -aliphatic residue; a C ₃ . ₆ -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C _1-4 -aliphatic residue and a 0-C _1- - aliphatic residue, and in each case optionally bridged via an unsubstituted C^ aliphatic group, on the condition that at least one of R ³⁰³ , R ³⁰⁴ , R ³⁰⁵ and R ³⁰⁶ is≠ H.

Preferably,

_R 303 _R 304 _R 305 _{gnd R} 306 _egch j _ndependent | _{y of one} another represent H; F; CI; Br; I; CN; CF ₃ ;

OCF ₃ ; SCF ₃ ; C(=0)H; C(=0)-OH; C(=0)-NH ₂ ; S(=0) ₂ -OH; N0 ₂ ; a C _1-4 -aliphatic residue, a C(=0)- C _1- aliphatic residue, a C(=0)-0-C _1-4 aliphatic residue, a 0-C ₁ _ ₄ -aliphatic residue, a 0-C(=0)-C _1- - aliphatic residue, a S-Ci. -aliphatic residue, a S(=0) ₂ -C _1- -aliphatic residue, wherein the C^- aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and a 0-Ci_ ₄ -aliphatic residue; a C ₃ _ ₆ -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C^-aliphatic residue and a O-C^-aliphatic residue, and in each case optionally bridged via an unsubstituted C _1-4 aliphatic group,

on the condition that at least one of R ³⁰³ , R ³⁰⁴ , R ³⁰⁵ and R ³⁰⁶ is≠ H. More preferably,

_R 303 _R 304 _R 305 _{gnd R} 306 _egch j _ndependent | _{y of one} another represent H; F; CI; Br; I; CN; CF ₃ ;

OCF ₃ ; SCF ₃ ; C(=0)H; N0 ₂ ; a C^-aliphatic residue, a C(=0)-C _1-4 aliphatic residue, a C^OJ-O-C _! . 4 aliphatic residue, a O-C^-aliphatic residue, a S-C^-aliphatic residue, wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and a O-C^-aliphatic residue; a C _3-6 -cycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a Ci _-4 -aliphatic residue and a O-C^-aliphatic residue, and in each case optionally bridged via an unsubstituted C _1-4 aliphatic group,

on the condition that at least one of R ³⁰³ , R ³⁰⁴ , R ³⁰⁵ and R ³⁰⁶ is≠ H. In a further preferred embodiment of the present invention

_R 303 _R 304 _R 305 _{gnd R} 306 _egcn independently ₀ f one another are selected from the group

consisting of H; F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; OCF ₃ ; SCF ₃ ; a (C=0)-C _1-4 aliphatic residue, a C _1- - aliphatic residue, O-C^ aliphatic residue, a S- C _1-4 aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, and 0-CH ₃ ;

on the condition that at least one of R ³⁰³ , R ³⁰⁴ , R ³⁰⁵ and R ³⁰⁶ is≠ H.

Preferably,

_R 303 _R 304 _R 305 _{gnd R} 306 _egcn independently _{0 one} another are selected from the group

consisting of H; F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; OCF ₃ ; SCF ₃ ; methyl; ethyl; n-propyl; iso-propyl; n- butyl; sec-butyl; tert.-butyl; cyclopropyl; C(=0)-methyl; C(=0)-ethyl; (C=0)-isopropyl; (C=0)-t- butyl; O-methyl; O-ethyl; O-isopropyl; O-t-butyl; 0-(CH ₂ ) ₂ -0-CH ₃ ; S-Methyl; S-Ethyl;

on the condition that at least one of R ³⁰³ , R ³⁰⁴ , R ³⁰⁵ and R ³⁰⁶ is≠ H.

In particular,

_R 303 _R 304 _R 305 _{and R} 306 _{gre egcn} independently of one another are selected from the group

consisting of H; F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; (C=0)-methyl; (C=0)-ethyl; (C=0)-isopropyl; (C=0)-t- butyl; methyl; ethyl; isopropyl; t-butyl; O-methyl; O-Ethyl; O-isopropyl; O-t-butyl; OCF ₃ ; S-methyl; S-ethyl; and SCF ₃ ;

on the condition that at least one of R ³⁰³ , R ³⁰⁴ , R ³⁰⁵ and R ³⁰⁶ is≠ H. More particularly,

_R 303 _R 30 _R 305 _{and R} 306 _{gre egcn} j _nc | _e p _enc |ently of one another selected from the group

consisting of H; F; CI; Br; CF ₃ ; CN; OCF ₃ and N0 ₂ ;

on the condition that at least one of R ³⁰³ , R ³⁰⁴ , R ³⁰⁵ and R ³⁰⁶ is≠ H.

Most preferred,

_R 303 _R 304 _{and R} 306 _egcn independently of one another represent H or F; and

R ³⁰⁵ denotes F; CF ₃ ; OCF ₃ ; CN; or N0 ₂ .

In a preferred embodiment of the compound according to general formula (3-I), the residue

R ³⁰⁷ denotes a C^o-aliphatic residue, preferably a C e-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an Nh^C^ aliphatic residue), an N(C-|. ₄ aliphatic residue) ₂ , OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-Ci _-4 -aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, a C(=0)-0- residue, and C(=0) OH, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue,

or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C-|_ ₄ aliphatic residue), an N(d. ₄ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, a C(=0)-0-C ₁ _ ₄ -aliphatic residue a C ₃ . ₆ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF3, CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the C _3-6 cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an N^C^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF3, SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)- OH,

and wherein the C ₃ . ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C^e aliphatic group, preferably a C _-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an aliphatic residue), an N C^ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, a C(=0)-0-C _1- -aliphatic residue, OCF3, SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)-OH, on the condition that if R ³⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom.

and

R ³⁰⁸ denotes H or a C^o-aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _J( aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue,

or

R ³⁰⁷ and R ³⁰⁸ form together with the nitrogen atom connecting them a 3 to 10 membered

heterocycloaliphatic residue, preferably a 3 to 6 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C^ ₄ aliphatic residue) ₂ ,

OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C- aliphatic residue, CF ₃ , CN, a C^- aliphatic residue, C(=0)-OH, a cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1- aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _-4 -aliphatic residue and C(=0)-OH.

In a further preferred embodiment of the compound according to general formula (3-1), the residue R ³⁰⁷ denotes a C^o-aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I,

N0 ₂ , OH, =0, an 0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 -aliphatic residue, a C(=0)-0- C^-aliphatic residue, CF ₃ , CN, and a C^-aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1- -aliphatic residue,

or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, a C(=0)-0-C _1- -aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, a C ₃ . ₆ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, and a C _1-4 - aliphatic residue,

and wherein the C ₃ . ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C^ aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-C _1-4 aliphatic residue, a C(=0)-0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, and a C _-4 - aliphatic residue,

on the condition that if R ³⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,

and R ³⁰⁸ denotes H or a C _1-10 -aliphatic residue, preferably a C _1-e -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, and a C ^aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue,

or

R ³⁰⁷ and R ³⁰⁸ form together with the nitrogen atom connecting them a 3 to 10 membered

heterocycloaliphatic residue, preferably a 3 to 6 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1- aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, a C^ecycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the d^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the C ₃ _ ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, and a C _1-4 - aliphatic residue.

Preferably,

R ³⁰⁷ denotes a C _1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 -aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , and a C- - aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or.

polysubstituted with at least one substituent selected from the group consisting of F, CI,

Br, I, OH, CF ₃ and an unsubstituted 0-Ci. ₄ -aliphatic residue,

or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a C(=0)-0- C _1-4 -aliphatic residue, a S-C^ aliphatic residue, CF ₃ , and a C _-4 -aliphatic residue,

wherein the residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and and wherein the C ₃ . ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a Ci _-8 aliphatic group, preferably a C^ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C- aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , CN, and a C ₁ _ ₄ -aliphatic residue,

on the condition that if R ³⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,

and

R ³⁰⁸ denotes H or a Ci_ ₁₀ -aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, and a C _1- -aliphatic residue,

wherein the C- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted O-C^-aliphatic residue,

or

R ³⁰⁷ and R ³⁰⁸ form together with the nitrogen atom connecting them a 3 to 10 membered

heterocycloaliphatic residue, preferably a 3 to 6 membered heterocycloaliphatic residue, more preferably selected from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl and piperazinyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted O-C^-aliphatic residue.

More preferably,

R ³⁰⁷ denotes a C _1-8 -aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, CF ₃ , a C(=0)-0-d. ₄ - aliphatic residue, and a C _1-4 -aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted 0-Ci_ ₄ -aliphatic residue,

or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S-C^ aliphatic residue, a C(=0)-0-C _lJ4 -aliphatic residue, CF ₃ , and a C^-aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue is in each case bridged via a C^e aliphatic group, preferably a C^ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , CN, and a C _-4 -aliphatic residue,

and

R ³⁰⁸ denotes H or a C^-aliphatic residue, preferably a C _1-4 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, and a C^-aliphatic residue,

wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted O-C^-aliphatic residue,

or

and R ³⁰⁸ form together with the nitrogen atom connecting them a 3 to 6 membered

heterocycloaliphatic residue, preferably selected from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl and piperazinyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-Ci_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, and a C^-aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted O-C^-aliphatic residue.

Even more preferably,

R ³⁰⁷ denotes a C _-8 -aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, a C(=0)-0-C ₁ . ₄ - aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue,

wherein the C- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes a C ₃ _i ₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , SCF ₃ , a S-C^ aliphatic residue, a residue, CF ₃ , and a C _-4 -aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the C _3- i ₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue is in each case bridged via a unsubstituted C _1-8 aliphatic group, preferably an unsubstituted C _1-4 aliphatic group,

and R ³⁰⁸ denotes H or an unsubstituted C _1- -aliphatic residue, preferably selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl and tert.-butyl, more preferably selected from the group consisting of methyl and ethyl

or

307 308

R and R form together with the nitrogen atom connecting them a 3 to 6 membered

heterocycloaliphatic residue, preferably selected from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl, and azetidinyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-C _1- aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, and a C^-aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted O-C^-aliphatic residue.

Still more preferably,

R ³⁰⁷ denotes a C-i_ ₆ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^-aliphatic residue, a C(=0)-0-C ₁ . -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, CF ₃ , and a C _1-4 - aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case is unsubstituted,

or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-Ci_ ₄ aliphatic residue, OCF ₃ , SCF ₃ , a S-C _1-4 aliphatic residue, a C(=0)-0-C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with OH or an unsubstituted 0-C _1-4 -aliphatic residue.

and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue is in each case bridged via a unsubstituted Ci_ ₄ aliphatic group,

R ³⁰⁸ denotes H or an unsubstituted C^-aliphatic residue, preferably H, methyl, ethyl, n-propyl, 2- propyl, n-butyl, isobutyl, sec-butyl or tert.-butyl,

or

307 308

R and R form together with the nitrogen atom connecting them a morpholinyl, piperidinyl,

pyrrolidinyl, or azetidinyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, and a C _1-4 -aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with OH or an unsubstituted residue.

Most preferred,

R ³⁰⁷ denotes a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, and O-methyl, preferably unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, and O-methyl, more preferably unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F and O-methyl,

R ³⁰⁸ denotes H, methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl or tert.-butyl, preferably methyl or ethyl,

or

R ³⁰⁷ and R ³⁰⁸ form together with the nitrogen atom connecting them a morpholinyl, piperidinyl,

pyrrolidinyl, or azetidinyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _1-4 aliphatic residue, and a C _1-4 -aliphatic residue, more preferably unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI and a 0-Ci_ aliphatic residue, preferably O-methyl.

Particularly preferred is also a compound according to general formula (I), wherein

represents the partial structure (3-T1),

_ _(CR 308a _R 308b _)m ^ _R 308c ₍₃ . _{T1 }} wherein

m3 is 0, 1 or 2 and

R ^308a and R ^308b each independently of one another represent H, F, a 0-C _1-4 aliphatic residue or a C _1-4 aliphatic residue; preferably H, F, CH ₃ or OCH ₃ ;

R ^308c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted O-C^ aliphatic residue, CF ₃ , and an unsubstituted C _1-4 -aliphatic residue,

or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted O-C^ aliphatic residue, CF ₃ , and an unsubstituted C _1-4 -aliphatic residue,

or

wherein

m3 is 0,

R ^308a and R ^308b each independently of one another represent H, F, a O-C^ aliphatic residue or a

C^ aliphatic residue; preferably H, F, CH ₃ or OCH ₃ ; and

R ^308c denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _1- aliphatic residue, OCF ₃ , CF ₃ , CN, a C^-aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ ,

C(=0)-0-CH ₃ , C(=0)-0-C ₂ H ₅ and phenyl,

wherein phenyl may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and

C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ , R is selected from the group consisting of H; F; CI; CF ₃ ; CH ₃ ; C ₂ H ₅ , iso-propyl; cyclopropyl; and O- CH ₃ , R ³⁰³ , R ³⁰⁴ , R ³⁰⁵ and R ³⁰⁶ are each independently of one another selected from the group

consisting of H; F; CI; CF ₃ ; CN; OCF ₃ and N0 ₂ ;

on the condition that at least one of R ³⁰³ , R ³⁰⁴ , R ³⁰⁵ and R ³⁰⁶ is≠ H,

R ³⁰⁷ denotes a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, and O-methyl, preferably unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, and O-methyl, more preferably unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F and O-methyl,

R ³⁰⁸ denotes H, methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl or tert.-butyl, preferably methyl or ethyl,

or

form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, and a C^-aliphatic residue, more preferably unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI and a 0-C _1-4 aliphatic residue, preferably O-methyl.

Another embodiment of the present invention therefore relates to a compound of general formula (I), wherein the compound is selected from a compound according to general formula (4-I),

wherein

R ⁴⁰¹ represents a C^o-aliphatic residue, unsubstituted or mono- or polysubstituted; a C^o- cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C^e aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C^e aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted, R ⁴⁰² represents H; F; CI; Br; I; CN; CF ₃ ; C(=0)H; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C^-aliphatic residue, a C(=0)- C^ aliphatic residue, a C(=0)-0-C ₁ . ₄ aliphatic residue, a C(=0)-NH-C _M aliphatic residue, a aliphatic residue) ₂ , wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a 0-C _1- -aliphatic residue, a 0-C(=0)-C ₁ . ₄ -aliphatic residue, a S-Ci. ₄ -aliphatic residue, a S(=0) ₂ -C _lJ »-aliphatic residue, a

residue, wherein the aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C ₃ . ₆ -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a Ci_4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted,

_R 403 _R 404 _R 405 _{AND R} 406 _EGCH j _ndependent | _{y of one ano} ther represent H; F; CI; Br; I; CN; CF ₃ ; C(=0)H;

C(=0)-OH; C(=0)-NH ₂ ; SCF ₃ ; S(=0) ₂ -OH; N0 ₂ ; OCF ₃ ; a

aliphatic residue, a aliphatic residue, a C(=0)- N(C _1-4 aliphatic residue) ₂ , wherein the C _1- aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a 0-C _1-4 -aliphatic residue, a 0-C(=0)-C _lJ( -aliphatic residue, a S-Ci_ ₄ - aliphatic residue, a S(=0) ₂ -C ₁ _ ₄ -aliphatic residue, a S(=0) ₂ -0-C ₁ . -aliphatic residue, wherein the C^ aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a NH(Ci_ 4 aliphatic residue), a N(C _1-4 aliphatic residue) ₂ , a ΝΗ-ΰ(=0)-ΰ _1- aliphatic residue, a NH-S(=0) ₂ - Ci_ ₄ -aliphatic residue, a N(C _1-4 aliphatic residue)-C(=0)-C ₁ - ₄ aliphatic residue, or a N(C-,. ₄ aliphatic aliphatic residue, wherein the C- aliphatic residue may in each case be unsubstituted or mono- or polysubstituted; a Cs-6-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

on the condition that at least one of R ⁴⁰³ , R ⁴⁰⁴ , R ⁴⁰⁵ and R ⁴⁰⁶ is≠ H,

R ⁴⁰⁷ represents a C ₂ . ₁₀ -aliphatic residue, unsubstituted or mono- or polysubstituted; a C^o- cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

on the condition that if R ⁴⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the binding is carried out via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue, in which an "aliphatic group" and "aliphatic residue" can in each case be branched or unbranched, saturated or unsaturated, in which a "cycloaliphatic residue" and a "heterocycloaliphatic residue" can in each case be saturated or unsaturated, in which "mono- or polysubstituted" with respect to an "aliphatic group" and an "aliphatic residue" relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N C^ aliphatic residue) ₂ , a NH-C(=0)-C _1-4 aliphatic residue, a NH-S(=0) ₂ -C ₁ . ₄ aliphatic residue, =0, OH, OCF ₃ , a 0-C _1-4 -aliphatic residue, a 0-C(=0)-C ₁ _ ₄ - aliphatic residue, SH, SCF ₃ , a S-C^-aliphatic residue, S(=0) ₂ OH, a S(=0) ₂ -C _1-4 -aliphatic residue, a S(=0) ₂ -0-d. ₄ -aliphatic residue, a S(=0) ₂ -NH-C ₁ . ₄ -aliphatic residue, CN, CF ₃ , CHO, COOH, a C _1- - aliphatic residue, a C(=0)-C ₁ . ₄ -aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, a C ₃ . ₆ -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(=0)-NH ₂ , a C(=0)-NH(C ₁ . ₄ aliphatic residue), and a C(=0)-N(C ₁ . aliphatic residue) ₂ ; in which "mono- or polysubstituted" with respect to a "cycloaliphatic residue" and a "heterocycloaliphatic residue" relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _lJt aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , a NH-C(=0)-C _1-4 aliphatic residue, a NH-S(=0) ₂ -C ₁ . ₄ aliphatic residue, =0, OH, OCF ₃ , a O-C^-aliphatic residue, a O- C(=0)-C ₁ ^-aliphatic residue, SH, SCF ₃ , a S-C^-aliphatic residue, S(=0) ₂ OH, a S(=0) ₂ -C ₁ ^ _t -aliphatic residue, a S(=0) ₂ -0-C ₁ ^-aliphatic residue, a S(=0) ₂ -NH-C ₁ . ₄ -aliphatic residue, CN, CF ₃ , CHO, COOH, a C _1-4 -aliphatic residue, a C(=0)-C ₁ . ₄ -aliphatic residue, a C(=0)-0-C ₁ _ ₄ -aliphatic residue, a C ₃ . ₆ - cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(=0)-NH ₂ , a C(=0)-NH(C ₁ _ aliphatic residue), and a C(=0)-N(C _1-4 aliphatic residue) ₂ ; in which "mono- or polysubstituted" with respect to "aryl" and a "heteroaryl" relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ ,

?Ό _t > _t f ^¾ ^ ⁰ Ί _t an NHCC^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , an NH-C(=0)-C _1-4 aliphatic residue, OH, OCF ₃ , a 0-d. ₄ -aliphatic residue, a 0-C(=0)-C _1-4 -aliphatic residue, SH, SCF ₃ , a S-C _1-4 - aliphatic residue, S(=0) ₂ OH, a S(=0) ₂ -C ₁ ^-aliphatic residue, a S(=0) ₂ -0-C _lJi -aliphatic residue, a S(=0) ₂ -

residue, a C(=0)-0-C _-4 -aliphatic residue, a C^-cycloaliphatic residue, a 3 to 6 membered

heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(=0)-NH ₂ , a C(=0)-NH(C ₁ . ₄ aliphatic residue), and a C(=0)-N(C ₁ . ₄ aliphatic residue) ₂ .

The compounds according to general formula (4-I) are known from WO 2012/205238 A1 , which is fully included by reference.

Preferred embodiments of the compound according to general formula (I) have general formulae (4-la), (4-lb), (4-lc) or (4-ld),

(4-la) (4-lb)

(4-lc) (4-ld)

Another preferred embodiment of present invention is a compound according to general formula (4-1), wherein

R ⁴⁰¹ denotes a C _1-10 -aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(d. aliphatic residue) ₂ , OH, =0, an 0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, CF ₃ , CN, a C _-4 -aliphatic residue and C(=0)- OH,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted residue,

or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-d^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-d. aliphatic residue, CF ₃ , CN, a Ci _-4 -aliphatic residue, C(=0)-OH, a C ₃ . ₆ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C - -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF3, CF ₃ and an unsubstituted residue, and wherein the C^ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d_ ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-d_ aliphatic residue, OCF3, SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

and wherein the C ₃ _ ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, preferably a d-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d_ ₄ aliphatic residue), an N(d. ₄ aliphatic residue) ₂ , OH, =0, an 0-d. ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C|_ ₄ aliphatic residue, CF ₃ , CN, a d_ ₄ -aliphatic residue and C(=0)-OH,

or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an 0-Ci- ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-Ci aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0- residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1- aliphatic residue), an N(C _-4 aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a C _1-8 aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _! _ ₄ aliphatic residue) ₂ , OH, =0, an 0-C ₁ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN and C(=0)-0H, represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S-C^-aliphatic residue, a O-C^-aliphatic residue, wherein the C _-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C^-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted, preferably represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S-C _1-4 -aliphatic residue, a 0-C _1-4 -aliphatic residue, wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted O-C^-aliphatic residue; a C ₃ _ ₆ -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C^-aliphatic residue and an 0-C _1-4 -aliphatic residue, wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted 0-Ci_ ₄ -aliphatic residue, and wherein the C _ ₆ -cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, an unsubstituted C _1-4 - aliphatic residue and an unsubstituted O-C^-aliphatic residue,

_R 403 _R 404 _R 405 _{GND R} 406 _egch j _ndependent | _{y of one ano} ther represent H; F; CI; Br; I; CN; CF ₃ ;

OCF ₃ ; SCF ₃ ; C(=0)H; C(=0)-OH; C(=0)-NH ₂ ; S(=0) ₂ -OH; N0 ₂ ; a C _1-4 -aliphatic residue, a C(=0)- Ci_ ₄ aliphatic residue, a C(=0)-0-C ₁ . ₄ aliphatic residue, a C(=0)-NH-C ₁ . ₄ aliphatic residue, a C(=0)-N(C _J( aliphatic residue) ₂ , a O-C^-aliphatic residue, a 0-C(=0)-C _Jt -aliphatic residue, a S- C . ₄ -aliphatic residue, a S(=0) ₂ -C _1-4 -aliphatic residue, a NH^ ^ aliphatic residue), a N(Ci aliphatic residue) ₂ , a NH-C(=0)-C ₁ . ₄ aliphatic residue, and a NH-S(=0) ₂ -C ₁ . ₄ -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and a O- C^-aliphatic residue; a C ₃ _ ₆ -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a d. ₄ -aliphatic residue and a 0-C _1-4 - aliphatic residue, and in each case optionally bridged via an unsubstituted C _-4 aliphatic group, on the condition that at least one of R ⁴⁰³ , R ⁴⁰⁴ , R ⁴⁰⁵ and R ⁴⁰⁶ is≠ H,

R ⁴⁰⁷ denotes a C ₂ . ₁₀ -aliphatic residue, preferably a C ₂ . ₈ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH^.,, aliphatic residue), an NKC^ aliphatic residue) ₂ , OH, =0, an 0-C _1- -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)- OH,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted residue,

or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C^ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, and C(=0)-OH,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a Ci_ ₈ aliphatic group, preferably a Ci _-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C-|. ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-CL ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH,

on the condition that if R ⁴⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom. In a preferred embodiment of the compound according to general formula (4-1), the residue

R ⁴⁰¹ denotes a C _1-10 -aliphatic residue, preferably a Ci_ ₈ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1- aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, CF ₃ , CN, a C _-4 -aliphatic residue and C(=0)- OH,

wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue,

or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C _lJt aliphatic residue) ₂ , OH, =0, an 0-C,. ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-d_ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, a C ₃ . _e cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)- OH,

and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _-8 aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an ΝΗ(0^ aliphatic residue), an Ν(0^ aliphatic residue) ₂ , OH, =0, an 0-d_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-d^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)-OH,

or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_ ₄ aliphatic residue), an N(d. ₄ aliphatic residue) ₂ , OH, an 0-Ci_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-Ci_ ₄ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C ₃ . ₆ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, , benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the d_ ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-d^-aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an Nh^C^ aliphatic residue), an N(C _-4 aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ ,

C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C^ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue,

OCF ₃ , SH, SCF ₃ , a S-C _M aliphatic residue, CF ₃ , CN, a Ci _-4 -aliphatic residue and C(=0)- OH,

and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a C^e aliphatic group, preferably a C^ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I,

N0 ₂ , NH ₂ , an ΝΗ(0^ aliphatic residue), an N(C^ ₄ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN and C(=0)-OH.

In a further preferred embodiment of the compound according to general formula (4-1), the residue R ⁴⁰¹ represents the partial structure (4-T1 )

_ _{(C R} 408a _R 408b _)m4 _ _R 408c wherein

m4 denotes 0, 1 , 2, 3 or 4, preferably denotes 0, 1 , or 2,

R ^408a and R ^408b each independently of one another represent H, F, CI, Br, I, N0 ₂ , NH ₂ , a NH(C^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C- aliphatic residue, CF ₃ , CN, a C^ aliphatic residue or C(=0)-OH, or together denote =0, preferably each independently of one another represent H, F, CI, Br, I, NH ₂ , a ΝΗ(0^ aliphatic residue), a N(C _1J( aliphatic residue) ₂ , OH, 0-C _1-4 aliphatic residue or a C _1j( aliphatic residue, more preferably each independently of one another represent H, F, CI, Br, I, an O-C1.4 aliphatic residue or a Ci_ ₄ aliphatic residue,

even more preferably each independently of one another represent H, F, an 0-C _1-4 aliphatic residue or a C _1-4 aliphatic residue, and R ^408c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an ΝΗ(0^ aliphatic residue), an N(C!. ₄ aliphatic residue) ₂ , OH, =0, an 0-C-i_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S- Ci. ₄ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH,

or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, preferably when m4 is≠ 0, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C!. ₄ aliphatic residue) ₂ , OH, =0, an O-C- aliphatic residue, OCF ₃ , SH, SCF ₃ , a S- residue, C(=0)-OH, a C ₃ . ₆ cycloaliphatic residue and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-d. ₄ -aliphatic residue, and wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(Ci. _A aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF3, SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

or denotes - preferably when m is = 0 - an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an 0-C-,. aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _M aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C ₃ _ ₆ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, ?~0 _{t t t} benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1J( aliphatic residue), an N(C _1J( aliphatic residue) ₂ , OH, an aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0- CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-C-i_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)- OH. Preferably,

R ⁴⁰ represents the partial structure (4-T1 ),

wherein

m4 denotes 0, 1 , or 2,

R ^408a and R ^408b each independently of one another represent H, F, CI, Br, I, an 0-d_ ₄ aliphatic residue or a C _1-4 aliphatic residue, preferably each independently of one another represent H, F, a 0-Ci_ ₂ aliphatic residue or a C _1-2 aliphatic residue, and

R ^408c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , a C^-aliphatic residue and C(=0)-OH,

or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , a C1-4- aliphatic residue, C(=0)-OH, a C^ cycloaliphatic residue, and a 3 to 6 membered

heterocycloaliphatic residue,

wherein the Ci_ ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF3, CF ₃ and an unsubstituted O-C- -aliphatic residue, and wherein the C^ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , a C _1-4 -aliphatic residue and C(=0)-OH,

or denotes - preferably when m4 is = 0 - an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C4 aliphatic residue, CF ₃ , CN, a C ₁ -4- aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C ₃ . ₆ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl or oxazolyl,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI,

Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1- -aliphatic residue, C(=0)-OH,

C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ , wherein the C ₃ _ ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _-4 aliphatic residue, OCF ₃ , CF ₃ a C _1-4 -aliphatic residue and C(=0)-OH.

More preferably,

R ⁴⁰¹ represents the partial structure (4-T1),

wherein

m4 denotes 0, 1 , or 2, R ^408a and R ^408b each independently of one another represent H, F, CI, Br, I, an 0-C _1- aliphatic residue or a C . ₄ aliphatic residue,

preferably each independently of one another represent H, F, a O-C^ aliphatic residue or a C _1-2 aliphatic residue, and

R ^408c denotes a C _1- aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, an O-C^ aliphatic residue, CF ₃ , and a C^-aliphatic residue,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue,

or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an 0-C _1-4 aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI,

CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes - preferably when m4 is = 0 - an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-CH ₃ , C(=0)- C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C^ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl,

wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ , and

wherein the C^e cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-Ci_ ₄ aliphatic residue, OCF ₃ , CF ₃ a C _1-4 -aliphatic residue and C(=0)-OH.

In a further preferred embodiment of the compound according to general formula (4-I), the residue R ⁴⁰¹ represents the partial structure (4-T1),

wherein

m4 is 0, 1 or 2 and

R ^408a and R ^408b each independently of one another represent H, F, a 0-C-|. ₄ aliphatic residue or a C _1-4 aliphatic residue; preferably H, F, CH ₃ or OCH ₃ ;

R ^408c denotes a C^ aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, an unsubstituted O-C^ aliphatic residue, CF ₃ , and an unsubstituted Ci. ₄ -aliphatic residue, or denotes a C ₃ „ ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted O-C^ aliphatic residue, CF ₃ , and an unsubstituted C^-aliphatic residue,

or

wherein

m4 is 0,

R ^408a and R ^408b each independently of one another represent H, F, a O-C- aliphatic residue or a

aliphatic residue; preferably H, F, CH ₃ or OCH ₃ ; and

R ^408c denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , CN, a C^-aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ , C(=0)-0-C ₂ H ₅ and phenyl,

wherein phenyl may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the, group consisting of F, CI, Br, I, OH, an 0-C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C- - aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ .

Particularly preferred is a compound according to general formula (4-I) which has the following general formula (4-le),

In a preferred embodiment of the compound according to general formula (4-I), the residue

R ⁴⁰² represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C^-aliphatic residue, a S-d. ₄ -aliphatic residue, a O-C^-aliphatic residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C3. ₆ -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted.

Preferably,

R ⁴⁰² represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S-C^-aliphatic residue, a O-C^-aliphatic residue,

wherein the C - -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted O-C^-aliphatic residue, a C3.6-cycloaliphat.ic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C^-aliphatic residue and a O-C^-aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted O-C- -aliphatic residue,

and wherein the C3. ₆ -cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C- aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, an unsubstituted C _1-4 -aliphatic residue and an unsubstituted O- Ci_4-aliphatic residue.

More preferably,

R ⁴⁰² represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a d. ₄ -aliphatic residue, a S-C _1-4 -aliphatic residue, a O-C^-aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted O-C^-aliphatic residue,

cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, morpholinyl, or piperidinyl, preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, an unsubstituted C^-aliphatic residue and an unsubstituted O-C^-aliphatic residue,

and wherein cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, 4- methylpiperazinyl, morpholinyl or piperidinyl may in each case be optionally bridged via an CM aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, an unsubstituted C _1- -aliphatic residue and an unsubstituted O-C^-aliphatic residue.

Even more preferably,

R ⁴⁰² represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec-butyl; tert.-butyl; O-methyl; O-ethyl; 0-(CH ₂ ) ₂ -0-CH ₃ ; 0-(CH ₂ ) ₂ -OH; S-Methyl; S-Ethyl; cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

Still more preferably,

R ⁴⁰² is selected from the group consisting of H; F; CI; CF ₃ ; CN; SCF ₃ ; OCF ₃ ; CH ₃ ; C ₂ H ₅ ; n-propyl; iso- propyl; t-butyl; cyclopropyl; 0-CH ₃ and 0-C ₂ H ₅ .

In particular,

R ⁴⁰² is selected from the group consisting of H; F; CI; CF ₃ ; CH ₃ ; C ₂ H ₅ , iso-propyl; cyclopropyl; and O- CH ₃ ; preferably selected from the group consisting of H; F; CI; CF ₃ ; CH ₃ ; and 0-CH ₃ . In a particular preferred embodiment of the compound according to general formula (4-1), the residue R ⁴⁰² is≠ H.

In a preferred embodiment of the compound according to general formula (4-1), the residues

_R 403 _R 404 _R 405 _{and R} 406 _egch j _ndepenc j _ent | _{y of one} another represent H; F; CI; Br; I; CN; CF ₃ ;

OCF ₃ ; SCF ₃ ; C(=0)H; C(=0)-OH; C(=0)-NH ₂ ; S(=0) ₂ -OH; N0 ₂ ; a C^-aliphatic residue, a C(=0)- C _1-4 aliphatic residue, a C(=0)-0-C ₁ . ₄ aliphatic residue, a C^C -NH-C^ aliphatic residue, a C(=0)-N(C _1- aliphatic residue) ₂ , a O-C^-aliphatic residue, a 0-C(=0)-C _lJ( -aliphatic residue, a S- C _1-4 -aliphatic residue, a S(=0) ₂ -C ₁ . ₄ -aliphatic residue, a NHiC^ aliphatic residue), a N(Ci_ aliphatic residue) ₂ , a NH-C(=0)-C ₁ . ₄ aliphatic residue, and a NH-S(=0) ₂ -C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and a O- C _-4 -aliphatic residue; a C ₃ . ₆ -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C^-aliphatic residue and a O-C^- aliphatic residue, and in each case optionally bridged via an unsubstituted aliphatic group, on the condition that at least one of R ⁴⁰³ , R ⁴⁰⁴ , R ⁴⁰⁵ and R ⁴⁰⁶ is≠ H.

Preferably,

_R 403 _R 404 _R 405 _{and R} 406 _egch j _ndependent | _{y of one ano} ther represent H; F; CI; Br; I; CN; CF ₃ ;

OCF ₃ ; SCF ₃ ; C(=0)H; C(=0)-OH; C(=0)-NH ₂ ; S(=0) ₂ -OH; N0 ₂ ; a C^-aliphatic residue, a C(=0)- C^ aliphatic residue, a C(=0)-0-C _ ₄ aliphatic residue, a O-C^-aliphatic residue, a 0-C(=0)-C _1J( - aliphatic residue, a S-C^-aliphatic residue, a S(=0) ₂ -C _1-4 -aliphatic residue, wherein the C _1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and a O-C^-aliphatic residue; a C ₃ . ₆ -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C _-4 -aliphatic residue and a 0-Ci. -aliphatic residue, and in each case optionally bridged via an unsubstituted C,_ ₄ aliphatic group,

on the condition that at least one of R ⁴⁰³ R ⁴⁰⁴ . R ⁴⁰⁵ and R ⁴⁰⁶ is≠ H.

More preferably,

_R 403 _R 404 _R 405 _{and R} 406 _eacn j _ndependent | _{y of one} another represent H; F; CI; Br; I; CN; CF ₃ ;

OCF ₃ ; SCF ₃ ; C(=0)H; N0 ₂ ; a C^-aliphatic residue, a C(=0)-C _1-4 aliphatic residue, a C(=0)-0-C ₁ . 4 aliphatic residue, a O-C^-aliphatic residue, a S-C^-aliphatic residue, wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and a O-C^-aliphatic residue; a C ₃ . ₆ -cycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C _1-4 -aliphatic residue and a 0-C _1-4 -aliphatic residue, and in each case optionally bridged via an unsubstituted C _1-4 aliphatic group,

on the condition that at least one of R ⁴⁰³ , R ⁴⁰⁴ , R ⁴⁰⁵ and R ⁴⁰⁶ is≠ H. In a further preferred embodiment of the present invention

R ⁴⁰³ , R ⁴⁰⁴ , R ⁴⁰⁵ and R ⁴⁰⁶ each independently of one another are selected from the group

consisting of H; F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; OCF ₃ ; SCF ₃ ; a (C=0)-C ₁ . ₄ aliphatic residue, a C^- aliphatic residue, 0-d_ ₄ aliphatic residue, a S- C _1-4 aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, and 0-CH ₃ ;

on the condition that at least one of R ⁴⁰³ , R ⁴⁰⁴ , R ⁴⁰⁵ and R ⁴⁰⁶ is≠ H.

Preferably,

R ⁴⁰³ , R ⁴⁰⁴ , R ⁴⁰⁵ and R ⁴⁰⁶ each independently of one another are selected from the group

consisting of H; F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; OCF ₃ ; SCF ₃ ; methyl; ethyl; n-propyl; iso-propyl; n- butyl; sec-butyl; tert.-butyl; cyclopropyl; C(=0)-methyl; C(=0)-ethyl; (C=0)-isopropyl; (C=0)-t- butyl; O-methyl; O-ethyl; O-isopropyl; O-t-butyl; 0-(CH ₂ )2-0-CH ₃ ; S-Methyl; S-Ethyl;

on the condition that at least one of R ⁴⁰³ , R ⁴⁰⁴ , R ⁴⁰⁵ and R ⁴⁰⁶ is≠ H.

In particular,

R ⁴⁰³ , R ⁴⁰⁴ , R ⁴⁰⁵ and R ⁴⁰⁶ are each independently of one another are selected from the group

consisting of H; F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; (C=0)-methyl; (C=0)-ethyl; (C=0)-isopropyl; (C=0)-t- butyl; methyl; ethyl; isopropyl; t-butyl; O-methyl; O-Ethyl; O-isopropyl; O-t-butyl; OCF ₃ ; S-methyl; S-ethyl; and SCF ₃ ;

on the condition that at least one of R ⁴⁰³ , R ⁴⁰⁴ , R ⁴⁰⁵ and R ⁴⁰⁶ is≠ H. More particularly,

_R 403 _R 404 _R 405 _{and R} 406

are each independently of one another selected from the group consisting of H; F; CI; Br; CH ₃ ; CF ₃ ; CN; OCF ₃ and N0 ₂ ;

on the condition that at least one of R ⁴⁰³ , R ⁴⁰⁴ , R ⁴⁰⁵ and R ⁴⁰⁶ is≠ H.

Most preferred,

_R 403 _R 404 _anc j _R 406 _Qac ^ j _nc | _e p _enc ) _en t|y _are selected from the group consisting of H and F; and R ⁴⁰⁵ denotes F; CI; Br; CH ₃ ; CF ₃ ; OCF ₃ ; CN; or N0 ₂ ; preferably denotes F, Br, CF ₃ or CN.

In a particular preferred embodiment of the compound according to general formula (4-I)

at least one of the residues R ⁴⁰³ , R ⁴⁰⁴ , R ⁴⁰⁵ and R ⁴⁰⁶ is≠ H.

In a preferred embodiment of the compound according to general formula (4-I), the residue

R ⁴⁰⁷ denotes a C ₂ . ₁₀ -aliphatic residue, preferably a C ₂ . ₈ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an HiC^ aliphatic residue), an N(C _-4 aliphatic residue) ₂ , OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C- -aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, a C(=0)-0- Ci _-4 -aliphatic residue, and C(=0)-OH, wherein the d. ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes a residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d.4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, a C(=0)-0-C _1- -aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an N^C^ aliphatic residue), an N(Ci_4 aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, OCF3, SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH, on the condition that if R ⁴⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom.

In a further preferred embodiment of the compound according to general formula (4-I), the residue R ⁴⁰⁷ denotes a C ₂ . ₁₀ -aliphatic residue, preferably a C ₂ _ ₈ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , a NH(C _1-4 aliphatic residue), a N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a residue, CF ₃ , CN, and a C^-aliphatic residue

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-C, ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C - aliphatic residue, a residue, wherein the Ci. ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue,

and wherein the C ₃ _ ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C-,,β aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-C-i_ ₄ aliphatic residue, a C(=0)-0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, and a C _1-4 - aliphatic residue. on the condition that if R ⁴⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom.

Preferably,

R ⁴⁰⁷ denotes a C ₂ -8-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1- -aliphatic residue, OCF ₃ , a NH(C _1-4 aliphatic residue), a N(C^. aliphatic residue) ₂ , SH, SCF ₃ , a S-C^-aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , and a C^-aliphatic residue

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI,

Br, I, OH, CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue,

or denotes a C3_ ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a C(=0)-0- C^-aliphatic residue, a S-C- aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue,

and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C^e aliphatic group, preferably a Ci _-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1- aliphatic residue, a C(=0)-0-C _1-4 -aliphatic residue, CF ₃ , CN, and a C^-aliphatic residue.

on the condition that if R ⁴⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom.

More preferably,

R ⁴⁰⁷ denotes a C ₂ .8-aliphatic residue, preferably a C ₂ _ ₆ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH,

=0, an 0-C _1- -aliphatic residue, OCF ₃ , a NH(C _1- aliphatic residue), a N(C^ aliphatic residue) ₂ , SH, SCF ₃ , a S-C _1-4 -aliphatic residue, CF ₃ , a C(=0)-0-C ₁ ^,-aliphatic residue, and a C _1-4 -aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI,

Br, I, OH, CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes a C3_io-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S-C^ aliphatic residue, a C(=0)-0-C ₁ _ ₄ -aliphatic residue, CF ₃ , and a d. ₄ -aliphatic residue, wherein the d. ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and wherein the C3_ ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, preferably a Ci_ ₄ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _ aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , CN, and a C^-aliphatic residue,

on the condition that if R ⁴⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom.

Even more preferably,

R ⁴⁰⁷ denotes a C ₂ -8-aliphatic residue, preferably a C ₂ -6-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^-aliphatic residue, OCF ₃ , an NHiC^ aliphatic residue), an N(C _J( aliphatic residue) ₂ , SH, SCF ₃ , a S-C _1-4 -aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , and a C^-aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes a C ₃ _ ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , SCF ₃ , a S-C _1-4 aliphatic residue, a C(=0)-0-d. ₄ -aliphatic residue, CF ₃ , and a C _1- -aliphatic residue,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C-i_ ₄ -aliphatic residue, and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a unsubstituted Ci _-8 aliphatic group, preferably an unsubstituted C,. _A aliphatic group,

on the condition that if R ⁴⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom.

Still more preferably,

R ⁴⁰⁷ denotes a C ₂ -6-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^-aliphatic residue, an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , a C(=0)-0-C ₁ . ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, CF ₃ , and a C^-aliphatic residue,

wherein the Ci_ ₄ -aliphatic residue in each case is unsubstituted,

or denotes a C ₃ . ₁₀ -cycloaliphatic residue, preferably a C ₃ . ₆ -cycloaliphatic residue, or a 3 to 10 membered heterocycloaliphatic residue, preferably a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S-C ₁ _4 aliphatic residue, a C(=0)-0-C _lJ( -aliphatic residue, CF ₃ , and a C^-aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with OH or an unsubstituted O-C^-aliphatic residue,

and wherein the C ₃ . ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a unsubstituted C _1-4 aliphatic group,

on the condition that if R ⁴⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom.

In particular,

R ⁴⁰⁷ denotes a C ₂ -6-aliphatic residue, preferably selected from the group consisting of ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec. -butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, ethenyl and propenyl (-CH ₂ CH=CH ₂ , -CH=CH-CH ₃ , -C(=CH ₂ )-CH ₃ ), unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 -aliphatic residue, an NH(C _1-4 aliphatic residue), an N(C ₄ aliphatic residue) ₂ , a C(=0)-0-C ₁ . ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, CF ₃ , and a C^- aliphatic residue, preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, an 0-C _1-4 -aliphatic residue, an NH(C _1- aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , CF ₃ , and a C^-aliphatic residue, more preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, an 0-Ci. ₄ -aliphatic residue and an N(C _1J( aliphatic residue) ₂ , even more preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of O-methyl, OH and N(methyl) ₂ , wherein the C _1-4 -aliphatic residue in each case is unsubstituted,

or denotes a C ₃ . _e -cycloaliphatic residue, preferably selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, or a 3 to 6 membered heterocycloaliphatic residue, preferably selected from the group consisting of piperidinyl (preferably piperidin-4-yl or piperidin-3-yl), tetrahydrofuranyl, and tetrahydropyranyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an

aliphatic residue, CF ₃ , and a C- -aliphatic residue, preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, an 0-C _1-4 -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, more preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, and an O-C^-aliphatic residue, preferably O-methyl,

wherein the C _1- -aliphatic residue in each case is unsubstituted,

and wherein the C ₃ . ₆ -cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case optionally bridged via an unsubstituted C- aliphatic group, preferably via an unsubstituted C _1-2 aliphatic group, on the condition that if R ⁴⁰⁷ denotes a 3 to 6 membered heterocycloaliphatic residue, the 3 to 6 membered heterocycloaliphatic residue is linked via a carbon atom.

Most preferred,

R ⁴⁰⁷ denotes ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, ethenyl or propenyl (-CH ₂ CH=CH ₂ , -CH=CH-CH ₃ , -C(=CH ₂ )-CH ₃ ), in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, 0-CH ₃ , CF ₃ , and N(CH ₃ ) ₂ , preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, 0-CH ₃ , and N(CH ₃ ) ₂ , more preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of 0-CH ₃ , OH and N(CH ₃ ) ₂ , or denotes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, piperidinyl (preferably piperidin-4- yl or piperidin-3-yl), tetrahydrofuranyl, or tetrahydropyranyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, an O-C^-aliphatic residue, CF ₃ , and a C-i_ ₄ -aliphatic residue, preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, and an O-C^-aliphatic residue, preferably O-methyl,

wherein the C^-aliphatic residue in each case is unsubstituted,

and wherein cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, piperidinyl (preferably piperidin- 4-yl or piperidin-3-yl), tetrahydrofuranyl, and tetrahydropyranyl may in each case be optionally bridged, preferably are bridged, via an unsubstituted C^ aliphatic group, preferably via an unsubstituted C _-2 aliphatic group,

on the condition that if R ⁴⁰⁷ denotes piperidinyl tetrahydrofuranyl, or tetrahydropyranyl, piperidinyl tetrahydrofuranyl, or tetrahydropyranyl, each of these residues is linked via a carbon atom.

Particularly preferred is also a compound according to general formula (4-I), wherein

R ⁴⁰¹ represents the partial structure (4-T1),

wherein

m4 is 0, 1 or 2 and

R ^408a and R ^408b each independently of one another represent H, F, a 0-C _1-4 aliphatic residue or a Ci_4 aliphatic residue; preferably H, F, CH ₃ or OCH ₃ ;

,408c

R ^' denotes a C^ aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, an unsubstituted 0-C _1-4 aliphatic residue, CF ₃ , and an unsubstituted C^-aliphatic residue,

or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted 0-C _1- aliphatic residue, CF ₃ , and an unsubstituted C^-aliphatic residue, or wherein

m4 is 0,

R ^408a and R ^408b each independently of one another represent H, F, a O-C^ aliphatic residue or a C _1-4 aliphatic residue; preferably H, F, CH ₃ or OCH ₃ ; and

R ^408c denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue,

OCF ₃ , CF ₃ , CN, a d_4-aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ , C(=0)-0-C ₂ H ₅ and phenyl,

wherein phenyl may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C^- aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ ,

R ⁴⁰² is selected from the group consisting of H; F; CI; CF ₃ ; CH ₃ ; C ₂ H ₅ , iso-propyl; cyclopropyl; and O- CH ₃ ,

_R 403 _R 404 _R 405 _{and R} 406 _{gre egch} j _nc | _e p _enc | _en t|y ₀ f one another selected from the group

consisting of H; F; CI; CF ₃ ; CN; OCF ₃ and N0 ₂ ,

on the condition that at least one of R ⁴⁰³ , R ⁴⁰⁴ , R ⁴⁰⁵ and R ⁴⁰⁸ is≠ H,

R ⁴⁰⁷ denotes ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, ethenyl or propenyl (-CH ₂ CH=CH ₂ , -CH=CH-CH ₃ , -C(=CH ₂ )-CH ₃ ), in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, 0-CH ₃ , CF ₃ , and N(CH ₃ ) ₂ , preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, 0-CH ₃ , and N(CH ₃ ) ₂ , more preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of 0-CH ₃ , OH and N(CH ₃ ) ₂ , or denotes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, piperidinyl (preferably piperidin-4- yl or piperidin-3-yl), tetrahydrofuranyl, or tetrahydropyranyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, an 0-C _1-4 -aliphatic residue, CF ₃ , and a C^-aliphatic residue, preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, and an O-C^-aliphatic residue, preferably O-methyl,

wherein the C _1- -aliphatic residue in each case is unsubstituted,

and wherein cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, piperidinyl (preferably piperidin- 4-yl or piperidin-3-yl), tetrahydrofuranyl, and tetrahydropyranyl may in each case be optionally bridged via an unsubstituted C^ aliphatic group, preferably via an unsubstituted C _1-2 aliphatic group,

on the condition that if R ⁴⁰⁷ denotes piperidinyl, tetrahydrofuranyl, or tetrahydropyranyl, each of these residues is linked via a carbon atom. Another embodiment of the present invention therefore relates to a compound of general formula (I), wherein the compound is selected from a compound according to general formula (5-1).

denotes O or S, preferably O, represents a C^o-aliphatic residue, unsubstituted or mono- or polysubstituted; a C^o- cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C,_ _s aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C.e aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; represents F; CI; Br; I; CN; CF ₃ ; C(=0)H; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C^-aliphatic residue, a C(=0)-C ₁ . ₄ aliphatic residue, a C(=0)-0-C- ₄ aliphatic residue, a C(=0)-NH-C ₁ . ₄ aliphatic residue, a C(=0)- N(CM aliphatic residue) ₂ , wherein the CM aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a 0-C _1j4 -aliphatic residue, a 0-C(=0)-C ₁ . ₄ -aliphatic residue, a S-CM- aliphatic residue, a residue, wherein the C aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C ₃ _ ₆ - cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

_R 504 _R 505 _{AND R} 5oe _each j _ndependent | _{y of one ano} ther represent H; F; CI; Br; I; CN; CF ₃ ; C(=0)H; C(=0)-OH; C(=0)-NH ₂ ; SCF ₃ ; S(=0) ₂ -OH; N0 ₂ ; OCF ₃ ; a C _1-4 -aliphatic residue, a C(=0)-C _1-4 aliphatic residue, a C(=0)-0-C _1-4 aliphatic residue, a C(=0)-NH-C ₁ . ₄ aliphatic residue, a C(=0)- N(CM aliphatic residue) ₂ , wherein the C-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a O-C-4-aiiphatic residue, a 0-C(=0)-C-4-aliphatic residue, a S-C _1-4 - aliphatic residue, a residue, wherein the C-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a NI-KC. 4 aliphatic residue), a N(CM aliphatic residue) ₂ , a NH-C(=0)-C ₁ . ₄ aliphatic residue, a NH-S(=0) ₂ - C- ₄ -aliphatic residue, a N(Ci_ ₄ aliphatic residue)-C(=0)-C- ₄ aliphatic residue, or a N(C- ₄ aliphatic residue)-S(=0) ₂ -C ₁ . ₄ aliphatic residue, wherein the C aliphatic residue may in each case be unsubstituted or mono- or polysubstituted; a C^-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C- ₄ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; preferably on the condition that at least one of R ⁵⁰³ , R ⁵⁰⁴ , R ⁵⁰⁵ and R ⁵⁰⁶ is≠ H,

R ⁵⁰⁷ represents a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C ₃ _ ₁₀ - cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a Ci_ ₈ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

on the condition that if R ⁵⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, in which an "aliphatic group" and "aliphatic residue" can in each case be branched or unbranched, saturated or unsaturated, in which a "cycloaliphatic residue" and a "heterocycloaliphatic residue" can in each case be saturated or unsaturated, in which "mono- or polysubstituted" with respect to an "aliphatic group" and an "aliphatic residue" relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), a NH-C^OJ-C^ aliphatic residue, a NH-S(=0) ₂ -C _1-4 aliphatic residue, OH, OCF ₃ , a 0-C _lJr aliphatic residue, a 0-C(=0)-C ₁ _ ₄ -aliphatic residue, SH, SCF ₃ , a S- residue, a S(=0) ₂ -NH-C ₁ ^-aliphatic residue, CN, CF ₃ , CHO, COOH, a d. ₄ -aliphatic residue, a C(=0)-C _1-4 -aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, a C^e-cycloaliphatic residue, a 3 to 6 membered

heterocycloaliphatic residue, C(=0)-NH ₂ , a C(=0)-NH(C ₁ . ₄ aliphatic residue), and a aliphatic residue) ₂ ; in which "mono- or polysubstituted" with respect to a "cycloaliphatic residue" and a "heterocycloaliphatic residue" relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an N (C^ ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , a NH-C(=0)-C _1-4 aliphatic residue, a aliphatic residue, =0, OH, OCF ₃ , a 0-Ci_ -aliphatic residue, a O- C(=0)-C ₁ . ₄ -aliphatic residue, SH, SCF ₃ , a S-C _1-4 -aliphatic residue, S(=0) ₂ OH, a S(=0) ₂ -C _lJ( -aliphatic residue, a S(=0) ₂ -0-C _1-4 -aliphatic residue, a S(=0) ₂ -NH-C ₁ . ₄ -aliphatic residue, CN, CF ₃ , CHO, COOH, a C^-aliphatic residue, a C(=0)-C ₁ . ₄ -aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, a C ₃ . ₆ - cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(=0)-NH ₂ , a C(=0)-NH(C _1J( aliphatic residue), and a aliphatic residue) ₂ ; in which "mono- or polysubstituted" with respect to "aryl" and a "heteroaryl" relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , , aliphatic residue, an NH-S(=0) ₂ -C ₁ . ₄ aliphatic residue, OH, OCF ₃ , a O-C^-aliphatic residue, a 0-C(=0)-C ₁ . ₄ - aliphatic residue, SH, SCF ₃ , a S-C^-aliphatic residue, S(=0) ₂ OH, a S(=0) ₂ -C _1-4 -aliphatic residue, a S(=0) ₂ -0-C ₁ . ₄ -aliphatic residue, a S(=0) ₂ -NH-C ₁ . ₄ -aliphatic residue, CN, CF ₃ , C(=0)H, C(=0)OH, a d. ₄ - aliphatic residue, a C(=0)-C ₁ . ₄ -aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, a C ₃ . ₆ -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(=0)-NH ₂ , a C(=0)- HiC^ aliphatic residue), and a C(=0)-N(C _H aliphatic residue) ₂ .

The compounds according to general formula (5-I) are known from WO 2012/025239 A1 , which is fully included by reference.

Preferred embodiments of the compound according to general formula (5-I) have general formulae (5-I-I), and/or (5-I-II),

(5-I-I) (5-I-II)

Particularly preferred is a compound according to general formula (5-I-I), i.e. a compound according to general formula (5-I), wherein X ⁵ denotes O.

Further preferred embodiments of the compound according to general formula (I) have general formulae (5-la), (5-lb), (5-lc) and/or (5-ld),

(5-la) (5-lb)

Another preferred embodiment of present invention is a compound according to general formula (5-1), wherein

R ⁵⁰¹ denotes a C^o-aliphatic residue, preferably a Ci_ ₈ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an Nh^C^ aliphatic residue), OH, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S- C^-aliphatic residue, CF ₃ , CN, a Ci_ ₄ -aliphatic residue, and C(=0)-OH,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C _M aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-Ci_ ₄ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, a C^cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _ ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a d. ₄ -aliphatic residue and C(=0)- OH,

and wherein the C ₃ . ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, preferably a C _-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an ΝΗ(0^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1- -aliphatic residue and C(=0)-OH,

or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(Ci. ₄ aliphatic residue) ₂ , OH, an O-C^ aliphatic. residue, OCF ₃ , SH, SCF ₃ , a S-Ci-4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0- residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci„ aliphatic residue), an (d^ aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C^ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C^ ₄ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a C _1-8 aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(CL ₄ aliphatic residue), OH, an O-C^ aliphatic residue, 0CF ₃ , SH, SCF ₃ , a S-C^ 4 aliphatic residue, CF ₃ , CN and C(=0)-OH,

X ⁵ represents O or S,

R ⁵⁰² represents F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S-C _1-4 -aliphatic residue, a O-C^-aliphatic residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C^-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted, preferably represents F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S-C^-aliphatic residue, a O-C^-aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, and an unsubstituted 0-Ci_ ₄ -aliphatic residue; a C ₃ . ₆ -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C _1-4 -aliphatic residue and an 0-C _-4 -aliphatic residue, wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted O-C^-aliphatic residue, and wherein the C3_ ₆ -cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an unsubstituted C^-aliphatic residue and an unsubstituted 0-Ci_ ₄ -aliphatic residue,

_R 503 _R 504 _R 505 _{and R} 506 _each j _ndependent | _{y of one ano} ther represent H; F; CI; Br; I; CN; CF ₃ ;

OCF ₃ ; SCF ₃ ; C(=0)H; C(=0)-OH; C(=0)-NH ₂ ; S(=0) ₂ -OH; N0 ₂ ; a C^-aliphatic residue, a C(=0)- C _1-4 aliphatic residue, a C(=0)-0-C ₁ . ₄ aliphatic residue, a C(=0)-NH-C _1-4 aliphatic residue, a residue, a S- Ci-4-aliphatic residue, a S(=0) ₂ -C _ ₄ -aliphatic residue, a ^C^ aliphatic residue), a NKC^ aliphatic residue) ₂ , a residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, and a 0-C _1-4 - aliphatic residue; a C3. ₆ -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, a C _1- -aliphatic residue and a 0-C _1-4 -aliphatic residue, and in each case optionally bridged via an unsubstituted C _1-4 aliphatic group,

preferably on the condition that at least one of R ⁵⁰³ , R ⁵⁰⁴ , R ⁵⁰⁵ and R ⁵⁰⁶ is≠ H,

R ⁵⁰⁷ denotes a C _1-10 -aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), OH, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S- C _1- -aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue and C(=0)-OH,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_ ₄ aliphatic residue), an aliphatic residue) ₂ , OH, =0, an 0-C . ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, a C^e cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_ ₄ aliphatic residue), an N(C _! _ ₄ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-CL4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)- OH,

and wherein the C ₃ . ₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a aliphatic group, preferably a aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _-4 aliphatic residue), OH, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)-OH,

on the condition that if R ⁵⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom.

In a preferred embodiment of the compound according to general formula (5-I), the residue

R ⁵⁰¹ denotes a C^o-aliphatic residue, preferably a C _1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C ₁ . ₄ aliphatic residue), OH, an 0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S- C^-aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1- -aliphatic residue,

or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, a C^ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and wherein the C _M cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d_ aliphatic residue), an N(d_ ₄ aliphatic residue) ₂ , OH, =0, an 0-Ci_ aliphatic residue, OCF3, SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a d_ ₄ -aliphatic residue and C(=0)- OH,

and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a d. ₈ aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(Ci_4 aliphatic residue) ₂ , OH, =0, an 0-d. ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _-4 -aliphatic residue and C(=0)-OH,

or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_ ₄ aliphatic residue), an N(d. ₄ aliphatic residue) ₂ , OH, an 0-d_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ a S-d. ₄ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a c cloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, >> ⁰ , , , t) , benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or o'ysubsMuted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d. ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an 0-d_ ₄ aliphatic residue, OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH, SCF ₃ , a S-d.4 aliphatic residue, CF ₃ , CN, a d_ ₄ -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d. ₄ aliphatic residue), an N(d. ₄ aliphatic residue) ₂ , OH, =0, an 0-d. ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-d. ₄ aliphatic residue, CF ₃ , CN, a C ₁ _ ₄ -aliphatic residue and C(=0)- OH,

and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a d_ ₈ aliphatic group, preferably a C _-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1J( aliphatic residue), OH, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-d_ 4 aliphatic residue, CF ₃ , CN and C(=0)-OH.

In a further preferred embodiment of the compound according to general formula (5-I), the residue R ⁵⁰¹ represents the partial structure (5-T1), -(CR ^508a R ^508b ) _m ^-R ^508c (5-T1),

wherein

m5 denotes 0, 1 , 2, 3 or 4, preferably denotes 0, 1 , or 2,

R ^508a and R ^508b each independently of one another represent H, F, CI, Br, I, N0 ₂ , NH ₂ , a NH(d. ₄ aliphatic residue), OH, an 0-d_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-d_ ₄ aliphatic residue, CF ₃ , CN, a d-4 aliphatic residue or C(=0)-OH,

preferably each independently of one another represent H, F, CI, Br, I, NH ₂ , a NH(C _1-4 aliphatic residue), OH, O-C1.4 aliphatic residue or a d_ ₄ aliphatic residue,

more preferably each independently of one another represent H, F, CI, Br, I, an 0-d_ ₄ aliphatic residue or a C _1-4 aliphatic residue, even more preferably each independently of one another represent H, F, an O-C1.4 aliphatic residue or a aliphatic residue, and denotes a d_ ₄ aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), OH, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-Ci_ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH,

or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, preferably when m is≠ 0, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an Η(0^ aliphatic residue), an N(d_ ₄ aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S- Ci_4 aliphatic residue, CF ₃ , CN, a C _-4 -aliphatic residue, C(=0)-OH, a C^ cycloaliphatic residue and a 3 to 6 membered heterocycloaliphatic residue,

wherein the d^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and wherein the C3_ ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _lJt aliphatic residue), an N(d_ ₄ aliphatic residue) ₂ , OH, =0, an O-d^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-d_ ₄ aliphatic residue, CF ₃ , CN, a d^-aliphatic residue and C(=0)-OH,

or denotes - preferably when m5 is = 0 - an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an aliphatic residue), an N(d_ aliphatic residue) ₂ , OH, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-d^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C3.6 cycloaliphatic

0> ^ V\ N ⁰

residue, a 3 to 6 membered heterocycloaliphatic residue, , _{t t} , benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-d. ₄ -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d. ₄ aliphatic residue), an N(d_ ₄ aliphatic residue) ₂ , OH, an 0-d_ ₄ aliphatic residue, 0CF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)- CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C^ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C-|. ₄ aliphatic residue), an N(d_ ₄ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)-OH.

Preferably,

R ⁵⁰¹ represents the partial structure (5-T1),

wherein

m5 denotes 0, 1 , or 2,

R ^508a and R ^508b each independently of one another represent H, F, CI, Br, I, an 0-C _1-4 aliphatic residue or a C _1-4 aliphatic residue,

preferably each independently of one another represent H, F, a O-C^ aliphatic residue or a C^ aliphatic residue, and

R ^508c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , a C _1- -aliphatic residue and C(=0)-OH,

or denotes a C3_ ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , a C^- aliphatic residue, C(=0)-0H, a C3_ ₆ cycloaliphatic residue, and a 3 to 6 membered

heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, 0CF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and

wherein the C _M cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-Ci_ ₄ aliphatic residue, OCF ₃ , CF ₃ , a C _1-4 -aliphatic residue and C(=0)-OH,

or denotes - preferably when m5 is = 0 - an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C,. ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C _M cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl or oxazolyl,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ , wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , CF ₃ a C _1-4 -aliphatic residue and C(=0)-OH.

More preferably,

R ⁵⁰¹ represents the partial structure (5-T1),

wherein

m5 denotes 0, 1 , or 2,

R ^508a and R ^508b each independently of one another represent H, F, CI, Br, I, an O-C^ aliphatic residue or a Ci_4 aliphatic residue,

preferably each independently of one another represent H, F, a 0-Ci_ ₂ aliphatic residue or a C^ aliphatic residue, and

R ^508c denotes a C^ aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, an O-C^ aliphatic residue, CF ₃ , and a C- -aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an O-C^ aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes - preferably when m5 is = 0 - an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-CH ₃ , C(=0)- C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C ₃ . ₆ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl,

wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , CN, a C^-aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ , and

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , CF ₃ a C^-aliphatic residue and C(=0)-OH.

In a further preferred embodiment of the compound according to general formula (5-I), the residue R ⁵⁰¹ represents the partial structure (5-T1),

wherein

m5 is 0, 1 or 2 and

R ^508a and R ^508b each independently of one another represent H, F, a 0-C _1-4 aliphatic residue or a C-|. ₄ aliphatic residue; preferably H, F, CH ₃ or OCH ₃ ;

R ^508c denotes a aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, an unsubstituted O-C^ aliphatic residue, CF ₃ , and an unsubstituted C _1-4 -aliphatic residue,

or denotes a C ₃ . ₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted O-C^ aliphatic residue, CF ₃ , and an unsubstituted C _-4 -aliphatic residue,

or

wherein

m5 is 0,

R ^508a and R ^508b each independently of one another represent H, F, a 0-Ci_ ₄ aliphatic residue or a Ci_4 aliphatic residue; preferably H, F, CH ₃ or OCH ₃ ; and

R ^508c denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _1- aliphatic residue, OCF ₃ , CF ₃ , CN, a d. ₄ -aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ , C(=0)-0-C ₂ H ₅ and phenyl,

wherein phenyl may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 - aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ .

Particularly preferred is a compound according to general formula (5-1) which has the following general formula (5-le):

In particular,

R ⁵⁰¹ represents aryl, preferably phenyl, or heteroaryl, preferably pyridyl or thienyl, in each case

unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCH ₃ , OCF ₃ , CF ₃ , CN, and CH ₃ ,

preferably represents phenyl, unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCH ₃ , OCF ₃ , CF ₃ , CN, and CH ₃ , or represents an unsubstituted C _1-6 -aliphatic residue.

In a further preferred embodiment of the compound according to general formula (5-I), the residue X ⁵ denotes O.

In another preferred embodiment of the compound according to general formula (5-I), the residue X ⁵ denotes S.

In a preferred embodiment of the compound according to general formula (5-1), the residue

R ⁵⁰² represents F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C^-aliphatic residue, a S-C _1-4 -aliphatic residue, a aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C3_ ₆ -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted.

Preferably,

R ⁵⁰² represents F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S-C _1-4 -aliphatic residue, a O-C^-aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, and an unsubstituted O-C^-aliphatic residue,

a C^-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C ₁ _ ₄ -aliphatic residue and a O-C^-aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, and an unsubstituted O-C^-aliphatic residue,

and wherein the C^-cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C-^ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, an unsubstituted C^-aliphatic residue and an unsubstituted O- C^-aliphatic residue.

More preferably,

R ⁵⁰² represents F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C^-aliphatic residue, a S-C _1-4 -aliphatic residue, or a O-C^-aliphatic residue,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, and an unsubstituted O-C^-aliphatic residue,

cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, morpholinyl, or piperidinyl, preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, an unsubstituted C _1-4 -aliphatic residue and an unsubstituted O-C- -aliphatic residue,

and wherein cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, 4- methylpiperazinyl, morpholinyl or piperidinyl may in each case be optionally bridged via an C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, an unsubstituted C _1-4 -aliphatic residue and an unsubstituted O-C^-aliphatic residue.

Even more preferably,

R ⁵⁰² represents F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec-butyl; tert.-butyl; O-methyl; O-ethyl; 0-(CH ₂ ) ₂ -0-CH ₃ ; 0-(CH ₂ ) ₂ -OH; S-Methyl; S-Ethyl;

cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

Still more preferably,

R ⁵⁰² is selected from the group consisting of F; CI; Br; CF ₃ ; CN; SCF ₃ ; OCF ₃ ; CH ₃ ; C ₂ H ₅ ; n-propyl; iso- propyl; t-butyl; cyclopropyl; 0-CH ₃ and 0-C ₂ H ₅ .

In particular,

R ⁵⁰² is selected from the group consisting of F; CI; Br; CF ₃ ; CH ₃ ; C ₂ H ₅ , iso-propyl; cyclopropyl; and O- CH ₃ .

In a preferred embodiment of the compound according to general formula (5-I), the residues

_R 503 _R 504 _R 505 _{AND R} 506 _{egch jndepenc} | _ent | _{y of one} another represent H; F; CI; Br; I; CN; CF ₃ ;

OCF ₃ ; SCF ₃ ; C(=0)H; C(=0)-OH; C(=0)-NH ₂ ; S(=0) ₂ -OH; N0 ₂ ; a C^-aliphatic residue, a C(=0)- C _1- aliphatic residue, a C(=0)-0-C ₁ . aliphatic residue, a C(=0)-NH-C ₁ . ₄ aliphatic residue, a C(=0)-N(C _1-4 aliphatic residue) ₂ , a O-C^-aliphatic residue, a 0-C(=0)-C ₁ ^-aliphatic residue, a S- C^-aliphatic residue, a S(=0) ₂ -C ₁ ^-aliphatic residue, a NH(C _-4 aliphatic residue), a N(C _-4 aliphatic residue) ₂ , a NH-C(=0)-C _1-4 aliphatic residue, and a NH-S(=0) ₂ -C _1-4 -aliphatic residue, wherein the Ci_ ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, and a 0-C _1-4 - aliphatic residue; a Cs-e-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C^-aliphatic residue and a 0-Ci_ ₄ -aliphatic residue, and in each case optionally bridged via an unsubstituted C _1-4 aliphatic group,

preferably on the condition that at least one of R ⁵⁰³ , R ⁵⁰⁴ , R ⁵⁰⁵ and R ⁵⁰⁶ is≠ H.

Preferably,

_R 503 _R 504 _R 505 _{AND R} 506 _each j _ndependent | _{y of one} another represent H; F; CI; Br; I; CN; CF ₃ ;

OCF ₃ ; SCF ₃ ; C(=0)H; C(=0)-OH; C(=0)-NH ₂ ; S(=0) ₂ -OH; N0 ₂ ; a d. ₄ -aliphatic residue, a C(=0)- C- aliphatic residue, a C(=0)-0-C ₁ . ₄ aliphatic residue, a O-C^-aliphatic residue, a 0-C(=0)-C _1-4 - aliphatic residue, a S-Ci_ ₄ -aliphatic residue, a residue, wherein the C- - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, and a 0-C _1- -aliphatic residue; a C ₃ . ₆ -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C _1-4 -aliphatic residue and a 0-Ci_ ₄ -aliphatic residue, and in each case optionally bridged via an unsubstituted C _1-4 aliphatic group,

preferably on the condition that at least one of R ⁵⁰³ , R ⁵⁰⁴ , R ⁵⁰⁵ and R ⁵⁰⁶ is≠ H.

More preferably,

R ⁵⁰³ , R ⁵⁰⁴ , R ⁵⁰⁵ and R ⁵⁰⁶ each independently of one another represent H; F; CI; Br; I; CN; CF ₃ ;

OCF ₃ ; SCF ₃ ; C(=0)H; N0 ₂ ; a C _1-4 -aliphatic residue, a C(=0)-C ₁ _ ₄ aliphatic residue, a C(=0)-0-C ₁ . 4 aliphatic residue, a O-C^-aliphatic residue, a S-C _1-4 -aliphatic residue, wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, and a O-C^-aliphatic residue; a C ₃ . ₆ -cycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a

aliphatic residue, and in each case optionally bridged via an unsubstituted C^ aliphatic group, preferably on the condition that at least one of R ⁵⁰³ , R ⁵⁰⁴ , R ⁵⁰⁵ and R ⁵⁰⁶ is≠ H. In a further preferred embodiment of the present invention

_R 503 _R 504 _R 505 _{and R} 506 _egch j _nc j _ep endently of one another are selected from the group

consisting of H; F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; OCF ₃ ; SCF ₃ ; a (C=0)-d. aliphatic residue, a C^- aliphatic residue, O-C^ aliphatic residue, a S-C^aliphatic residue, wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, and 0-CH ₃ ;

preferably on the condition that at least one of R ⁵⁰³ , R ⁵⁰⁴ , R ⁵⁰⁵ and R ⁵⁰⁶ is≠ H.

Preferably,

_R 503 _R 504 _R 505 _{and R} 506 _egch j _nc j _ep endently of one another are selected from the group

consisting of H; F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; OCF ₃ ; SCF ₃ ; methyl; ethyl; n-propyl; iso-propyl; n- butyl; sec-butyl; tert-butyl; cyclopropyl; C(=0)-methyl; C(=0)-ethyl; (C=0)-isopropyl; (C=0)-t- butyl; O-methyl; O-ethyl; O-isopropyl; O-t-butyl; 0-(CH ₂ ) ₂ -0-CH ₃ ; S-Methyl; S-Ethyl;

preferably on the condition that at least one of R ⁵⁰³ , R ⁵⁰⁴ , R ⁵⁰⁵ and R ⁵⁰⁶ is≠ H. In particular,

_R 503 _R 50 _R 505 _{and R} 506 _{gre egcn} j _nc j _e pendently of one another are selected from the group consisting of H; F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; (C=0)-methyl; (C=0)-ethyl; (C=0)-isopropyl; (C=0)-t- butyl; methyl; ethyl; isopropyl; t-butyl; O-methyl; O-Ethyl; O-isopropyl; O-t-butyl; OCF ₃ ; S-methyl; S-ethyl; and SCF ₃ ;

preferably on the condition that at least one of R ⁵⁰³ , R ⁵⁰⁴ , R ⁵⁰⁵ and R ⁵⁰⁸ is≠ H.

More particularly, R ⁵⁰³ , R ⁵⁰⁴ , R ⁵⁰⁵ and R ⁵⁰⁶ are each independently of one another selected from the group consisting of H; F; CI; Br; CF ₃ ; CN; OCF ₃ and N0 ₂ ;

preferably on the condition that at least one of R ⁵⁰³ , R ⁵⁰⁴ , R ⁵⁰⁵ and R ⁵⁰⁶ is≠ H. Most preferred,

504

R , R aanr d R each independently of one another represent H or F, preferably each denotes H; and

R ⁵⁰⁵ denotes H; F; CI; Br; CF ₃ ; OCF ₃ ; CN; or N0 ₂ ; preferably denotes F; CI; Br; CF ₃ ; OCF ₃ ; or CN. In a particular preferred embodiment of the compound according to general formula (5-1)

at least one of the residues R ⁵⁰³ , R ⁵⁰⁴ , R ⁵⁰⁵ and R ⁵⁰⁶ is≠ H.

In another particular preferred embodiment of the compound according to general formula (5-1) at least two of the residues R ⁵⁰³ , R ⁵⁰⁴ , R ⁵⁰⁵ and R ⁵⁰⁶ denote H, preferably at least two of R ⁵⁰³ , R ⁵⁰⁴ and R ⁵⁰⁶ denote H.

In a preferred embodiment of the compound according to general formula (5-1), the residue

R ⁵⁰⁷ denotes a C _-10 -aliphatic residue, preferably a C _1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), OH, an 0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-

C^-aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, a C(=0)-0-C _1-4 -aliphatic residue, and

C(=0)-OH,

wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-Ci_4-aliphatic residue,

or denotes a C ₃ _ ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _! _ ₄ aliphatic residue), an N(C^ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, a C(=0)-0-C ₁ . ₄ -aliphatic residue a C ₃ _ ₆ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _-4 -aliphatic residue, and wherein the cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci _-4 aliphatic residue), an N(C _! . ₄ aliphatic residue) ₂ , OH, =0, an 0-C _-4 aliphatic residue, 0CF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

and wherein the C ₃ . ₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a Ci_ ₈ aliphatic group, preferably a C1.4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an Nh^C^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-d.4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH, on the condition that if R ⁵⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom.

In a further preferred embodiment of the compound according to general formula (5-1), the residue R ⁵⁰⁷ denotes a C^o-aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I,

N0 ₂ , OH, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, a C(=0)-0-C ₁ .

4- aliphatic residue, COOH, CF ₃ , CN, and a C _1-4 -aliphatic residue

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue,

or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a

5- C _{1 4} aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, a C ₃ . ₆ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF3, CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-C _{1 4} aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, and a C _1-4 - aliphatic residue,

and wherein the C3. ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case be optionally bridged, preferably is bridged, via a-C^e aliphatic group, preferably a C^ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an O- C _1-4 aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue,

on the condition that if R ⁵⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom.

Preferably,

R ⁵⁰⁷ denotes a C _1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^-aliphatic residue,

OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, COOH, CF ₃ , and a Ci- -aliphatic residue wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes a C ₃ _ ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a C(=0)-0- C^-aliphatic residue, a S-C^ aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and and wherein the C ₃ _ ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C^e aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C ₁ -4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, a C(=0)-0-C _1^( -aliphatic residue, CF ₃ , CN, and a C^-aliphatic residue,

on the condition that if R ⁵⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom. More preferably,

R ⁵⁰⁷ denotes a Ci_ ₈ -aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, COOH, CF ₃ , a C(=0)-0- C^-aliphatic residue, and a C _1-4 -aliphatic residue,

wherein the Ci_ ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted 0-Ci. ₄ -aliphatic residue,

or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _-4 aliphatic residue, OCF ₃ , SCF ₃ , a S-C^ aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , and a C^-aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1- -aliphatic residue, and

wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue in each case may be bridged, preferably is bridged, via a C _1-8 aliphatic group, preferably a C- aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , CN, and a d. 4-aliphatic residue,

on the condition that if R ⁵⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom. Even more preferably,

R ⁵⁰⁷ denotes a C _-8 -aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-Ci.4-aliphatic residue, COOH, a C(=0)-0-C ₁ . ₄ - aliphatic residue, CF ₃ , and a Ci_ ₄ -aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , SCF ₃ , a S-C _1-4 aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI,

Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case be bridged, preferably is bridged, via a unsubstituted C _1-8 aliphatic group, preferably an unsubstituted C _1-4 aliphatic group,

on the condition that if R ⁵⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom.

Still more preferably,

R ⁵⁰⁷ denotes a C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _1-4 -aliphatic residue,

COOH, a C(=0)-0-C ₁ ^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-d. ₄ -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, OH, CF ₃ and an unsubstituted residue,

or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S-C^ aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , and a C _1- -aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with OH or an unsubstituted 0-C _1-4 -aliphatic residue,

and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue in each case may be bridged, preferably is bridged, via a unsubstituted C _-4 aliphatic group, on the condition that if R ⁵⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom.

In particular, R ⁵⁰⁷ denotes a C _1-e -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^-aliphatic residue, COOH, a C^OJ-O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 -aliphatic residue, CF ₃ , and a Ci_4-aliphatic residue, preferably unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, an 0-C _1-4 -aliphatic residue, OCF ₃ , CF ₃ , and a C _1-4 -aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of OH, and an unsubstituted 0-C-i_ ₄ -aliphatic residue,

or denotes a C ₃ . ₆ -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S-C _1-4 aliphatic residue, a residue, on the condition that if R ⁵⁰⁷ denotes a 3 to 6 membered heterocycloaliphatic residue, the 3 to 6 membered heterocycloaliphatic residue is linked via a carbon atom.

Most preferred,

R ⁵⁰⁷ denotes a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, OH, a C(=0)-0-C ₁ ^-aliphatic residue, COOH and an 0-C _-4 -aliphatic residue, preferably at least one substituent selected from the group consisting of OH, a C(=0)-0-C _lJr aliphatic residue, COOH and an 0-C _1-4 -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of OH, and an unsubstituted O-C^-aliphatic residue,

or denotes a C ₃ . ₆ -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, a C(=0)-0-C _1-4 -aliphatic residue, CF ₃ , and a C^-aliphatic residue,

on the condition that if R ⁵⁰⁷ denotes a 3 to 6 membered heterocycloaliphatic residue, the 3 to 6 membered heterocycloaliphatic residue is linked via a carbon atom.

In particular most preferred

R ⁵⁰⁷ is selected from the group consisting of CH ₃ , C ₂ H ₅ , C ₃ H ₇ , C ₄ H ₉ , C ₅ H , CH(CH ₃ ) ₂ , C ₂ H ₄ -

CH(CH ₃ ) ₂ , C ₃ H ₆ -CH(CH ₃ ) ₂ , CH ₂ OH, C ₂ H ₄ OH, CH ₂ -OCH ₃ , C ₂ H ₄ -OCH ₃ , C ₃ H ₆ -OCH ₃ , CH ₂ -0-C ₂ H ₅ , C ₂ H ₄ -0-C ₂ H ₅ , CH ₂ -CH(CH ₃ )(OCH ₃ ), CH ₂ -CH(C ₂ H5)(0CH ₃ ), CH(CH ₃ )(CH ₂ -OCH ₃ ), CH(C ₂ H ₄ - OCH ₃ ) ₂ , CH(C ₂ H ₅ )(CH ₂ -OCH ₃ ), C ₂ H ₄ -0-C ₂ H ₄ -0-CH ₃ , CH ₂ -0-C ₂ H ₄ -0-CH ₃ , C ₂ H ₄ -0-C ₂ H ₄ -OH, CH ₂ - 0-C ₂ H ₄ -OH, CH ₂ -C(=0)0-CH ₃ , C ₂ H ₄ -C(=0)OCH ₃ , C ₂ H ₄ -C(=0)OH, CH ₂ -C(=0)OH,

or denotes an unsubstituted C^e-cycloaliphatic residue or an unsubstituted 3 to 6 membered heterocycloaliphatic residue, preferably tetrahydropyranyl or piperidinyl.

Particularly preferred is also a compound according to general formula (I), wherein

R ⁵⁰¹ represents the partial structure (5-T1 ), _ _(CR 508a _R 508b _)mi _ _R 508c wherein

m5 is 0, 1 or 2 and

R ^508a and R ^508b each independently of one another represent H, F, a 0-C _1-4 aliphatic residue or a C^ aliphatic residue; preferably H, F, CH ₃ or OCH ₃ ;

R ⁵⁰⁸ denotes a Ci. ₄ aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, an unsubstituted 0-C _1-4 aliphatic residue, CF ₃ , and an unsubstituted C _1-4 -aliphatic residue,

or denotes a C3. ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted 0-C _1-4 aliphatic residue, CF ₃ , and an unsubstituted C _1-4 -aliphatic residue,

or

wherein

m5 is 0,

R ^508a and R ^508b each independently of one another represent H, F, a 0-C _1-4 aliphatic residue or a C^ aliphatic residue; preferably H, F, CH ₃ or OCH ₃ ; and

R508c denotes _{an ar} y| _or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue,

OCF ₃ , CF ₃ , CN, a C^-aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ , C(=0)-0-C ₂ H ₅ and phenyl,

wherein phenyl may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , CN, a C _-4 - aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ , X ⁵ represents O or S, preferably O,

R ⁵⁰² is selected from the group consisting of F; CI; Br; CF ₃ ; CH ₃ ; C ₂ H ₅ , iso-propyl; cyclopropyl; and O- CH ₃ , R ⁵⁰³ , R ⁵⁰⁴ , R ⁵⁰⁵ and R ⁵⁰⁶ are each independently of one another selected from the group

consisting of H; F; CI; Br; CF ₃ ; CN; OCF ₃ and N0 ₂ ;

preferably on the condition that at least one of R ⁵⁰³ , R ⁵⁰⁴ , R ⁵⁰⁵ and R ⁵⁰⁶ is≠ H,

R ⁵⁰⁷ denotes a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^-aliphatic residue,

COOH, a C(=0)-0-C ₁ . ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, preferably unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, an O-C^-aliphatic residue, OCF ₃ ,

CF ₃ , and a C^-aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of OH, and an unsubstituted O-C^-aliphatic residue,

or denotes an unsubstituted C^-cycloaliphatic residue or an unsubstituted 3 to 6 membered heterocycloaliphatic residue,

on the condition that if R ⁵⁰⁷ denotes a 3 to 6 membered heterocycloaliphatic residue, the 3 to 6 membered heterocycloaliphatic residue is linked via a carbon atom.

Particularly preferred is also a compound according to general formula (5-1), wherein

R ⁵⁰¹ represents aryl, preferably phenyl, or heteroaryl, preferably pyridyl or thienyl, in each case

unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCH ₃ , OCF ₃ , CF ₃ , CN, and CH ₃ ,

preferably represents phenyl, unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCH ₃ , OCF ₃ , CF ₃ , CN, and CH ₃ ;

X ⁵ is 0;

R ⁵⁰² is selected from the group consisting of F, CI, CF ₃ , CH ₃ , C ₂ H ₅ , iso-propyl, cyclopropyl, and 0-CH ₃ ;

preferably is selected from the group consisting of CH ₃ , C ₂ H ₅ , OCH ₃ and CF ₃ ;

R ⁵⁰³ , R ⁵⁰⁴ , R ⁵⁰⁵ and R ⁵⁰⁶ are each independently of one another selected from the group

consisting of H, F, CI, Br, CF ₃ , CN, OCF ₃ and N0 ₂ ;

preferably on the condition that at least one of R ⁵⁰³ , R ⁵⁰⁴ , R ⁵⁰⁵ and R ⁵⁰⁶ is≠ H, more preferably on the condition that R ⁵⁰⁵ is≠ H;

R ⁵⁰⁷ denotes a saturated C^-aliphatic residue, unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, 0-CH ₃ , 0-C ₂ H ₅ , OCF ₃ ,

OC ₂ H ₄ -0-CH ₃ , COOH, C(=0)OCH ₃ , SCF ₃ , and CF ₃ ,

preferably denotes a saturated Cve-aliphatic residue, unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of OH, 0-CH ₃ , 0-C ₂ H ₅ , OCF ₃ , OC ₂ H ₄ - 0-CH ₃ , COOH, and C(=0)OCH ₃ .

Another embodiment of the present invention therefore relates to a compound of general formula (I), wherein the compound is selected from a compound according to general formula (6-1).

wherein

R ⁶⁰¹ represents a C^o-aliphatic residue, unsubstituted or mono- or polysubstituted; a C3. ₁₀ - cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a Ci_ ₈ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C^ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

FT" represents F; CI; Br; I; CN; CF ₃ ; C(=0)H; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a C(=0)-d. ₄ aliphatic residue, a aliphatic residue, a C(=0)- N( ^ aliphatic residue) ₂ , wherein the C - aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a O-C^-aliphatic residue, a 0-C(=0)-C ₁ . ₄ -aliphatic residue, a S-C^- aliphatic residue, a S(=0) ₂ -C ₁ . ₄ -aliphatic residue, a S(=0) ₂ -0-C ₁ . -aliphatic residue, wherein the C .4 aliphatic residue may in each case be unsubstituted or mono- or polysubstituted; a C ₃ . ₆ - cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a Ci_ ₄ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

R ⁶⁰³ represents H; F; CI; Br; I; CN; CF ₃ ; SCF ₃ ; N0 ₂ ; OCF ₃ ; a C _1-4 -aliphatic residue, a 0-C _1-4 -aliphatic residue, a S-C _1-4 -aliphatic residue, wherein the Ci_ ₄ aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C ₃ . ₆ -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or- mono- or polysubstituted;

R ⁶⁰⁴ represents a

cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C^e aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged, preferably in each case bridged, via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

on the condition that if R ⁶⁰⁴ denotes a 3 to 10 membered heterocycloaliphatic residue or a heteroaryl, the 3 to 10 membered heterocycloaliphatic residue or the heteroaryl is linked via a carbon atom;

R ⁶⁰⁵ denotes H or a Ci-10-aliphatic residue, preferably a Ci_ -aliphatic residue, unsubstituted or mono- or polysubstituted; or

R ⁶⁰⁴ and R ⁶⁰⁵ form together with the nitrogen atom connecting them a 3 to 10 membered

heterocycloaliphatic residue, preferably a 4 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted, which may optionally be condensed with aryl or heteroaryl, preferably selected from the group consisting of phenyl, pyridyl and thienyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted; R ⁶⁰⁶ represents a C _2- io-aliphatic residue, unsubstituted or mono- or polysubstituted; a C ₃ . ₀ - cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a Ci_ ₈ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

on the condition that if R ⁸⁰⁶ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, or

denotes S-R ⁶⁰⁷ , O-R ⁶⁰⁸ or N(R ⁶⁰⁹ R ⁸¹⁰ ),

wherein ^'

R ⁸⁰⁷ and R ⁶⁰⁸ in each case represent a C _{- 0} -aliphatic residue, unsubstituted or mono- or polysubstituted; a C3_ ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C^e aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

on the condition that if R ⁶⁰⁷ or R ⁶⁰⁸ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,

R ⁶⁰⁹ represents a C^o-aliphatic residue, unsubstituted or mono- or polysubstituted; a C^o-cycloaliphatic residue or a 3 to 10 membered

heterocycloaliphatic residue, in each case unsubstituted or mono- or

polysubstituted and in each case optionally bridged via a aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

on the condition that if R ⁸⁰⁹ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom;

R ⁸¹⁰ denotes H or a C^o-aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted; or

R ⁶⁰⁹ and R ⁶¹⁰ form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, preferably a 4 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted; which may optionally be condensed with aryl or heteroaryl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted; in which an "aliphatic group" and an "aliphatic residue" can in each case be branched or unbranched, saturated or unsaturated, in which a "cycloaliphatic residue" and a "heterocycloaliphatic residue" can in each case be saturated or unsaturated, in which "mono- or polysubstituted" with respect to an "aliphatic group" and an "aliphatic residue" relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_ ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , a NH-C(=0)-C ₁ . ₄ aliphatic residue, a

aliphatic residue, SH, SCF ₃ , a S-C _1-4 -aliphatic residue, S(=0) ₂ OH, a S(=0) ₂ -C ₁ . ₄ -aliphatic residue, a S(=0) ₂ -0-C _1-4 -aliphatic residue, a S(=0) ₂ -NH-C _1-4 -aliphatic residue, CN, CF ₃ , CHO, COOH, a C _1-4 - aliphatic residue, a C(=0)-C ₁ . ₄ -aliphatic residue, a C(=0)-0-C ₁ _ ₄ -aliphatic residue, a C ₃ . ₆ -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(=0)-NH ₂ , a C(=0)-NH(C ₁ . ₄ aliphatic residue), and a C(=0)-N(C _1-4 aliphatic residue) ₂ ; in which "mono- or polysubstituted" with respect to a "cycloaliphatic residue" and a "heterocycloaliphatic residue" relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C ₁ _ ₄ aliphatic residue) ₂ , a NH-C^OJ-C^ aliphatic residue, a aliphatic residue, =0, OH, OCF ₃ , a 0-C _1-4 -aliphatic residue, a O- C(=0)-C^-aliphatic residue, SH, SCF ₃ , a S-C _1-4 -aliphatic residue, S(=0) ₂ OH, a S(=0) ₂ -C ₁ . ₄ -aliphatic residue, a S(=0) ₂ -0-C ₁ . ₄ -aliphatic residue, a S(=0) ₂ -NH-C _1-4 -aliphatic residue, CN, CF ₃ , CHO, COOH, a C-|. ₄ -aliphatic residue, a C(=0)-C ₁ . ₄ -aliphatic residue, a C(=0)-0-C _1-4 -aliphatic residue, a C ₃ . ₆ - cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(=0)-NH ₂ , a C(=0)-NH(C _1J » aliphatic residue), and a aliphatic residue) ₂ ; in which "mono- or polysubstituted" with respect to "aryl" and a "heteroaryl" relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , ,

, an aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , an aliphatic residue, an NH-S(=0) ₂ -C ₁ . ₄ aliphatic residue, OH, OCF ₃ , a 0-Ci_ ₄ -aliphatic residue, a 0-C(=0)-C _1- - aliphatic residue, SH, SCF ₃ , a S-C^-aliphatic residue, S(=0) ₂ OH, a S(=0) ₂ -C _1-4 -aliphatic residue, a S(=0) ₂ -0-C _1-4 -aliphatic residue, a S(=0) ₂ -NH-C ₁ . ₄ -aliphatic residue, CN, CF ₃ , C(=0)H, C(=0)OH, a C _1-4 - aliphatic residue, a C(=0)-C ₁ _ ₄ -aliphatic residue, a C(=0)-0-C _-4 -aliphatic residue, a C ₃ . ₆ -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(=0)-NH ₂ , a C(=0)- NH(C _1-4 aliphatic residue), and a C(=0)-N(C . ₄ aliphatic residue) ₂ .

In an particularly preferred embodiment of the compound according to general formula (6-I) radicals R ⁶⁰¹ , R ⁶⁰² , R ⁶⁰³ , R ⁶⁰⁴ , R ⁶⁰⁵ and R ⁶⁰⁶ have the meanings described herein in connection with the compounds according to the invention and preferred embodiments thereof, with the proviso that R ⁶⁰ comprises at least 4 atoms selected from the group consisting of carbon and heteroatoms, preferably at least 4 atoms selected from the group consisting of carbon atoms and heteroatoms selected from the group consisting of N, O and S. The compounds according to general formula (6-1) are known from WO 2012/052167 A1 , which is fully included by reference.

The present invention further relates to a substituted compound of general formula (6-I),

represents a C^o-aliphatic residue, unsubstituted or mono- or polysubstituted; a C ₃ . ₁₀ - cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a Ci_ ₈ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; represents F; CI; Br; I; CN; CF ₃ ; C(=0)H; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C _1- -aliphatic residue, a C(=0)-C _1-4 aliphatic residue, a C(=0)-0-C _lJt aliphatic residue, a C(=0)-NH-C ₁ . ₄ aliphatic residue, a C(=0)- N(C^ aliphatic residue) ₂ , wherein the C-i_ ₄ aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a 0-C _1-4 -aliphatic residue, a 0-C(=0)-C ₁ . ₄ -aliphatic residue, a S-C _1-4 - aliphatic residue, a S(=0) ₂ -C ₁ . ₄ -aliphatic residue, a S(=0) ₂ -0-C _1-4 -aliphatic residue, wherein the C _1J( aliphatic residue may in each case be unsubstituted or mono- or polysubstituted; a C^- cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C^ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; represents H; F; CI; Br; I; CN; CF ₃ ; SCF ₃ ; N0 ₂ ; OCF ₃ ; a C _1-4 -aliphatic residue, a 0-C _1- -aliphatic residue, a S-C _-4 -aliphatic residue, wherein the C^ aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a Cs-e-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; represents a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C^o- cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged, preferably in each case bridged, via a C^ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; on the condition that if R ⁶⁰⁴ denotes a 3 to 10 membered heterocycloaliphatic residue or a heteroaryl, the 3 to 10 membered heterocycloaliphatic residue or the heteroaryl is linked via a carbon atom;

R ⁶⁰⁵ denotes H or a Ci. ₁₀ -aliphatic residue, preferably a C _1- -aliphatic residue, unsubstituted or mono- or polysubstituted; or

R ⁶⁰⁴ and R ⁶⁰⁵ form together with the nitrogen atom connecting them a 3 to 10 membered

heterocycloaliphatic residue, preferably a 4 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted,

R ⁶⁰⁶ represents a C _2- io-aliphatic residue, unsubstituted or mono- or polysubstituted; a C ₃ . ₁₀ - cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C-i_ ₈ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

on the condition that if R ⁶⁰⁶ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, or

denotes S-R ⁶⁰⁷ , O-R ⁶⁰⁸ or N(R ⁶⁰⁹ R ⁶¹⁰ ),

wherein

R ⁶⁰⁷ and R ⁶⁰⁸ in each case represent a C^o-aliphatic residue, unsubstituted or mono- or polysubstituted; a C^o-cycloaliphatic residue or a 3 to 10 membered

heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

on the condition that if R ⁶⁰⁷ or R ⁶⁰⁸ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,

R ⁶⁰⁹ represents a Ci_ ₁₀ -aliphatic residue, unsubstituted or mono- or polysubstituted; a C3_io-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group,

which in turn may be unsubstituted or mono- or polysubstituted;

on the condition that if R ⁶⁰⁹ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom;

R ⁶¹⁰ denotes a Ci-i ₀ -aliphatic residue, preferably a C _1-4 -aliphatic residue, unsubstituted or mono- or polysubstituted; or R ⁶⁰⁹ and R ⁶¹⁰ form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, preferably a 4 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted; in which an "aliphatic group" and an "aliphatic residue" can in each case be branched or unbranched, saturated or unsaturated, in which a "cycloaliphatic residue" and a "heterocycloaliphatic residue" can in each case be saturated or unsaturated, in which "mono- or polysubstituted" with respect to an "aliphatic group" and an "aliphatic residue" relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _-4 aliphatic residue), an NKC^ aliphatic residue) ₂ , a NH-C(=0)-C . ₄ aliphatic residue, a NH-S(=0) ₂ -C ₁ . ₄ aliphatic residue, =0, OH, OCF ₃ , a O-C^-aliphatic residue, a 0-C(=0)-C ₁ . ₄ - aliphatic residue, SH, SCF ₃ , a S-C^-aliphatic residue, S(=0) ₂ OH, a S(=0) ₂ -C _1-4 -aliphatic residue, a S(=0) ₂ -0-C ₁ . ₄ -aliphatic residue, a S(=0) ₂ -NH-C ₁ . ₄ -aliphatic residue, CN, CF ₃ , CHO, COOH, a C _1-4 - aliphatic residue, a C(=0)-C _-4 -aliphatic residue, a C(=0)-0-C _-4 -aliphatic residue, a C ₃ . ₆ -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(=0)-NH ₂ , a C(=0)-NH(C _lJt aliphatic residue), and a C(=0)-N(C _1-4 aliphatic residue) ₂ ; in which "mono- or polysubstituted" with respect to a "cycloaliphatic residue" and a "heterocycloaliphatic residue" relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an

aliphatic residue, a NH-S(=0) ₂ -C ₁ . ₄ aliphatic residue, =0, OH, OCF ₃ , a 0-C _-4 -aliphatic residue, a O- C(=0)-C _lJt -aliphatic residue, SH, SCF ₃ , a S-C^-aliphatic residue, S(=0) ₂ OH, a S(=0) ₂ -C ₁ ^ ₍ -aliphatic residue, a S(=0) ₂ -0-C _lJ( -aliphatic residue, a S(=0) ₂ -NH-C ₁ . ₄ -aliphatic residue, CN, CF ₃ , CHO, COOH, a C^-aliphatic residue, a C(=0)-C - -aliphatic residue, a C(=0)-0-C _lJ( -aliphatic residue, a C^- cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(=0)-NH ₂ , a aliphatic residue), and a C(=0)-N(C ₁ ^ aliphatic residue) ₂ ; in which "mono- or polysubstituted" with respect to "aryl" and a "heteroaryl" relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one anothe t least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , an NH-C(=0)-C ₁ . ₄ aliphatic residue, an NH-S(=0) ₂ -C _1-4 aliphatic residue, OH, OCF ₃ , a O-C^-aliphatic residue, a 0-C(=0)-C _1-4 - aliphatic residue, SH, SCF ₃ , a S-C^-aliphatic residue, S(=0) ₂ OH, a S(=0) ₂ -C ₁ . ₄ -aliphatic residue, a S(=0) ₂ -0-C ₁ . ₄ -aliphatic residue, a S(=0) ₂ -NH-C _1-4 -aliphatic residue, CN, CF ₃ , C(=0)H, C(=0)OH, a C _1-4 - aliphatic residue, a C(=0)-C ₁ . ₄ -aliphatic residue, a residue, a C ₃ . ₆ -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(=0)-NH ₂ , a C(=0)- Nh C^ aliphatic residue), and a C(=0)-N(C ₁ . ₄ aliphatic residue) ₂ . In another preferred embodiment of the compound according to formula (6-I), preferred substituents of "cycloaliphatic residue" and "heterocycloaliphatic residue" are selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1- aliphatic residue), an N(C . ₄ aliphatic residue) ₂ , a NH-C(=0)-C _1J , aliphatic residue, a NH-S(=0) ₂ -C ₁ . ₄ aliphatic residue, =0, OH, OCF ₃ , a 0-C _{1 4} -aliphatic residue, a 0-C(=0)-C _1-4 - aliphatic residue, SH, SCF ₃ , a S-C^-aliphatic residue, S(=0) ₂ OH, a S(=0) ₂ -C ₁ ^-aliphatic residue, a S(=0) ₂ -0-C ₁ . ₄ -aliphatic residue, a residue, CN, CF ₃ , CHO, COOH, a C- - aliphatic residue, CH ₂ OH, CH ₂ -OCH ₃ , C ₂ H ₄ -OH, C ₂ H ₄ -OCH ₃ CH ₂ -CF ₃ , a C(=0)-C ₁ . ₄ -aliphatic residue, a C(=0)-0-C _1-4 -aliphatic residue, a Cs- ₆ -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(=0)-NH ₂ , a aliphatic residue) ₂ .

In another preferred embodiment of the compound according to formula (6-I), preferred substituents of

residue, an NH-S^O^-C^ aliphatic residue, OH, OCFH ₂ , OCF ₂ H, OCF ₃ , a O-C^-aliphatic residue, SH, SCF ₃ , a S-C^-aliphatic residue, S(=0) ₂ OH, a S(=0) ₂ -C _1-4 -aliphatic residue, a S(=0) ₂ -NH-C ₁ . ₄ -aliphatic residue, CN, CF ₃ , CF ₂ H, CHF ₂ , a d. ₄ -aliphatic residue, CH ₂ OH, CH ₂ -OCH ₃ , C ₂ H ₄ -OH, C ₂ H ₄ -OCH ₃ , a residue, a C ₃ . ₆ -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, CONH ₂ , a C(=0)-NH(C ₁ ^ aliphatic residue), a C(=0)-N(C ₁ _ ₄ aliphatic residue) ₂ , aryl, preferably phenyl, or benzyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, CN, CF ₃ , CH ₃ , C ₂ H ₅ , iso-propyl, tert.-butyl, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , 0-CH ₃ , OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH, S-CH ₃ , SCF ₃ , N0 ₂ , NH ₂ , N(CH ₃ ) ₂ , N(CH ₃ )(C ₂ H ₅ ) and N(C ₂ H ₅ ) ₂ , heteroaryl, preferably pyridyl, thienyl, furyl, thiazolyl or oxazolyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, CN, CF ₃ , CH ₃ , C ₂ H ₅ , iso-propyl, tert.-butyl, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)- 0-C ₂ H ₅ , 0-CH ₃ , OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH, S-CH ₃ , SCF ₃ , N0 ₂ , NH ₂ , N(CH ₃ ) ₂ , N(CH ₃ )(C ₂ H ₅ ) and N(C ₂ H ₅ ) ₂ .

In yet another preferred embodiment of the compound according to general formula (6-I) the particular radicals R ⁶⁰ .R ⁶⁰⁵ have the meanings described herein in connection with the compounds according to the invention and preferred embodiments thereof and

R represents a C ₂ _ ₁₀ -aliphatic residue, unsubstituted or mono- or polysubstituted; a C ₃ _ ₁₀ - cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a Ci_ ₈ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

on the condition that if R ⁶⁰⁶ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, or

denotes S-R ⁶⁰⁷ or O-R ⁶⁰⁸

wherein R ⁶⁰⁷ and R ⁶⁰⁸ in each case represent a C^o-aliphatic residue, unsubstituted or mono- or polysubstituted; a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; on the condition that if R ⁶⁰⁷ or R ⁶⁰⁸ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom.

In another preferred embodiment of the present invention the compound according to general formula (6· I) has the general formula (6-l-a)

wherein

the particular radicals R ⁶⁰¹ .R ⁶⁰⁵ and R ⁶⁰⁷ have the meanings described herein in connection with the compounds according to the invention and preferred embodiments thereof.

In another preferred embodiment of the present invention the compound according to general formula (6- I) has the general formula (6-l-b)

(6-l-b), wherein the particular radicals R ⁶⁰¹ .R ⁶⁰⁵ have the meanings described herein in connection with the compounds according to the invention and preferred embodiments thereof,

and wherein

R ⁶¹¹ represents O-R ⁶⁰⁸ or N(R ⁶⁰⁹ R ⁶¹⁰ ),

wherein R ⁶⁰⁸ , R ⁶⁰⁹ and R ⁶¹⁰ have the meanings described herein in connection with the compounds according to the invention and preferred embodiments thereof, or represents a C ₂ -io-aliphatic residue, unsubstituted or mono- or polysubstituted; a C^o- cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

on the condition that if R ⁶¹¹ denotes a 3 to 10 membered heterocycloaliphatic residue, the binding is carried out via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue.

In a particular preferred embodiment of the present invention, radical R ⁶¹¹ in general formula

(6-l-b) and radical R ⁶⁰⁸ in general formula (6-I) represents O-R ⁶⁰⁸ , wherein R ⁶⁰⁸ has the meanings described herein in connection with the compounds according to the invention and preferred

embodiments thereof.

In another particular preferred embodiment of the present invention, radical R ^{6 1} in general formula (6-l-b) and radical R ⁶⁰⁶ in general formula (6-I) represents N(R ⁶⁰⁹ R ⁶¹⁰ ), wherein R ⁶⁰⁹ and R ^{6 0} have the meanings described herein in connection with the compounds according to the invention and preferred

embodiments thereof.

In yet another particular preferred embodiment of the present invention, radical R ⁶¹¹ in general formula (6- l-b) and radical R ⁶⁰⁶ in general formula (6-I) represents a C ₂ -i ₀ -aliphatic residue, unsubstituted or mono- or polysubstituted; a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C^e aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted,

on the condition that if R ⁶¹¹ denotes a 3 to 10 membered heterocycloaliphatic residue, the binding is carried out via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue.

Another preferred embodiment of the compound according to general formula (6-I) has the general formula (6-l-c),

(6-l-c),

wherein the particular radicals R ^BU1 , R ⁶⁰² , R ⁶⁰⁴ , R ⁶⁰⁵ and R ⁶⁰⁶ have the meanings described herein in connection with the compounds according to the invention and preferred embodiments thereof.

Another preferred embodiment of the compound according to general formula (6-1) has the general formula (6-l-e) or (6-l-f),

(6-l-e), (6-l-f)

wherein the particular radicals

have the meanings described herein in connection with the compounds according to the invention and preferred embodiments thereof.

In yet another preferred embodiment of the compound according to general formula (6-I) radicals R ⁶⁰² , _R 603 ^604 ^605 _an ^ _R 606 ^ _ave ^ _mean j _n g _S described herein in connection with the compounds according to the invention and preferred embodiments thereof, and R ⁶⁰¹ represents aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted.

In case R ⁶⁰⁴ and R ⁶⁰⁵ of the compound of general formula (6-1) form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaiiphatic residue, preferably a 4 to 7 membered heterocycloaiiphatic residue, unsubstituted or mono- or polysubstituted, said heterocycloaiiphatic residue may optionally be condensed with aryl or heteroaryl or with a C^o cycloaliphatic residue or with a 3 to 10 membered heterocycloaiiphatic residue, wherein the aryl, heteroaryl, C ₃ .i ₀ cycloaliphatic or 3 to 10 membered heterocycloaiiphatic residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted. Preferably, said heterocycloaiiphatic residue formed by R ⁶⁰⁴ and R ⁶⁰⁵ of the compound of general formula (6-I) together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, wherein the aryl, or heteroaryl, preferably selected from the group consisting of phenyl, pyridyl and thienyl condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted.

Particularly preferably, in case R ⁶⁰⁴ and R ⁶⁰⁵ form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaiiphatic residue, preferably a 4 to 7 membered heterocycloaiiphatic residue, unsubstituted or mono- or polysubstituted, said heterocycloaiiphatic residue may optionally be condensed with aryl or heteroaryl, preferably selected from the group consisting of phenyl, pyridyl and thienyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted.

In case R ⁶⁰⁹ and R ⁶¹⁰ of the compound of general formula (6-I) form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaiiphatic residue, preferably a 4 to 7 membered heterocycloaiiphatic residue, unsubstituted or mono- or polysubstituted, said heterocycloaiiphatic residue may optionally be condensed with aryl or heteroaryl or with a C^o cycloaliphatic residue or with a 3 to 10 membered heterocycloaiiphatic residue, wherein the aryl, heteroaryl, C ₃ . ₁₀ cycloaliphatic or 3 to 10 membered heterocycloaiiphatic residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted. Preferably, said heterocycloaiiphatic residue formed by R ⁶⁰⁹ and R ⁶¹⁰ of the compound of general formula (6-I) together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, wherein the aryl, or heteroaryl, preferably selected from the group consisting of phenyl, pyridyl and thienyl condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted.

Particularly preferably, in case R ⁶⁰⁹ and R ^{6 0} form together with the nitrogen atom connecting

them a 3 to 10 membered heterocycloaliphatic residue, preferably a 4 to 7 membered

heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted, said heterocycloaliphatic residue may optionally be condensed with aryl or heteroaryl, preferably selected from the group consisting of phenyl, pyridyl and thienyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted.

Yet another preferred embodiment of present invention is a compound according to general formula (6-1), wherein

R ⁶⁰ denotes a C^o-aliphatic residue, preferably a C^s-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an Nh^C^ aliphatic residue), an N(C _-4 aliphatic residue) ₂ , OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, a S(=0) ₂ -C . ₄ -aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)-OH, preferably denotes a C^o-aliphatic residue, more preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_ ₄ aliphatic residue), an N(Ci_4 aliphatic residue) ₂ , OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 -aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1J( aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1- -aliphatic residue, C(=0)-OH, a C _M cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1- -aliphatic residue and C(=0)- OH, and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a aliphatic group, preferably a aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d_ ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-Ci_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)-OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an 0-C _-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-Ci aliphatic residue, a S(=0) ₂ -C ₁ . ₄ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C =0)-0-C ₂ H a C cycloali hatic residue, a 3 to 6 membered heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C ₁ aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C - -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C^ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, , benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-Ci- ₄ -aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _! _ ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an 0-d. ₄ aliphatic residue, OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C^e cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a C _-8 aliphatic group, preferably a C _-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci. ₄ aliphatic residue), an N(Ci_ ₄ aliphatic residue) ₂ , OH, =0, an 0-C _1- aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C,^ aliphatic residue, CF ₃ , CN and C(=0)-OH, represents F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S-C _1-4 -aliphatic residue, a 0-Ci. ₄ -aliphatic residue, wherein the C^ aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C^-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted,

preferably represents F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S-C _1-4 - aliphatic residue, a O-C^-aliphatic residue, wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted O-C^-aliphatic residue; a C^- cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C _-4 -aliphatic residue and an O-C^-aliphatic residue, wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted 0-C _-4 -aliphatic residue, and wherein the j-e-cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a Ci. ₄ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, an unsubstituted C _1-4 - aliphatic residue and an unsubstituted O-C^-aliphatic residue, represents H; F; CI; Br; I; CN; CF ₃ ; SCF ₃ ; N0 ₂ ; OCF ₃ ; a C _-4 -aliphatic residue, a O-C^-aliphatic residue, a S-Ci. ₄ -aliphatic residue,

wherein the Ci. ₄ aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted O-C^-aliphatic residue;

a C^-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C _1-4 -aliphatic residue and a O-C^-aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted O-C^-aliphatic residue,

and wherein the C ₃ . ₆ -cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C^ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, an unsubstituted C^-aliphatic residue and an unsubstituted 0- C _1- -aliphatic residue, denotes a Ci_ ₁₀ -aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an Nh^C^ aliphatic residue), an N C^ aliphatic residue) ₂ , OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 -aliphatic residue, CF ₃ , CN, a C^- aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, and C(=0)-OH,

wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, or denotes a C3. ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, a C(=0)-0-C _lJt -aliphatic residue a C^ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF3, CF ₃ and an unsubstituted 0-C _ ₄ -aliphatic residue, and

wherein the C _M cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH^.., aliphatic residue), an N(C _! . ₄ aliphatic residue) ₂ , OH, =0, an 0-C _1- aliphatic residue, OCF3, SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _-8 aliphatic group, preferably a C^ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, a C(=0)-0-C _ ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C ₁ . ₄ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)-OH, on the condition that if R ⁶⁰⁴ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an ^C^ aliphatic residue) ₂ , OH, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C,. ₄ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0- c residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1-4 -alip atic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH, SCF ₃ , a S-d.4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci.4 aliphatic residue), an N(C _1- aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF3, SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)- OH,

and wherein the aryl or the heteroaryl residue may in each case be optionally bridged, preferably in each case is bridged, via a C^e aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C _-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN and C(=0)-OH,

R ⁶⁰⁵ denotes H or a C _{1- 0} -aliphatic residue, preferably a C _-4 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(d. ₄ aliphatic residue) ₂ , OH, =0, an O-C1.4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-d. ₄ -aliphatic residue, or

R ⁶⁰⁴ and R ⁶⁰⁵ form together with the nitrogen atom connecting them a 3 to 10 membered

heterocycloaliphatic residue, preferably a 4 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d_ ₄ aliphatic residue), an N(d. ₄ aliphatic residue) ₂ , OH, =0, an 0-d_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a d. ₄ - aliphatic residue, C(=0)-OH, a C3_ ₆ cycloaliphatic residue, and a 3 to 6 membered

heterocycloaliphatic residue,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, OCF ₃ , CF ₃ and an unsubstituted 0-d. ₄ -aliphatic residue, preferably selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue and

wherein the C^ cycloaliphatic residue and the 3 to 6 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an N^C^ aliphatic residue), an N(C _1- aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH,

and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁴ and R ⁵ together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, preferably with phenyl or pyridyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C ₃ . ₆ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁴ and R ⁵ together with the nitrogen atom connecting them may optionally be condensed with a C ₃ . 0 cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, wherein the C^o cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1J( aliphatic residue), an N(C†.4 aliphatic residue) ₂ , =0, OH, an O- C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1- aliphatic residue, CF ₃ , CN, a C^- aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C^ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1- -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH^. 4 aliphatic residue), an N(Ci. aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , and wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an Nh^C^ aliphatic residue), an N(C- aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _-4 -aliphatic residue and C(=0)-OH, denotes a C ₂ . ₁₀ -aliphatic residue, preferably a C _2-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(Ci_ ₄ aliphatic residue) ₂ , OH, =0, an O-C- -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 -aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, and C(=0)-OH,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and

and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C^e aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1J( aliphatic residue), an N(Ci_4 aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH,

on the condition that if R ⁶⁰⁶ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, or

R ⁶⁰⁶ denotes S-R ⁶⁰⁷ , O-R ⁶⁰⁸ or N(R ⁶⁰⁹ R ⁶¹⁰ ),

wherein

R ⁶⁰⁷ and R ⁶⁰⁸ in each case represent a Ci.io-aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an H^.,, aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^- aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH, wherein the Ci_ ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, or in each case represent a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, a C ₃ _6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_ ₄ aliphatic residue), an N(Ci_ ₄ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH,

and wherein the Cs-io-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _-8 aliphatic group, preferably a Ci_ ₄ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C!. ₄ aliphatic residue), an N(Ci. ₄ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH,

on the condition that if R ⁶⁰⁷ or R ⁶⁰⁸ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue,

R ⁶⁰⁹ denotes a Ci_ ₁₀ -aliphatic residue, preferably a C^e-aliphatic residue,

unsubstituted or mono- or polysubstituted with at least one substituent

selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^

aliphatic residue), an N(C _-4 aliphatic residue) ₂ , OH, =0, an O-C^-aliphatic

residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, a residue, and C(=0)-OH,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1- aliphatic residue), an N(C^. aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, a C(=0)-0-C _lJr aliphatic residue a C3.6 cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the C ₃ . _e cycloaliphatic residue and the 3 to 6 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-Ο,_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)-OH,

and wherein the C ₃ . ₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C^ aliphatic group, preferably a C _-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C^ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, a aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH,

on the condition that if R ⁶⁰⁹ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue,

R ^{6 0} denotes H or a C^o-aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C!. ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH; preferably denotes a Ci. ₀ - aliphatic residue, more preferably a C _-4 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH^.,, aliphatic residue), an N(C _-4 aliphatic residue) ₂ , OH, =0, an O- C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-Ci_ ₄ aliphatic residue, CF ₃ , CN, a C^- aliphatic residue and C(=0)-OH,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, or

R ⁶⁰⁹ and R ⁶¹⁰ form together with the nitrogen atom connecting them a 3 to 10

membered heterocycloaliphatic residue, preferably a 3 to 6 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NhKC^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, a C^ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the C3_ _e cycloaliphatic residue and the 3 to 6 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _lJt aliphatic residue), an N(Ci_ ₄ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a Ci.4-aliphatic residue and C(=0)-OH,

and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁶⁰⁹ and R ^{6 0} together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, preferably with phenyl or pyridyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_ ₄ aliphatic residue), an N(Ci _-4 aliphatic residue) ₂ , OH, an 0-C _1- aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0- CH ₃ and C(= ₂ H ₅ , a C3_ ₆ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, ' 0 _i _ _ _ benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an 0-C _1-4 aliphatic residue, OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _! . ₄ aliphatic residue) ₂ , OH, =0, an 0-C _1- aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C ₁ . ₄ -aliphatic residue and C(=0)- OH.

In a preferred embodiment of the compound according to general formula (6-I), the residue R ,601

denotes a C _-10 -aliphatic residue, preferably a C _1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _-4 aliphatic residue) ₂ , OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, a S(=0) ₂ -C ₁ ^-aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH, preferably denotes a C^o-aliphatic residue, more preferably a C^s-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an Nh^C^ aliphatic residue), an N(Ci_4 aliphatic residue) ₂ , OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH,

wherein the residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, or denotes a C ₃ .i ₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _-4 aliphatic residue), an N(Ci_ ₄ aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _-4 -aliphatic residue, C(=0)-OH, a C ₃ . ₆ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted residue, and

wherein the C^e cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _! . ₄ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a d. ₄ -aliphatic residue and C(=0)- OH,

and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _-8 aliphatic group, preferably a Ci_ ₄ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C^ aliphatic residue), an aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)-OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(Ci_ aliphatic residue) ₂ , OH, an 0-C _lJt aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-Ci_ ₄ aliphatic residue, a S(=0) ₂ -C ₁ . ₄ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C =0)-0-C ₂ H a C cycloali hatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1- aliphatic residue) ₂ , OH, an 0-Ci_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C^ ₆ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, , benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_ ₄ aliphatic residue), an N(C _-4 aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH, SCF ₃ , a S-Ci_4 aliphatic residue, CF ₃ , CN, a d. ₄ -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C^ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-Ci_ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _M aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)- OH,

and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a C _1-8 aliphatic group, preferably a C^ _A aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _-4 aliphatic residue), an N(C^ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN and C(=0)-OH.

In a further preferred embodiment of the compound according to general formula (6-I), the residue R ⁶⁰¹ represents the partial structure (6-T1)

_ _{(C R} 612a _R 612b _)mf _ _R ,l612c

(6-T1 ), wherein

m6 denotes 0, 1 , 2, 3 or 4, preferably denotes 0, 1 , 2 or 3, more preferably denotes 0, 1 , or 2, R ^612a and R ^612b each independently of one another represent H, F, CI, Br, I, N0 ₂ , NH ₂ , a NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 aliphatic residue or C(=0)-OH, or together denote =0, preferably each independently of one another represent H, F, CI, Br, I, NH ₂ , a NHiC^ aliphatic residue), a N(C ₁ _ ₄ aliphatic residue) ₂ , OH, O-C^ aliphatic residue or a aliphatic residue, or together denote =0,

more preferably each independently of one another represent H, F, CI, Br, I, OH, an O-C^ aliphatic residue or a C1.4 aliphatic residue, or together denote =0, even more preferably each independently of one another represent H, F, OH, an 0-C _1-4 aliphatic residue or a C _1-4 aliphatic residue, or together denote =0, and denotes a C _-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an Η(^_ ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1- aliphatic residue, a S(=0) ₂ -C _1- aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-0H, preferably denotes a C^ aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _-4 aliphatic residue), an N(Ci_4 aliphatic residue) ₂ , OH, =0, an 0-C _{1 4} aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue and C(=0)-OH,

or denotes a C ₃ . ₀ -cycloaliphatic residue or a 3 to 10 membered

heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, a C ₃ . ₆ cycloaliphatic residue and a 3 to 6 membered heterocycloaliphatic residue, preferably when m6 is≠ 0,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O- C _1-4 -aliphatic residue, and

wherein the C^ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _-4 aliphatic residue), an N(C . ₄ aliphatic residue) ₂ , OH, =0, an 0-Ci_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)-OH,

or denotes - preferably when m6 is 0 or 2, more preferably when m6 is 0 - an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1- aliphatic residue), an N{C^ aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, a S(=0) ₂ -C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C3- ₆ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, , benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, preferably denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_ ₄ aliphatic residue), an NfC^ aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)- 0-C ₂ H ₅ , a C ₃ _ ₆ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, > 0 _t t ^' aO _ _t ? ΐ^ ⁾ , benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, preferably when m6 is = 0,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O- C _1-4 -aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d_ ₄ aliphatic residue), an N(d. ₄ aliphatic residue) ₂ , OH, an 0-C _-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue,

CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C _M cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C^ aliphatic residue), an N(C^ aliphatic residue) ₂ , OH, =0, an O-C- aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-Ci. ₄ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH.

Preferably,

R ⁶⁰¹ represents the partial structure (6-T1),

wherein

m6 denotes 0, 1 , 2 or 3, preferably denotes 0, 1 or 2,

R ^612a and R ^612b each independently of one another represent H, F, CI, Br, I, OH, an O-C^

aliphatic residue or a C1- ₄ aliphatic residue, or together denote =0, preferably each independently of one another represent H, F, OH, a 0-C _1-2 aliphatic residue or a C-|. ₂ aliphatic residue, or together denote =0,

and denotes a aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, a S(=0) ₂ -C . 4-aliphatic residue and C(=0)-0H, preferably denotes denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1- aliphatic residue, 0CF ₃ , CF ₃ , a C _-4 -aliphatic residue and C(=0)-0H,

or denotes a C3-io-cycloaliphatic residue or a 3 to 10 membered

heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , CF ₃ , a d_ ₄ -aliphatic residue, C(=0)-OH, a C ₃ . ₆ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0- C _1- -aliphatic residue, and

wherein the C^e cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , CF ₃ , a C _1-4 -aliphatic residue and C(=0)-OH,

or denotes - preferably when m6 is 0 or 2, more preferably when m6 is 0 - an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C1.4 aliphatic residue, a S(=0) ₂ -C ₁ _ ₄ aliphatic residue, N0 ₂ , N(C _1J( aliphatic residue) ₂ , CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ , C(=0)-0-C ₂ H ₅ , ^' $ ^' 0 ,

a C ₃ .6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl or oxazolyl, preferably denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O- Ci_4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-Ci_ ₄ aliphatic residue, CF ₃ , CN, a C^. 4-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ , C(=0)-0- C ₂ H5, a C3_ ₆ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl or oxazolyl, preferably when m6 is 0,

wherein the Ci _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O- C _-4 -aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O- Ci_4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-O-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ ,

wherein the Cs-e cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , CF ₃ a C _1-4 -aliphatic residue and C(=0)-OH.

represents the partial structure (6-T1),

wherein

m6 denotes 0, 1 , 2 or 3, preferably denotes 0, 1 or 2,

R ^612a and R ^612b each independently of one another represent H, F, CI, Br, I, OH, an O-C^

aliphatic residue or a C _-4 aliphatic residue, or together denote =0,

preferably each independently of one another represent H, F, OH, a O-C1.2 aliphatic residue or a C^ aliphatic residue, or together denote =0, and

R ^612c denotes a aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C1.4 aliphatic residue, CF ₃ , CN, a residue, preferably denotes a C^ aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an 0-C _1-4 aliphatic residue, CF ₃ , and a C _1- -aliphatic residue,

wherein the residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an 0-C _1-4 aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, wherein the d. ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, or denotes - preferably when m6 is 0 or 2, more preferably when m6 is 0 - an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-Ci_ ₄ aliphatic residue, OCF ₂ H, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , CH ₂ -

¾-0 \-0

OH, CH ₂ -OCH ₃ , S(=0) ₂ -CH ₃ , SCF ₃ , N0 ₂ , N(d_ ₄ aliphatic residue) ₂ , o , , C(=0)-0- CH ₃ and C(=0)-0-C ₂ H ₅ , a C ₃ . ₆ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl, preferably denotes - preferably when m6 is 0 or 2, more preferably when m6 is 0 - an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0- C ₂ H ₅ , a C^ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl,

wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-d_ ₄ aliphatic residue, OCF ₃ , CF ₃ , CN, a d^-aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ , and

wherein the C« cycloaliphatic residue and the 3 to 6 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , CF ₃ a C _1- -aliphatic residue and C(=0)-OH.

In a further preferred embodiment of the compound according to general formula (6-I), the residue R ⁶⁰¹ represents the partial structure (6-T1),

wherein

m6 is 0, 1 or 2, preferably 0 or 2, more preferably 2, and

R ^612a and R ^{6 2b} each independently of one another represent H, F, OH, a 0-d_ ₄ aliphatic residue or a C _-4 aliphatic residue or together denote =0; preferably H, F, OH, CH ₃ or OCH ₃ or together denote =0;

R ^612c denotes a d^ aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, CN, OH, an unsubstituted 0-d_ aliphatic residue, an unsubstituted S(=0) ₂ -C . aliphatic residue, CF ₃ , and an unsubstituted C- -aliphatic residue, preferably denotes a aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted O-C^ aliphatic residue, CF ₃ , and an unsubstituted C aliphatic residue

or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted O-C^ aliphatic residue, CF ₃ , and an unsubstituted C^-aliphatic residue,

or

wherein

m6 is 0 or 2, more preferably 0, and

R ^612a and R ^612b each independently of one another represent H, F, OH, a 0-C _1-4 aliphatic residue or a Ci_ aliphatic residue; preferably H, F, OH, CH ₃ or OCH ₃ ; and

R ^612c denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , S(=0) ₂ -CH ₃ , SCF ₃ , N0 ₂ , N(d_ ₄ aliphatic residue) ₂ , _ residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ , C(=0)-0-C ₂ H ₅ and phenyl, preferably denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-d^ aliphatic residue, OCF ₃ , CF ₃ , CN, a d. ₄ -aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ , C(=0)-0-C ₂ H ₅ and phenyl,

wherein phenyl may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ .

Preferably,

R ⁶⁰ represents the partial structure (6-T1 ),

wherein

m6 is 0, 1 or 2, preferably 0 or 2, more preferably 2, and

R ^{6 2a} and R ⁶¹² each independently of one another represent H, F, OH, CH ₃ or OCH ₃ or together denote =0, more preferably H, F, OH or CH ₃ , even more preferably H,

R ^612c denotes a C^ aliphatic residue, preferably methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, CN, OH, S(=0) ₂ -CH ₃ , an unsubstituted O-C^ aliphatic residue, preferably O-methyl and O-tert. -butyl, and CF ₃ , preferably denotes a C _1-4 aliphatic residue, preferably methyl, ethyl, n-propyl, 2-propyl, n- butyl, isobutyl, sec-butyl, or tert. -butyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted O-C^ aliphatic residue, preferably O-methyl and O-tert-butyl, and CF ₃ , or denotes a C3_i ₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, preferably cyclopropyl, cyclopentyl, cyclohexyl, morpholinyl, oxetanyl, or tetrahydropyranyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted O-C^ aliphatic residue, preferably O-methyl and O-ethyl, CF ₃ , and an unsubstituted C - - aliphatic residue, preferably methyl or ethyl,

or

wherein

m6 is 0 or 2, more preferably 0, and

R ^612a and R ^612b each independently of one another represent H, F, OH, CH ₃ or OCH ₃ ; preferably H, OH or CH ₃ , and

R ^612c denotes an aryl or heteroaryl, preferably phenyl or pyridyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, preferably OCH ₃ , OCF ₃ , OCF ₂ H, CH ₂ -OH,

CH ₂ -OCH ₃ , S(=0) ₂ -CH ₃ , SCF ₃ , N0 ₂ , N(CH ₃ ) ₂ , ^' 0 , H CF ₃ , CN, a C^-aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ , C(=0)-0-C ₂ H ₅ and phenyl, preferably denotes an aryl or heteroaryl, preferably phenyl or pyridyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C-i_ ₄ aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ , C(=0)-0-C ₂ H ₅ and phenyl,

wherein phenyl may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a d.4-aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ .

Particularly preferred is a compound according to general formula (I) which has the following general formula (6-l-d), wherein the particular radicals and parameters have the meanings described herein in connection with the compounds according to the invention and preferred embodiments thereof.

In a preferred embodiment of the compound according to general formula (6-1), the residue

R ⁶⁰² represents F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C _1- -aliphatic residue, a S-C^-aliphatic residue, a O-C^-aliphatic residue, wherein the C _1- aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C3_ ₆ -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted.

Preferably,

R ⁶⁰² represents F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C^-aliphatic residue, a S-C^-aliphatic residue, a 0-Ci. -aliphatic residue,

wherein the C-|. ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted O-C- -aliphatic residue,

a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C _1-4 -aliphatic residue and a 0-C _1- -aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted residue,

and wherein the C ₃ . ₆ -cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C- aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, an unsubstituted C _1-4 -aliphatic residue and an unsubstituted O- C^-aliphatic residue.

More preferably,

R ⁶⁰² represents F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S-C^-aliphatic residue, a O-C^-aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted 0-C-|. ₄ -aliphatic residue, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, morpholinyl, or piperidiny!, preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, an unsubstituted C^-aliphatic residue and an unsubstituted O-C^-aliphatic residue,

and wherein cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, 4- methylpiperazinyl, morpholinyl or piperidinyl may in each case be optionally bridged via an C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, an unsubstituted C^-aliphatic residue and an unsubstituted O-C^-aliphatic residue.

Even more preferably,

R ⁶⁰² represents F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec-butyl; tert.-butyl; CH ₂ -OH; CH ₂ -0-CH ₃ ; CH ₂ -CH ₂ -OH; CH ₂ -CH ₂ -OCH ₃ ; O-methyl; O-ethyl; O- (CH ₂ ) ₂ -0-CH ₃ ; 0-(CH ₂ ) ₂ -OH; S-Methyl; S-ethyl; cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl; preferably represents F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec-butyl; tert.-butyl; O-methyl; O-ethyl; 0-(CH ₂ ) ₂ -0-CH ₃ ; 0-(CH ₂ ) ₂ -OH; S- ethyl; S-ethyl; cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Still more preferably,

R ⁸⁰² is selected from the group consisting of F; CI; CF ₃ ; CN; SCF ₃ ; OCF ₃ ; CH ₃ ; C ₂ H ₅ ; n-propyl; iso- propyl; t-butyl; CH ₂ -OH; CH ₂ -0-CH ₃ ; cyclopropyl; 0-CH ₃ and 0-C ₂ H ₅ ; preferably is selected from the group consisting of F; CI; CF ₃ ; CN; SCF ₃ ; OCF ₃ ; CH ₃ ; C ₂ H ₅ ; n-propyl; iso-propyl; t-butyl; cyclopropyl; 0-CH ₃ and 0-C ₂ H ₅ .

In particular,

R ⁶⁰² is selected from the group consisting of F; CI; CF ₃ ; CH ₃ ; C ₂ H ₅ , iso-propyl; CH ₂ -0-CH ₃ ;

cyclopropyl; and 0-CH ₃ ; preferably is selected from the group consisting of F; CI; CF ₃ ; CH ₃ ; C ₂ H ₅ , iso-propyl; cyclopropyl; and 0-CH ₃ .

More particular,

R ⁶⁰² is selected from the group consisting of CF ₃ ; CH ₃ ; C ₂ H ₅ , iso-propyl; CH ₂ -0-CH ₃ ; and 0-CH ₃ ; preferably is selected from the group consisting of CH ₃ ; C ₂ H ₅ , iso-propyl; CH ₂ -0-CH ₃ ; and 0-CH ₃ . In a particular preferred embodiment of the compound according to general formula (6-1), the residue R ⁶⁰² denotes CH ₃ or CF ₃ , most preferably R ⁶⁰² denotes CH ₃ .

In a further preferred embodiment of the compound according to general formula (6-1), the residue R ⁶⁰³ represents H; F; CI; Br; I; CN; CF ₃ ; SCF ₃ ; N0 ₂ ; OCF ₃ ; a C^-aliphatic residue, a O-C^-aliphatic residue, a S-C^-aliphatic residue, wherein the C- aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted O-C^-aliphatic residue; a C ₃ _6-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C^-aliphatic residue and a O-C^-aliphatic residue,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted O-C^-aliphatic residue,

and wherein the C3_ ₆ -cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C^ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, an unsubstituted C _-4 -aliphatic residue and an unsubstituted O- C _1-4 -aliphatic residue.

Preferably,

R ⁶⁰³ represents H; F; CI; Br; I; CN; CF ₃ ; SCF ₃ ; N0 ₂ ; OCF ₃ ; a ^-aliphatic residue, a O-C^-aliphatic residue, a S-C^-aliphatic residue,

wherein the C^ aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted O-C^-aliphatic residue.

More preferably,

R ⁶⁰³ represents H; F; CI; Br; I; CN; CF ₃ ; SCF ₃ ; N0 ₂ ; OCF ₃ ; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec-butyl; tert.-butyl; O-methyl; O-ethyl; 0-(CH ₂ ) ₂ -0-CH ₃ ; 0-(CH ₂ ) ₂ -OH; S-Methyl; or S-Ethyl.

Even more preferably

R ⁶⁰³ represents H; F; CI; Br; I; CN; CF ₃ ; SCF ₃ ; OCF ₃ ; methyl; ethyl; O-methyl; or O-ethyl, preferably represents H; F; CI; Br; I; CF ₃ ; SCF ₃ ; OCF ₃ ; methyl; ethyl; O-methyl; or O-ethyl.

Still more preferably

R ⁶⁰³ represents H; F; CI; Br; CN; CF ₃ ; SCF ₃ ; OCF ₃ ; O-methyl or methyl, preferably represents H; F; CI;

CF ₃ ; SCF ₃ ; OCF ₃ ; O-methyl or methyl.

In particular

R ⁶⁰³ represents H; F; CI; Br; CN; or methyl, preferably H, F, CI, Br or CN, more preferably H, CI or Br, most preferably H.

In a further preferred embodiment of the compound according to general formula (6-I), the residue R ⁶⁰⁴ denotes a C^o-aliphatic residue, preferably a Ci. ₈ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(d. ₄ aliphatic residue) ₂ , OH, =0, an 0-d-4-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-d. ₄ -aliphatic residue, CF ₃ , CN, a d. ₄ -aliphatic residue, a C(=0)- 0-d- ₄ -aliphatic residue, and C(=0)-OH,

wherein the d. ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF3, CF ₃ and an unsubstituted 0-d_ ₄ -aliphatic residue,

or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d_4 aliphatic residue), an N(C _1- aliphatic residue) ₂ , OH, =0, an 0-C _1- aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, a C(=0)-0-C _1-4 -aliphatic residue a C^ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and

wherein the C _M cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d_ ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-d_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-d. ₄ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a d. ₈ aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an aliphatic residue), an N(d_ ₄ aliphatic residue) ₂ , OH, =0, an 0-d_ ₄ aliphatic residue, a C(=0)-0-C _lJ( -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-d., aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH, on the condition that if R ⁶⁰⁴ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1- aliphatic residue), an N(d_ ₄ aliphatic residue) ₂ , OH, an O-d^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0- c residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF3, CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an

aliphatic residue) ₂ , OH, an 0-C _1-4 aliphatic residue, OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a d. ₄ -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C ₃ _ ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an Nh^C^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a d. ₄ -aliphatic residue and C(=0)- OH,

and wherein the aryl or the heteroaryl residue may in each case be optionally bridged, preferably in each case is bridged, via a C _1-8 aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-CL ₄ aliphatic residue, CF ₃ , CN and C(=0)-OH,

R ⁶⁰⁵ denotes H or a C^o-aliphatic residue, preferably a C _1-4 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _! _ ₄ aliphatic residue) ₂ , OH, =0, an 0-Ci_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue,

or

R ⁶⁰⁴ and R ⁶⁰⁵ form together with the nitrogen atom connecting them a 3 to 10 membered

heterocycloaliphatic residue, preferably a 4 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C,. ₄ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, a C^ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and wherein the C ₃ _ ₆ cycloaliphatic residue and the 3 to 6 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C-|. ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue,

CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)-OH,

and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁴ and R ⁵ together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, preferably with phenyl, pyridyl or thienyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C^. _A aliphatic residue) ₂ , OH, an O- C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1- aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , 6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, ' O O , , benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁴ and R ⁵ together with the nitrogen atom connecting them may optionally be condensed with a C ₃ _ ₁₀ cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, wherein the C ₃ _io cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an N^C^ aliphatic residue), an N(C _ ₄ aliphatic residue) ₂ , =0, OH, an O- CM aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 - aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a Cs-e cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_ 4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an 0-C _1-4 aliphatic residue, OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(d. ₄ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)-OH. In a further preferred embodiment of the compound according to general formula (6-1), the residue R ⁶⁰⁴ represents the partial structure (6-T2)

_ _(CR61 3a _R 613b _)n6 _ _R 613c wherein

n6 denotes 0, 1 , 2, or 3, preferably denotes 1 , 2 or 3, more preferably denotes 1 or 2, even more preferably denotes 1 ,

R ^613a and R ^613b each independently of one another represent H, F, CI, Br, I, N0 ₂ , NH ₂ , a NH(C ₁ _ ₄ aliphatic residue), an (C^ _A aliphatic residue) ₂ , OH, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 aliphatic residue or C(=0)-OH, or together denote =0,

preferably each independently of one another represent H, F, CI, Br, I, NH ₂ , a ΝΗ(0|. aliphatic residue), a N(C _1- aliphatic residue) ₂ , OH, O-C1.4 aliphatic residue or a C _1-4 aliphatic residue or together denote =0,

more preferably each independently of one another represent H, F, CI, Br, I, an 0-Ci_ ₄ aliphatic residue or a C _1-4 aliphatic residue or together denote =0,

even more preferably each independently of one another represent H, F, an 0-C _1-4 aliphatic residue or a C^ aliphatic residue or together denote =0, and

R denotes a C _1J( aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue,

0CF ₃ , SH, SCF ₃ , a S-d. ₄ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)- OH,

or denotes - preferably when n6 is≠ 0, more preferably when n is 1 - a C ₃ . ₁₀ - cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1J( aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, a cycloaliphatic residue and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the C^ cycloaliphatic residue and the 3 to 6 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of

F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C^ aliphatic residue), an N(C!. ₄ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue,

CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)-OH,

or denotes - preferably when n6 is≠ 0, more preferably when n6 is 1 , - an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_4 aliphatic residue), an N(Ci_ aliphatic residue) ₂ , OH, an aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-CL4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)- CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C^cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, ? ° , ^Ό , phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d- aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a

residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _! . aliphatic residue), an N(Ci_ ₄ aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S- C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)-OH, denotes H or a Ci_i ₀ -aliphatic residue, preferably a Ci_ ₆ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-Ci. ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, and a C _-4 -aliphatic residue,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted 0-Ci_ ₄ -aliphatic residue, and R ⁶⁰⁵ form together with the nitrogen atom connecting them a 3 to 10 membered

heterocycloaliphatic residue, preferably a 4 to 7 membered heterocycloaliphatic residue, or preferably selected from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, 4-methylpiperazinyl, oxazepanyl, thiomorpholinyl, azepanyl,

-N O

, more preferably selected from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, 4-methylpiperazinyl, oxazepanyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, C(=0)-OH, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _-4 aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue, a C ₃ _ ₆ cycloaliphatic residue, preferably cyclopropyl, cyclobutyl or cyclopentyl, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, preferably selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted 0-Ci-4-aliphatic residue,

wherein the C3_ ₆ cycloaliphatic residue and the 3 to 6 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _lJt aliphatic residue), an N(Ci_ aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)-OH,

and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁴ and R ⁵ together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, preferably with phenyl, pyridyl or thienyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, a C ₃ . ₆ cycloaliphatic residue, a 3 to

6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, and pyridyl,

and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁴ and R ⁵ together with the nitrogen atom connecting them may optionally be condensed with a C ₃ _ 10 cycloaliphatic residue, preferably cyclopropyl, cyclobutyl or cycclopentyl, or a 3 to 10 membered heterocycloaliphatic residue, preferably oxetanyl or oxiranyl, wherein the C ₃ _i ₀ cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_4 aliphatic residue), an (C^ aliphatic residue) ₂ , =0, OH, an 0-Ci_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a d_ ₄ -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , 0-CH ₂ -OH, O-CH2-O-CH3, SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _-4 -aliphatic residue, and C(=0)-OH, and

wherein the C ₃ . _e cycloaliphatic residue and the 3 to 6 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-d. ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH.

Preferably,

R ⁶⁰⁴ represents the partial structure (6-T2),

wherein

n6 denotes 0, 1 , 2, or 3, preferably denotes 1 , 2 or 3, more preferably denotes 1 or 2, even more preferably denotes 1 ,

R ^613a and R ^613b each independently of one another represent H, F, CI, Br, I, an 0-C _1-4 aliphatic residue or a C- aliphatic residue or together denote =0,

preferably each independently of one another represent H, F, a 0-C _1-2 aliphatic residue or a C _1-2 aliphatic residue or together denote =0, and

R ^613c denotes a Ci_ ₄ aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , a C^-aliphatic residue and C(=0)-OH,

or denotes - preferably when n6 is≠ 0, more preferably when n6 is 1 -a C^o- cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C-1.4 aliphatic residue, OCF ₃ , CF ₃ , a C _1-4 - aliphatic residue, C(=0)-OH, a C^ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-Ci. ₄ -aliphatic residue, and

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C- aliphatic residue, OCF ₃ , CF ₃ , a C,^- aliphatic residue and C(=0)-OH,

or denotes - preferably when n6 is≠ 0, more preferably when n6 is 1 - an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _ ₄ -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C ₃ . ₆ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl or oxazolyl,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted, preferably

unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)- 0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ ,

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , CF ₃ a Ci_ ₄ - aliphatic residue and C(=0)-OH,

,605

R' denotes H or a C^-aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _{1 4} aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue,

wherein the Ci. ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted O-C^-aliphatic residue,

or

R ⁶⁰⁴ and R ⁶⁰⁵ form together with the nitrogen atom connecting them a 3 to 10 membered

heterocycloaliphatic residue, preferably a 4 to 7 membered heterocycloaliphatic residue, or idinyl,

morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, 4-methylpiperazinyl, oxazepanyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, C(=0)-OH, an O-C^ aliphatic residue, OCF ₃ , SCF ₃ , a S-C^ aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, and a C^ cycloaliphatic residue, preferably cyclopropyl, cyclobutyl or cyclopentyl,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, CF ₃ and an unsubstituted 0-C ₁ _ ₄ -aliphatic residue, preferably selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted 0-Ci_ 4-aliphatic residue,

wherein the C^e cycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, 0CF ₃ , SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _-4 -aliphatic residue and C(=0)-OH,

and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁶⁰⁴ and R ⁶⁰⁵ together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, preferably with phenyl or pyridyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , a C^-aliphatic residue, C(=0)-OH, a C ₃ . ₆ cycloaliphatic residue, benzyl, phenyl, thienyl, and pyridyl,

and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁶⁰⁴ and R ⁶⁰⁵ together with the nitrogen atom connecting them may optionally be condensed with a C ₃ . ₁₀ cycloaliphatic residue, preferably cyclopropyl, cyclobutyl or cycclopentyl, or a 3 to 10 membered heterocycloaliphatic residue, preferably oxetanyl or oxiranyl, wherein the C^o cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ ,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and wherein benzyl, phenyl, thienyl, and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _1-4 aliphatic residue, OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0- CH ₃ , SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a Ci_ ₄ -aliphatic residue, and C(=0)- OH, and

wherein the C^ cycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SCF ₃ , a S-C^ aliphatic residue, CF ₃ , a C _1- -aliphatic residue and C(=0)-OH. More preferably,

R ⁶⁰⁴ represents the partial structure (6-T2),

wherein

n6 denotes 0, 1 , 2 or 3, preferably denotes 1 or 2, more preferably denotes 1 ,

R ^613a and R ^613b each independently of one another represent H, F, CI, Br, I, an 0-C _1-4 aliphatic residue or a C-|_ ₄ aliphatic residue or together denote =0,

preferably each independently of one another represent H, F, a 0-C _1-2 aliphatic residue or a 0^2 aliphatic residue or together denote =0, and

R ^613c denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, an O-C^ aliphatic residue, CF ₃ , and a C _-4 -aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, CF ₃ and an unsubstituted 0-C ₁ _ ₄ -aliphatic residue, or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an O-C^ aliphatic residue, CF ₃ , and a C^-aliphatic residue,

wherein the Ci _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, CF ₃ and an unsubstituted O-C^-aliphatic residue, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O- C aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C^ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl,

wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , CN, a C _-4 -aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ , and

wherein the C3.6 cycloaliphatic residue and the 3 to 6 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-0,-4 aliphatic residue, OCF ₃ , CF ₃ a C^-aliphatic residue and C(=0)-OH, R ⁶⁰⁵ denotes H or an unsubstituted C _-4 -aliphatic residue or a C _1-4 -aliphatic residue monosubstituted with O-methyl, wherein the C^-aliphatic residue is in each case preferably selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl and tert.-butyl, more preferably selected from the group consisting of methyl and ethyl,

or

R ⁶⁰⁴ and R ⁶⁰⁵ form together with the nitrogen atom connecting them a 3 to 10 membered

heterocycloaliphatic residue, more preferably selected from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, 4-methylpiperazinyl, oxazepanyl, thiomorpholinyl,

azepanyl, , in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, C(=0)-OH, an O-C^ aliphatic residue, OCF ₃ , SCF ₃ , a S-C^ aliphatic residue, CF ₃ , and a Ci- ₄ -aliphatic residue, cyclopropyl, cyclobutyl and cyclopentyl,

wherein the C _1-4 -aliphatic residue is in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, CF ₃ and an unsubstituted O-C^-aliphatic residue, preferably is in each case unsubstituted,

and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁶⁰⁴ and R ⁶⁰⁵ together with the nitrogen atom connecting them may optionally be condensed with phenyl or pyridyl, wherein the phenyl or pyridyl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _1j( aliphatic residue, OCF ₃ , SCF ₃ , a S-C^ aliphatic residue, CF ₃ , a C _1- -aliphatic residue, C(=0)-OH, and a C ₃ . _e cycloaliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and wherein the C ₃ . ₆ cycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , a C^-aliphatic residue and C(=0)-OH, and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁶⁰⁴ and R ⁶⁰⁵ together with the nitrogen atom connecting them may optionally be condensed with a C ₃ . ₆ cycloaliphatic residue, preferably cyclopropyl, cyclobutyl or cycclopentyl, or a 4 to 7 membered

heterocycloaliphatic residue, preferably oxetanyl or oxiranyl, wherein the C^ cycloaliphatic residue or the 4 to 7 membered heterocycloaliphatic residue condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, an O-C^ aliphatic residue, OCF ₃ , SCF ₃ „ CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ .

Even more preferably, R ⁶⁰⁴ represents the partial structure (I-T2),

wherein

n6 denotes 0, 1 , 2 or 3, preferably denotes 1 or 2, more preferably denotes 1 , R ^613a and R ⁶¹³ each independently of one another represent H, F, a O-C^ aliphatic residue or a

0^4 aliphatic residue or together denote =0; preferably each independently of one another represent H, F, CH ₃ or OCH ₃ or together denote =0;

R ^613c denotes a C-|. ₄ aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, an unsubstituted O-

Ci_4 aliphatic residue, CF ₃ , and an unsubstituted C _1-4 -aliphatic residue, or denotes a C ₃ _ ₀ -cycloaliphatic residue, preferably selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, or a 3 to 10 membered heterocycloaliphatic residue, preferably selected from the group consisting of pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl and tetrahydropyranyl, more preferably tetrahydropyranyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted O-C^ aliphatic residue, CF ₃ , and an unsubstituted C^-aliphatic residue,

or denotes an aryl or heteroaryl, preferably phenyl or pyridyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C^-aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ , C(=0)-0-C ₂ H ₅ and phenyl, wherein phenyl may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ ,

CF ₃ , CN, a C^-aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ ,

R ⁶⁰⁵ denotes H or an unsubstituted C _-4 -aliphatic residue or a C _-4 -aliphatic residue, which is

monosubstituted with OCH ₃ , preferably H, methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec- butyl or tert.-butyl or CH ₂ -OCH ₃ , C ₂ H ₄ -OCH ₃ or C ₃ H ₆ -OCH ₃ , more preferably H, methyl or ethyl, preferably denotes H or an unsubstituted C^-aliphatic residue, preferably H, methyl, ethyl, n- propyl, 2-propyl, n-butyl, isobutyl, sec. -butyl or tert.-butyl, more preferably H, methyl or ethyl, or

R ⁶⁰⁴ and R ⁶⁰⁵ form together with the nitrogen atom connecting them a morpholinyl, piperidinyl,

pyrrolidinyl, azetidinyl, piperazinyl, 4-methylpiperazinyl, oxazepanyl, thiomorpholinyl, azepanyl,

^^^*/ , ^- , and \— y , tetrahydroquinolinyl, tetrahydroisoquinolinyl, tetrahydroimidazo[1 ,2-a]pyrazinyl, octahydropyrrolo[1 ,2-a]pyrazinyl, , , dihydroindolinyl, or dihydroisoindolyl, preferably a morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, 4-methylpiperazinyl, oxazepanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolinyl, or dihydroisoindolyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, C(=0)-OH, an 0-C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a S-d. ₄ aliphatic residue, CF ₃ , and a Ci_4-aliphatic residue, cyclopropyl, cyclobutyl and cyclopentyl,

wherein the C _1-4 -aliphatic residue is in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, OH, =0, CF ₃ and an unsubstituted O-C^-aliphatic residue, preferably is in each case unsubstituted. more preferably,

represents the partial structure (6-T2),

wherein

n6 denotes 0, 1 , 2 or 3, preferably denotes 1 or 2, more preferably denotes 1 ,

R ^613a and R ^613b each independently of one another represent H, F, CH ₃ or OCH ₃ or together denote =0, preferably each independently of one another represent H or CH ₃ , more preferably H,

R ^613c denotes a Ci_4 aliphatic residue, preferably methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, an unsubstituted O- Ci_4 aliphatic residue, and CF ₃ ,

or denotes cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl and tetrahydropyranyl, more preferably tetrahydropyranyl or morpholinyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted 0-C _1-4 aliphatic residue, CF ₃ , and an unsubstituted C^-aliphatic residue,

or denotes an aryl or heteroaryl, preferably phenyl or pyridyl, more preferably phenyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-Ci_ ₄ aliphatic residue, OCF ₃ , CF ₃ , CN, and a C^-aliphatic residue, denotes H, methyl or ethyl or C ₂ H ₄ OCH ₃ or C ₃ H ₆ OCH ₃ , more preferably H or methyl or ethyl, even more preferably methyl, or

R ⁶⁰⁴ and R ⁶⁰⁵ form together with the nitrogen atom connecting them a morpholinyl, piperidinyl,

pyrrolidinyl, azetidinyl, oxazepanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, thiomorpholinyl, azepanyl, or tetrahyd roim idazo[1 , 2-a] pyrazi ny I , octahydropyrrolo[1 ,2-a]pyrazinyl, , dihydroindolinyl, or dihydroisoindolyl, preferably a a morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazepanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolinyl, or dihydroisoindolyl, more preferably a morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazepanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, more preferably a morpholinyl, oxazepanyl, tetrahydroquinolinyl, or tetrahydroisoquinolinyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, C(=0)-OH, C(=0)-CH ₃ , C(=0)- OCH ₃ , O-methyl, O-ethyl, OCF ₃ , SCF ₃ , CF ₃ , methyl, CH ₂ CF ₃ , CH ₂ OH, CH ₂ -OCH ₃ , CH ₂ CH ₂ - OCH ₃ , ethyl, n-propyl, 2-propyl, cyclopropyl, and cyclobutyl, preferably selected from the group consisting of F, CI, OH, =0, C(=0)-OH, O-methyl, O-ethyl, OCF ₃ , SCF ₃ , CF ₃ , methyl, ethyl, n- propyl, 2-propyl, cyclopropyl, and cyclobutyl.

In a preferred embodiment of the compound according to general formula (6-1), the residue

R ⁶⁰⁶ denotes a C _2- io-aliphatic residue, preferably a C ₂ . ₈ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1J( aliphatic residue), an N(C^ _A aliphatic residue) ₂ , OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 -aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)- OH,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-Ci_ ₄ -aliphatic residue,

or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1- aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, and C(=0)-OH,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF3, CF ₃ and an unsubstituted O-C- -aliphatic residue, and and wherein the C3_ ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C^s aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C,. aliphatic residue), an (^_ ₄ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH,

on the condition that if R ⁶⁰⁶ denotes a 3 to 10 membered heterocycloaliphatic residue, the binding is carried out via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue, or otes S-R ⁶⁰⁷ , O-R ⁶⁰⁸ or N(R ⁶⁰⁹ R ⁶¹⁰ ),

wherein

R ⁶⁰⁷ and R ⁶⁰⁸ in each case represent a C _1-10 -aliphatic residue, preferably a C _1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an Nh^C^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, CF ₃ , CN, a C _1- -aliphatic residue and C(=0)-OH,

wherein the C _lJt -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue,

or in each case represent a C ₃ . ₀ -cycloaliphatic residue or a 3 to 10 membered

heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an ΝΗ(^. ₄ aliphatic residue), an N(C^. ₄ aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S- C- aliphatic residue, CF ₃ , CN, a cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF3, CF ₃ and an unsubstituted O-C^-aliphatic residue, and

wherein the Cs-e cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C^. aliphatic residue) ₂ , OH, =0, an 0-C _-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

and wherein the C ₃ . ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a Ci_ ₈ aliphatic group, preferably a C^ ₄ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_ aliphatic residue), an N(C!_ ₄ aliphatic residue) ₂ , OH, =0, an 0-d. ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-Ci_ ₄ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)-OH,

on the condition that if R ⁶⁰⁷ or R ⁶⁰⁸ denotes a 3 to 10 membered heterocycloaliphatic residue, the binding is carried out via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue,

R ⁶⁰⁹ denotes a C^o-aliphatic residue, preferably a C^e-aliphatic residue,

unsubstituted or mono- or polysubstituted with at least one substituent

selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci. ₄

aliphatic residue), an N{C^. ₄ aliphatic residue) ₂ , OH, =0, an O-C^-aliphatic

residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, a C(=0)-0-C _1-4 -aliphatic residue, and C(=0)-OH, wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-d. ₄ -aliphatic residue, or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an H(d.4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-d_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-d.4 aliphatic residue, CF ₃ , CN, a d. ₄ -aliphatic residue, C(=0)-OH, a C(=0)-0-C _lJt -aliphatic residue a C ₃ . ₆ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered

heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C^ aliphatic residue), an N(d_ ₄ aliphatic residue) ₂ , OH, =0, an 0-C aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1- aliphatic residue, CF ₃ , CN, a d^-aliphatic residue and C(=0)-OH,

and wherein the C ₃ . ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a d_ ₈ aliphatic group, preferably a d_ ₄ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_4 aliphatic residue), an N(d^ aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-d. ₄ aliphatic residue, CF ₃ , CN, a d. ₄ -aliphatic residue and C(=0)-OH,

on the condition that if R ⁶⁰⁹ denotes a 3 to 10 membered heterocycloaliphatic residue, the binding is carried out via a carbon atom of the 3 to 10 membered heterocycloaliphatic residue,

denotes H or a d. ₁₀ -aliphatic residue, preferably a d_ ₄ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _ ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-d_4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a d_4-aliphatic residue and C(=0)-OH, preferably denotes a d. ₀ -aliphatic residue, more preferably a d_ ₄ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d. aliphatic residue), an N(Ci_ ₄ aliphatic residue) ₂ , OH, =0, an 0-C _1- aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-d_4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-d. ₄ -aliphatic residue, or

R ⁶⁰⁹ and R ⁶¹⁰ form together with the nitrogen atom connecting them a 3 to 10 membered

heterocyc!oaliphatic residue, preferably a 3 to 6 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an Nh C^ aliphatic residue), an N(C _1J( aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C1-4 aliphatic residue, CF ₃ , CN, a C _1- -aliphatic residue, C(=0)-OH, a C3_ ₆ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and wherein the C^ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH,

and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁶⁰⁹ and R ⁶¹⁰ together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, preferably with phenyl or pyridyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1J( aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C ₁ . ₄ -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0- CH ₃ and C ₃ . ₆ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1- aliphatic residue), an N(C^ aliphatic residue) ₂ , OH, an 0-C _1-4 aliphatic residue, OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH, SCF ₃ , a S-d. ₄ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_ ₄ aliphatic residue), an N(d. ₄ aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)- OH. Preferably,

R ⁶⁰⁶ denotes a C ₂ .io-aliphatic residue, preferably a C ₂ . ₈ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 -aliphatic residue, a C(=0)-0-

C _-4 -aliphatic residue, CF ₃ , CN, and a Ci_ ₄ -aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1- -aliphatic residue,

or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , CN, a C ₁ _ ₄ -aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI,

Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an O-C^ aliphatic residue, a

C(=0)-0-C ₁ . ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, and a C _1-4 - aliphatic residue.

on the condition that if R ⁶⁰⁶ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,

or

R ⁶⁰⁶ denotes S-R ⁶⁰⁷ or O-R ⁶⁰⁸ ,

wherein

R ⁶⁰⁷ and R ⁶⁰⁸ in each case represent a C _1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, an NH(C _1-4 aliphatic residue), an N(Ci_ ₄ aliphatic residue) ₂ , a

residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted 0-Ci_ ₄ -aliphatic residue,

or in each case denote a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a C(=0)-0-C ₁ . ₄ -aliphatic residue, a S-C^ aliphatic residue, CF ₃ , and a C^-aliphatic residue, wherein the C^-aliphatic residue in each case may be unsubstltuted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstltuted 0-C _1-4 -aliphatic residue,

and wherein the C ₃ . ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a Ci _-8 aliphatic group, preferably a C1.4 aliphatic group, which in turn may be unsubstltuted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C-i.4 aliphatic residue, a C(=0)-0-C _lJ( -aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue.

on the condition that if R ⁶⁰⁷ or R ⁶⁰⁸ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,

or

R ⁶⁰⁶ denotes N(R ⁶⁰⁹ R ⁶¹⁰ ),

wherein

R ⁶⁰⁹ denotes a C^e-aliphatic residue, unsubstltuted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 -aliphatic residue, a C(=0)-0-C ₁ _ -aliphatic residue, CF ₃ , and a C^-aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstltuted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstltuted 0-C _1- -aliphatic residue,

or denotes a C3. ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstltuted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a C(=0)-0- C _-4 -aliphatic residue, a S-C _1-4 aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstltuted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstltuted residue,

and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, preferably a C- aliphatic group, which in turn may be unsubstltuted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a

residue,

on the condition that if R ⁶⁰⁹ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,

and

R ⁶¹⁰ denotes H or a C _1-10 -aliphatic residue, preferably a d. ₆ -aliphatic residue, unsubstltuted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, and a C _-4 -aliphatic residue, preferably denotes a C-Mo-aliphatic residue, more preferably a C^-aliphatic residue, unsubstltuted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-Ci.4 aliphatic residue, CF ₃ , CN, and a C^-aliphatic residue,

wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted O-C^-aliphatic residue,

or

R ⁶⁰⁹ and R ⁶¹⁰ form together with the nitrogen atom connecting them a 3 to 10 membered

heterocycloaliphatic residue, preferably a 3 to 6 membered heterocycloaliphatic residue, more preferably selected from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl and piperazinyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-Ci_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, and a C- - aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted O-C^-aliphatic residue,

and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁶⁰⁹ and R6 ¹⁰ together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, preferably with phenyl or pyridyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, an 0-C _1- aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-d. ₄ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, a C^

\° _} ^ v\ - S cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, , _{t 1} , benzyl, phenyl, thienyl, and pyridyl,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and

wherein benzyl, phenyl, thienyl, and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, an 0-C _1-4 aliphatic residue, OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, and C(=0)-OH, and wherein the C3. ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-C-|. ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH.

More preferably,

R ⁶⁰⁶ denotes a C ₂ . ₈ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a

aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue,

or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SCF ₃ , a C(=0)-0- C^-aliphatic residue, a S-C _1-4 aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue,

and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _4 aliphatic residue, a C(=0)-0-C _lJ( -aliphatic residue, CF ₃ , CN, and a C^-aliphatic residue,

on the condition that if R ⁶⁰⁶ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,

or

R ⁶⁰⁶ denotes S-R ⁶⁰⁷ or O-R ⁶⁰⁸ ,

wherein

R ⁶⁰⁷ and R ⁶⁰⁸ in each case denote a C^-aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-d. ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-d_ ₄ -aliphatic residue, an NH(d_ ₄ aliphatic residue), an N(d. ₄ aliphatic residue) ₂ , CF ₃ , a C(=0)-0-C ₁ . ₄ -aliphatic residue, and a C _1-4 -aliphatic residue,

wherein the C- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI,

Br, I, OH, CF ₃ and an unsubstituted 0-Ci. ₄ -aliphatic residue,

or in each case denote a C3.i ₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-d_ ₄ aliphatic residue, OCF ₃ , SCF ₃ , a S-C- aliphatic residue, a C(=0)-0-C _1-4 -aliphatic residue, CF ₃ , and a Ci. ₄ -aliphatic residue,

wherein the Ci_ ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted 'with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and wherein the C ₃ . ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may be bridged, preferably is bridged, via a C1-8 aliphatic group, preferably a Ci_ ₄ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1- aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _{1 4} aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , CN, and a C _1- -aliphatic residue,

on the condition that if R ⁶⁰⁷ or R ⁶⁰⁸ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,

or

R ⁶⁰⁶ denotes N(R ⁶⁰⁹ R ⁶¹⁰ ),

wherein

R ⁶⁰⁹ denotes a C^-aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-d. ₄ -aliphatic residue, CF ₃ , a C(=0)-0-C ₁ . ₄ -aliphatic residue, and a C _-4 -aliphatic residue,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted 0-Ci. ₄ -aliphatic residue,

or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-d.4 aliphatic residue, OCF ₃ , SCF ₃ , a S-C _1-4 aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , and a C _1- -aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, 0CF ₃ , CF ₃ and an unsubstituted 0-C _1- -aliphatic residue, and wherein the C ₃ _ ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case be bridged, preferably is bridged, via a C-i. ₈ aliphatic group, preferably a C _1- aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, a C(=0)-0-C _1-4 -aliphatic residue, CF ₃ , CN, and a d. 4-aliphatic residue,

on the condition that if R ⁶⁰⁹ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, and

R ⁶¹⁰ denotes H or a C _1-e -aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-CL ₄ aliphatic residue, CF ₃ , CN, and a C^-aliphatic residue, preferably denotes a C^-aliphatic residue, more preferably a Ci 4-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted O-C^-aliphatic residue, or

R ⁶⁰⁹ and R ⁶¹⁰ form together with the nitrogen atom connecting them a 3 to 10 membered

heterocycloaliphatic residue, preferably selected from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl and piperazinyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, NO2, OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-d. ₄ aliphatic residue, CF ₃ , CN, and a C^-aliphatic residue,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted O-C^-aliphatic residue,

and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R ⁶⁰⁹ and R ⁶¹⁰ together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, preferably with phenyl or pyridyl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _M aliphatic residue,

CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, residue, benzyl, phenyl, thienyl, and pyridyl,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein benzyl, phenyl, thienyl, and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, an 0-C _1j4 aliphatic residue, OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, and C(=0)-OH.

Even more preferably,

R ⁶⁰⁶ denotes a C ₂ _ ₆ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 -aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 -aliphatic residue, CF ₃ , and a C _-4 - aliphatic residue

wherein the C _-4 -aliphatic residue in each case is unsubstituted,

or denotes a C ₃ . ₁₀ -cycloaliphatic residue, preferably a C^e-cycloaliphatic residue, or a 3 to 10 membered heterocycloaliphatic residue, preferably a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ ,

SCF ₃ , a S-C1.4 aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , and a C _ ₄ -aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with OH or an unsubstituted 0-Ci. ₄ -aliphatic residue, and wherein the C3. ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a unsubstituted C _1-4 aliphatic group,

on the condition that if R ⁶⁰⁶ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,

or

R ⁶⁰⁶ denotes S-R ⁶⁰⁷ or O-R ⁶⁰⁸ ,

wherein

R ⁶⁰⁷ and R ⁶⁰⁸ in each case denote a C^-aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, an NHiC^ aliphatic residue), an N(C^. ₄ aliphatic residue) ₂ , a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , and a Ci_ ₄ -aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted 0-C _-4 -aliphatic residue,

or in each case denotes a Cs-io-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , SCF ₃ , a S-C _4 aliphatic residue, a C(=0)-0-C ₁ ^-aliphatic residue, CF ₃ , and a C - -aliphatic residue,

wherein the d. ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue in each case may be bridged, preferably is brisdged, via an unsubstituted Ci_ ₈ aliphatic group, preferably an unsubstituted Ci_4 aliphatic group,

on the condition that if R ⁶⁰⁷ or R ⁶⁰⁸ denotes a 3 to 10 membered heterocycloaliphatic residue, the

3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,

or

denotes N(R ⁶⁰⁹ R ⁶¹⁰ ),

wherein

R ⁶⁰⁹ denotes a Ci_ ₈ -aliphatic residue, preferably a Ci. ₆ -aHphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, a C(=0)-0 C^-aliphatic residue, CF ₃ , and a C^-aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes a C^!o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , SCF ₃ , a S-C^ aliphatic residue, a C(=0)-0-C ₁ _ ₄ -aliphatic residue, CF ₃ , and a Ci_ ₄ -aliphatic residue, wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the C ₃ . ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue is in each case bridged via a unsubstituted C _1-8 aliphatic group, preferably an unsubstituted C _1-4 aliphatic group,

on the condition that if R ⁶⁰⁹ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,

and

R ⁶¹⁰ denotes H or an unsubstituted C _1-4 -aliphatic residue, preferably selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec. -butyl and tert.-butyl, more preferably selected from the group consisting of methyl and ethyl, preferably denotes an unsubstituted C^-aliphatic residue, preferably selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl and tert.-butyl, more preferably selected from the group consisting of methyl and ethyl,

or

R ⁶⁰⁹ and R ⁶¹⁰ form together with the nitrogen atom connecting them a 3 to 6 membered

heterocycloaliphatic residue, preferably selected from the group consisting of morphoiinyl, piperidinyl, pyrrolidinyl, and azetidinyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, and a C^- aliphatic residue,

wherein the Ci- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted 0-Ci. ₄ -aliphatic residue,

and wherein the 3 to 6 membered heterocycloaliphatic residue formed by R ⁶⁰⁹ and R ⁶¹⁰ together with the nitrogen atom connecting them may optionally be condensed with phenyl or pyridyl, wherein the phenyl or pyridyl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-Ci_4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _-4 -aliphatic residue, C(=0)-OH, residue, benzyl, phenyl, and pyridyl,

wherein the C-i- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, and an unsubstituted O-C^-aliphatic residue, and wherein benzyl, phenyl, and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OCH ₃ , OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH, SCF ₃ , CF ₃ , and a C _1-4 -aliphatic residue.

Still more preferably, R ⁶⁰⁶ denotes a C ₂ -6-aliphatic residue, preferably selected from the group consisting of ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, ethenyl and propenyl (-CH ₂ CH=CH ₂ , -CH=CH-CH ₃ , -C(=CH ₂ )-CH ₃ ), unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _-4 -aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 - aliphatic residue, CF ₃ , and a Ci_ ₄ -aliphatic residue, preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, an 0-C _1-4 -aliphatic residue, CF ₃ , and a C^-aliphatic residue, more preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, and an O-C^-aliphatic residue, preferably O-methyl, even more preferably in each case unsubstituted,

wherein the C^-aliphatic residue in each case is unsubstituted,

or denotes a C ₃ _ ₆ -cycloaliphatic residue, preferably selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, or a 3 to 6 membered heterocycloaliphatic residue, preferably selected from the group consisting of piperidinyl (preferably piperidin-4-yl or piperidin-3-yl), tetrahydrofuranyl, and tetrahydropyranyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^-aliphatic residue, a C(=0)-0-C ₁ ^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^- aliphatic residue, CF ₃ , and a C^-aliphatic residue, preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI,

OH, an 0-Ci. ₄ -aliphatic residue, CF ₃ , and a Ci. ₄ -aliphatic residue, more preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, and an 0-C _1-4 -aliphatic residue, preferably O-methyl, even more preferably in each case unsubstituted,

wherein the C _-4 -aliphatic residue in each case is unsubstituted,

and wherein the Cs-e-cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case optionally bridged via an unsubstituted C-i_ ₄ aliphatic group, preferably via an unsubstituted C _1-2 aliphatic group,

on the condition that if R ⁶⁰⁶ a 3 to 6 membered heterocycloaliphatic residue, the 3 to 6 membered heterocycloaliphatic residue is linked via a carbon atom,

or

R ⁶⁰⁶ denotes S-R ⁶⁰⁷ or O-R ⁶⁰⁸ ,

wherein

R ⁶⁰⁷ and R ⁶⁰⁸ in each case denote a C^-aliphatic residue, preferably selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, ethenyl and propenyl (-CH ₂ CH=CH ₂ , -CH=CH-CH ₃ , -C(=CH ₂ )-CH ₃ ), unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _-4 -aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C-i_ ₄ -aliphatic residue, an NH(C _1J( aliphatic residue), an N C^ aliphatic residue) ₂ , CF ₃ , and a C _1-4 -aliphatic residue, more preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, and an O-C^-aliphatic residue, wherein the C _ ₄ -aliphatic residue in each case is unsubstituted,

or denotes a C ₃ . ₆ -cycloaliphatic residue, preferably cyclopropyl, or a 3 to 6 membered heterocycloaliphatic residue, preferably oxetanyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C ₁ .4 aliphatic residue, OCF ₃ , SCF ₃ , a S-C^ aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , and a C - -aliphatic residue, preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, an O-C- -aliphatic residue, CF ₃ , and a C^-aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with OH or an unsubstituted 0-Ci. ₄ -aliphatic residue,

and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue in each case may be bridged, preferably is bridged, via an unsubstituted C _-4 aliphatic group, on the condition that if R ⁶⁰⁷ orR ⁶⁰⁸ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,

or

R ⁶⁰⁶ denotes N(R ⁶⁰⁹ R ⁶¹⁰ ),

wherein

R ⁶⁰⁹ denotes a C _1-e -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 -aliphatic residue, a C(=0)-0-C _lJ( -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue, preferably an unsubstituted Ci_ ₆ -aliphatic residue, more preferably selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert.- butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl,

wherein the C^-aliphatic residue in each case is unsubstituted,

or denotes a C:3.6-cycloaliphatic residue, preferably selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, or a 3 to 6 membered heterocycloaliphatic residue, preferably selected from the group consisting of piperidinyl (preferably piperidin-4-yl or piperidin-3-yl), tetrahydrofuranyl, and tetrahydropyranyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, a C _1-4 - aliphatic residue and an O-C^-aliphatic residue, even more preferably in each case

unsubstituted,

wherein the C _1-4 -aliphatic residue in each case is unsubstituted,

and wherein the C^-cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case optionally bridged via an unsubstituted C _1-4 aliphatic group,

on the condition that if R ⁶⁰⁹ denotes a 3 to 6 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,

R ⁶¹⁰ denotes H or an unsubstituted C _1-4 -aliphatic residue, preferably represents an unsubstituted C _-4 -aliphatic residue, or denotes H, methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl or tert-butyl, preferably denotes methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl or tert-butyl,

or R ⁶⁰⁹ and R ⁶¹⁰ form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _1-4 aliphatic residue, and a Ci _-4 -aliphatic residue

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with OH or an unsubstituted 0-C _1- -aliphatic residue.

Most preferred,

R ⁶⁰⁶ denotes ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, ethenyl or propenyl (-CH ₂ CH=CH ₂ , -CH=CH-CH ₃ , -C(=CH ₂ )-CH ₃ ), in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, an O-C^-aliphatic residue, CF ₃ , and a C _-4 -aliphatic residue, preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, and an O-C^-aliphatic residue, preferably O-methyl, more preferably in each case unsubstituted,

wherein the C- -aliphatic residue in each case is unsubstituted,

or denotes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, piperidinyl, tetrahydrofuranyl, or tetrahydropyranyl, preferably denotes cyclopropyl or tetrahydropyranyl, more preferably cyclopropyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, an O-C^-aliphatic residue, CF ₃ , and a C _1-4 - aliphatic residue, preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, and an 0-Ci. ₄ -aliphatic residue, preferably O-methyl, more preferably in each case unsubstituted,

wherein the C _-4 -aliphatic residue in each case is unsubstituted,

and wherein cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, piperidinyl, tetrahydrofuranyl, and tetrahydropyranyl may in each case be optionally bridged via an unsubstituted C _-4 aliphatic group, preferably via an unsubstituted C _1-2 aliphatic group,

on the condition that if R ⁶⁰⁶ denotes piperidinyl, tetrahydrofuranyl, or tetrahydropyranyl, piperidinyl, tetrahydrofuranyl, or tetrahydropyranyl is linked via a carbon atom,

or

R ⁶⁰⁶ denotes S-R ⁶⁰⁷ or O-R ⁶⁰⁸ ,

wherein

R ⁶⁰⁷ and R ⁶⁰⁸ in each case denote methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, ethenyl and propenyl

(-CH ₂ CH=CH ₂ , -CH=CH-CH ₃ , -C(=CH ₂ )-CH ₃ ), in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH,

N(C^ aliphatic residue) ₂ and an O-C^-aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case is unsubstituted,

or in each case denote cyclopropyl, cyclobutyl, cyclopentyl cyclohexyl, oxetanyl, piperidinyl, tetrahydrofuranyl, or tetrahydropyranyl, preferably cyclopropyl or oxetanyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, an 0-C _1-4 -aliphatic residue, CF ₃ , and a d_ ₄ -aliphatic residue, preferably in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, and an O-C^-aliphatic residue, more preferably in each case unsubstituted,

wherein the Ci_ ₄ -aliphatic residue in each case is unsubstituted,

and wherein cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, oxetanyl, piperidinyl, tetrahydrofuranyl, and tetrahydropyranyl may in each case be optionally bridged via an unsubstituted aliphatic group,

on the condition that if R ⁶⁰⁷ or R ⁶⁰⁸ denotes piperidinyl, oxetanyl, tetrahydrofuranyl, or tetrahydropyranyl, each of these residues is linked via a carbon atom,

or

R ⁶⁰⁶ denotes N(R ⁶⁰⁹ R ⁶¹⁰ ),

wherein

R ⁶⁰⁹ denotes a C _1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, =0, OH, and O-methyl, preferably unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, and O-methyl, more preferably unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F and O-methyl, preferably denotes an unsubstituted C^e-aliphatic residue, more preferably selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl,

R ⁶¹⁰ denotes H, methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl or tert-butyl, preferably methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl or tert-butyl, more preferably methyl or ethyl,

or

R ⁶⁰⁹ and R ⁶¹⁰ form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, and a C^-aliphatic residue, more preferably unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI and a 0-C - aliphatic residue, preferably form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in each case unsubstituted .

In particular,

R ⁶⁰⁶ denotes ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, CH2-CH(CH ₃ )(C ₂ H5), C(CH ₃ )2(C ₂ H5), ethenyl or propenyl

(-CH ₂ CH=CH ₂ , -CH=CH-CH ₃ , -C(=CH ₂ )-CH ₃ ), CH ₂ -OCH ₃ , C ₂ H ₄ -OCH ₃ , C ₃ H ₆ -0CH ₃ , cyclopropyl, cyclobutyl, or tetrahydropyranyl, in each case unsubstituted,

or

R ⁶⁰⁶ denotes S-R ⁶⁰⁷ or O-R ⁶⁰⁸ ,

wherein R ⁶⁰⁷ and R ⁶⁰⁸ in each case denote methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, a N(C . _A aliphatic residue) ₂ , and an O-C^-aliphatic residue, preferably with at least one substituent selected from the group consisting of F, OH, N(CH ₃ ) ₂ , O-methyl and O-ethyl, or in each case denote CH ₂ -cyclopropyl or oxetanyl, preferably, R ⁷ and R ⁸ in each case denote methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl, CH ₂ -CH ₂ -F, CH ₂ CHF ₂ , CH2-OCH3, CH ₂ CH ₂ -OCH ₃ , CH ₂ CH ₂ -N(CH ₃ ) ₂ , CH ₂ -cyclopropyl or oxetanyl,

wherein the C _1-4 -aliphatic residue in each case is unsubstituted,

or

R ⁶⁰⁶ denotes N(R ⁶⁰⁹ R ⁶¹⁰ ),

wherein

R ⁶⁰⁹ denotes methyl, ethyl, C(=0)-CH ₃ , n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert.- butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl,

R ^{6 0} denotes H, methyl or ethyl, preferably methyl or ethyl,

or

R ⁶⁰⁹ and R ⁶¹⁰ form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in each case unsubstituted.

Particularly preferred is a compound according to general formula (6-I), wherein

R ⁶⁰¹ represents the partial structure (6-T1 ),

_ _(CR 6 ₁₂ a _R 612b _)m6 _ _R 612c

wherein

m6 is 0, 1 or 2, preferably 0 or 2, more preferably 2, and

R ^612a and R ^612b each independently of one another represent H, F, OH, CH ₃ or OCH ₃ or together denote =0, more preferably H, F, OH or CH ₃ , even more preferably H,

R ^{6 2c} denotes a C^ aliphatic residue, preferably methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec. -butyl, or tert.-butyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, CN, OH, S(=0) ₂ -CH ₃ , an unsubstituted 0-Ci_ ₄ aliphatic residue, preferably O-methyl and O-tert. -butyl, and CF ₃ , preferably denotes a C- aliphatic residue, preferably methyl, ethyl, n-propyl, 2-propyl, n- butyl, isobutyl, sec. -butyl, or tert.-butyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted O-C^ aliphatic residue, preferably O-methyl and O-tert.-butyl, and CF ₃ ,

or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, preferably cyclopropyl, cyclopentyl, cyclohexyl, morpholinyl, oxetanyl or tetrahydropyranyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted O-C^ aliphatic residue, preferably O-methyl and O-ethyl, CF ₃ , and an unsubstituted C _1-4 - aliphatic residue, preferably methyl or ethyl, or wherein

m6 is 0 or 2, more preferably 0, and

R ^612a and R ^{6 2b} each independently of one another represent H, F, CH ₃ or OCH ₃ ; and

R ^{6 2c} denotes an aryl or heteroaryl, preferably phenyl or pyridyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _1-4 aliphatic residue, OCF ₃ , OCF ₂ H, CH ₂ -OH, CH ₂ -OCH ₃ ,

S(=0) ₂ -CH ₃ , SCF ₃ , N0 ₂ , N(CH ₃ ) ₂ , ro , ^ , CF ₃ , CN, a (.^-aliphatic residue, C(=0)- CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ , C(=0)-0-C ₂ H ₅ and phenyl, preferably denotes an aryl or heteroaryl, preferably phenyl or pyridyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C^-aliphatic residue, C(=0)- CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ , C(=0)-0-C ₂ H ₅ and phenyl,

wherein phenyl may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C1.4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C ₁ . ₄ -aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ , represents F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec-butyl; tert.-butyl; CH ₂ -OH; CH ₂ -0-CH ₃ ; CH ₂ -CH ₂ -OH; CH ₂ -CH ₂ -OCH ₃ ; O-methyl; O-ethyl; O- (CH ₂ ) ₂ -0-CH ₃ ; 0-(CH ₂ ) ₂ -OH; S-Methyl; S-Ethyl; cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl; preferably represents F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec-butyl; tert.-butyl; CH ₂ -OH; O-methyl; O-ethyl; 0-(CH ₂ ) ₂ -0-CH ₃ ; 0-(CH ₂ ) ₂ - OH; S-Methyl; S-Ethyl; cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, represents H; F; CI; Br; I; CN; CF ₃ ; SCF ₃ ; N0 ₂ ; OCF ₃ ; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec-butyl; tert.-butyl; O-methyl; O-ethyl; 0-(CH ₂ ) ₂ -0-CH ₃ ; 0-(CH ₂ ) ₂ -OH; S-Methyl; or S-Ethyl, represents the partial structure (6-T2),

-(CR ^613a R ^613b ) _n6 -R ^613c (6-T2),

wherein

n6 denotes 0, 1 , 2 or 3, preferably denotes 1 or 2, more preferably denotes 1 ,

R ^613a and R ^613b each independently of one another represent H, F, CH ₃ or OCH ₃ , or together denote =0, preferably each independently of one another represent H or CH ₃ , more preferably H,

R denotes a C _1-4 aliphatic residue, preferably methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec. -butyl, or tert.-butyl, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, an unsubstituted O- C _1- aliphatic residue, and CF ₃ ,

or denotes cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl and tetrahydropyranyl, more preferably tetrahydropyranyl or morpholinyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted O-C^ aliphatic residue, CF ₃ , and an unsubstituted C _1-4 -aliphatic residue,

or denotes an aryl or heteroaryl, preferably phenyl or pyridyl, more preferably phenyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an 0-C _1-4 aliphatic residue, OCF ₃ , CF ₃ , CN, and a C _1- -aliphatic residue, denotes H, methyl or ethyl, C ₂ H ₄ OCH ₃ or C ₃ H ₆ OCH ₃ , more preferably H or methyl, even more preferably methyl,

and FT ^S form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazepanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolinyl, or dihydroisoindolyl, preferably a morpholinyl, piperidinyl, pyrrolidinyl, azeti oxazepanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, thiomorpholinyl, azepanyl, , tetrahydroimidazo[1 ,2-a]pyrazinyl, octahydropyrrolo[1 ,2- , ^{c ■} < ^\/ X ^\/ , ^{~ N} * fi /

a]pyrazinyl 1 , dihydroindolinyl, or dihydroisoindolyl, preferably a a morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazepanyl, tetrahydroquinolinyl,

tetrahydroisoquinolinyl, dihydroindolinyl, or dihydroisoindolyl, more preferably a morpholinyl, oxazepanyl, tetrahydroquinolinyl, or tetrahydroisoquinolinyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, =0, C(=0)-OH, O-methyl, O-ethyl, OCF ₃ , SCF ₃ , CF ₃ , C(=0)-CH ₃ , C(=0)-OCH ₃ , CH ₂ CF ₃ , CH ₂ OH, CH ₂ -OCH ₃ , CH ₂ CH ₂ -OCH ₃ , methyl, ethyl, n-propyl, 2-propyl, cyclopropyl, and cyclobutyl, preferably selected from the group consisting of F, CI, OH, =0, C(=0)-OH, O-methyl, O-ethyl, OCF ₃ , SCF ₃ , CF ₃ , methyl, ethyl, n-propyl, 2-propyl, cyclopropyl, and cyclobutyl,

R denotes ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, CH ₂ -CH(CH ₃ )(C ₂ H ₅ ), C(CH ₃ ) ₂ (C ₂ H ₅ ), ethenyl or propenyl

(-CH ₂ CH=CH ₂ , -CH=CH-CH ₃ , -C(=CH ₂ )-CH ₃ ), CH ₂ -OCH ₃ , C ₂ H ₄ -OCH ₃ , C ₃ H ₆ -OCH ₃ , cyclopropyl, cyclobutyl, or tetrahydropyranyl, in each case unsubstituted, or

R ⁶⁰⁶ denotes S-R ⁶⁰⁷ or O-R ⁶⁰⁸ , wherein R ⁶⁰⁷ and R ⁶⁰⁸ in each case denote methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, a N(d. ₄ aliphatic residue) ₂ , and an 0-C _1-4 -aliphatic residue, preferably with at least one substituent selected from the group consisting of F, OH, N(CH ₃ ) ₂ , O-methyl and O-ethyl, or in each case denote CH ₂ -cyclopropyl or oxetanyl, preferably, R ⁷ and R ⁸ in each case denote methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl, CH ₂ -CH ₂ -F, CH ₂ CHF ₂ , CH2-OCH3, CH ₂ CH ₂ -OCH ₃ , CH ₂ CH ₂ -N(CH ₃ ) ₂ , CH ₂ -cyclopropyl or oxetanyl,

wherein the Ci_ ₄ -aliphatic residue in each case is unsubstituted,

or

R ⁶⁰⁶ denotes N(R ⁶⁰⁹ R ⁶¹⁰ ),

wherein

R ⁶⁰⁹ denotes methyl, C(=0)-CH ₃ , ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert.- butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl,

R ⁶¹⁰ denotes H, methyl or ethyl, preferably methyl or ethyl,

or

R ⁶⁰⁹ and R ⁶¹⁰ form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in each case unsubstituted.

In another particularly preferred embodiment of the compound according to general formula (6-I), R ⁶⁰ represents phenyl or pyridyl, preferably phenyl, in each case unsubstituted or mono- or

disubstituted with at least one substituent selected from the group consisting of F, CI, Br, OH,

OCH ₃ , OCF ₃ , CF ₃ , and CH ₃ ,

R represents H; CF ₃ ; methyl; ethyl; iso-propyl; O-methyl; or cyclopropyl, R ⁶⁰³ represents H; F; CI; Br; I; CN; CF ₃ ; methyl; or O-methyl,

R ⁶⁰⁴ and R ⁶⁰⁵ form together with the nitrogen atom connecting them a morpholinyl, piperidinyl,

pyrrolidinyl, azetidinyl, oxazepanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolinyl, or dihydroisoindolyl, in each case unsubstituted, denotes ethyl, n-propyl, 2-propyl (iso-propyl), tert.-butyl, cyclopropyl, cyclobutyl or cyclopentyl tetrahydropyranyl, or

R ⁶⁰⁶ denotes S-R ⁶⁰⁷

wherein R -.607 and R in each case denote methyl, ethyl, 2-propyl, or tert-butyl, or

R ⁶⁰⁶ denotes N(R ⁶⁰⁹ R ⁶¹⁰ ), wherein

R ⁶⁰⁹ denotes methyl, ethyl, n-propyl, 2-propyl, or tert-butyl,

R ⁶¹⁰ denotes H, methyl or ethyl, preferably methyl or ethyl,

or

R ⁶⁰⁹ and R ⁶¹⁰ form together with the nitrogen atom connecting them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl.

Another embodiment of the present invention relates to a compound of general formula (I), wherein the compound is selected from a compound according to general formula (7-I).

represents a Ci_ ₁₀ -aliphatic residue, unsubstituted or mono- or polysubstituted; a C ₃ _ ₁₀ - cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C^e aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C-i_ ₈ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; represents H; F; CI; Br; I; CN; CF ₃ ; C(=0)H; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C^-aliphatic residue, a C(=0)- C _1- aliphatic residue, a C(=0)-0-C ₁ . ₄ aliphatic residue, a C(=0)-NH-C _1J , aliphatic residue, a

aliphatic residue) ₂ , wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a

residue, a S-C _1-4 -aliphatic residue, a S(=0) ₂ -C ₁ . ₄ -aliphatic residue, a S(=0) ₂ -0-C - ₄ -aliphatic residue, wherein the C - aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a C ₃ _ ₆ -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a Ci_ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

_R 704 _R 705 _{and R} 706 _egch j _nde p _endent |y _{of one} another represent H; F; CI; Br; I; CN; CF ₃ ;

C(=0)H; C(=0)-OH; C(=0)-NH ₂ ; SCF ₃ ; S(=0) ₂ -OH; N0 ₂ ; OCF ₃ ; a d_ ₄ -aliphatic residue, a C(=0)- C _1-4 aliphatic residue, a C(=0)-0-C ₁ . ₄ aliphatic residue, a C(=0)-NH-C ₁ . ₄ aliphatic residue, a C(=0)-N(C _1J( aliphatic residue) ₂ , wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a 0-C _-4 -aliphatic residue, a 0-C(=0)-C ₁ . ₄ -aliphatic residue, a S-C _1-4 -aliphatic residue, a

residue, wherein the C _1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a NH(C _1-4 aliphatic residue), a N(C _1- aliphatic residue) ₂ , a NH-C(=0)-C ₁ ^ ₍ aliphatic residue, a NH-S(=0) ₂ -C _1-4 -aliphatic residue, a N(C _-4 aliphatic residue)-C(=0)-C _lJ( aliphatic residue, or a N(C _1-4 aliphatic residue)-S(=0) ₂ -C _lJt aliphatic residue, wherein the aliphatic residue may in each case be unsubstituted or mono- or polysubstituted; a C^- cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

R ⁷⁰⁷ represents a C _1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C ₃ _ ₁₀ - cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C^e aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted;

on the condition that if R ⁷⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, in which an "aliphatic group" and "aliphatic residue" can in each case be branched or unbranched, saturated or unsaturated, in which a "cycloaliphatic residue" and a "heterocycloaliphatic residue" can in each case be saturated or unsaturated, in which "mono- or polysubstituted" with respect to an "aliphatic group" and an "aliphatic residue" relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _-4 aliphatic residue) ₂ , a NH-C(=0)-C _1-4 aliphatic residue, a NH-S(=0) ₂ -C ₁ _ ₄ aliphatic residue, =0, OH, OCF ₃ , a 0-C _1-4 -aliphatic residue, a 0-C(=0)-C ₁ . ₄ - aliphatic residue, SH, SCF ₃ , a S-Ci_4-aliphatic residue, S(=0) ₂ OH, a S(=0) ₂ -C ₁ . ₄ -aliphatic residue, a S(=0) ₂ -0-d. ₄ -aliphatic residue, a S(=0) ₂ -NH-C _1-4 -aliphatic residue, CN, CF ₃ , CHO, COOH, a C _1-4 - aliphatic residue, a C(=0)-C ₁ . -aliphatic residue, a C(=0)-0-C _1-4 -aliphatic residue, a C ₃ . ₆ -cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(=0)-NH ₂ , a aliphatic residue), and a C(=0)-N(C _1-4 aliphatic residue) ₂ ; in which "mono- or polysubstituted" with respect to a "cycloaliphatic residue" and a "heterocycloaliphatic residue" relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , a NH-C(=0)-C _1-4 aliphatic residue, a NH-S(=0) ₂ -C ₁ . ₄ aliphatic residue, =0, OH, OCF ₃ , a 0-C _1-4 -aliphatic residue, a O- C(=0)-C _1-4 -aliphatic residue, SH, SCF ₃ , a S-C^-aliphatic residue, S(=0) ₂ OH, a S(=0) ₂ -d. ₄ -aliphatic residue, a S(=0) ₂ -0-C ₁ ^-aliphatic residue, a S(=0) ₂ -NH-C ₁ ^-aliphatic residue, CN, CF ₃ , CHO, COOH, a C _-4 -aliphatic residue, a C(=0)-C ₁ . ₄ -aliphatic residue, a C(=0)-0-C _1- -aliphatic residue, a C ₃ . ₆ - cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, C(=0)-NH ₂ , a C(=0)-NH(C _J( aliphatic residue), and a C(=0)-N(C _1-4 aliphatic residue) ₂ ; in which "mono- or polysubstituted" with respect to "aryl" and a "heteroaryl" relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , ^■ s >

, ^ , ί ^' ^ , an NH(d. ₄ aliphatic residue), an N(Ci_ ₄ aliphatic residue) ₂ , an NH-C(=0)-C _-4 aliphatic residue, an

aliphatic residue, SH, SCF ₃ , a S-C^-aliphatic residue, S(=0) ₂ OH, a S(=0) ₂ -C _lJt -aliphatic residue, a S(=0) ₂ -0-C _1-4 -aliphatic residue, a S(=0) ₂ -NH-C ₁ . ₄ -aliphatic residue, CN, CF ₃ , C(=0)H, C(=0)OH, a C^- aliphatic residue, a C(=0)-C _1-4 -aliphatic residue, a C(=0)-0-C ₁ _ ₄ -aliphatic residue, a C^e-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(=0)-NH ₂ , a C(=0)- NH(C _-4 aliphatic residue), and a aliphatic residue) ₂ .

The compounds according to general formula (7-I) are known from WO 2010/102811 A1 , which is fully included by reference.

Preferred embodiments of the compound according to general formula (7-I) have general formulae (7-la), (7-lb), (7-lc) or (7-ld):

Another preferred embodiment of present invention is a compound according to general formula (7-I), wherein

R ⁷⁰¹ denotes a C _1-10 -aliphatic residue, preferably a C^e-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1J( aliphatic residue), an N(Ci_ ₄ aliphatic residue) ₂ , OH, =0, an 0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d. ₄ aliphatic residue), an N(Ci-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, a C^ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and

wherein the C^ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(d_ ₄ aliphatic residue) ₂ , OH, =0, an 0-d. ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C _1-8 aliphatic group, preferably a Ci_ ₄ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1J( aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-d_ aliphatic residue, CF ₃ , CN, a residue and C(=0)-OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C _1- aliphatic residue) ₂ , OH, an 0-C _1- aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a d. ₄ -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0- residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(d_ ₄ aliphatic residue) ₂ , OH, an 0-C _1-4 aliphatic residue, OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C!. ₄ aliphatic residue), an N(Ci. ₄ aliphatic residue) ₂ , OH, =0, an O-C1.4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a 0 _1-8 aliphatic group, preferably a Ci_ ₄ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1J( aliphatic residue), an N(C^. ₄ aliphatic residue) ₂ , OH, =0, an 0-Ci_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _M aliphatic residue, CF ₃ , CN and C(=0)-0H,

R ⁷⁰² represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a d.4-aliphatic residue, a S-C^-aliphatic residue, a O-C^-aliphatic residue, wherein the C- aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a Cs-e-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a Ci _-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted, preferably represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C ₁ _ ₄ -aliphatic residue, a S-C _1-4 -aliphatic residue, a O-C^-aliphatic residue, wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted 0-C _1-4 -aliphatic residue; a C ₃ . ₆ -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C _1-4 -aliphatic residue and an 0-C ₁ _ ₄ -aliphatic residue, wherein the C _-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted 0-C _1- -aliphatic residue, and wherein the C^e-cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a C1.4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, an unsubstituted C _1-4 - aliphatic residue and an unsubstituted 0-C-i_ ₄ -aliphatic residue,

_R 703 _R 704 _R 705 _{gnd R} 706 _egch j _ndependent | _{y of one anot} her represent H; F; CI; Br; I; CN; CF ₃ ;

OCF ₃ ; SCF ₃ ; C(=0)H; C(=0)-OH; C(=0)-NH ₂ ; S(=0) ₂ -OH; N0 ₂ ; a C^-aliphatic residue, a 0(=0)-0 _1-4 aliphatic residue, a C(=0)-0-C _1- aliphatic residue, a C^O^NH-C^ aliphatic residue, a residue, a 0-C(=0)-C ₁ . ₄ - aliphatic residue, a S-C _1-4 -aliphatic residue, a S(=0) ₂ -C ₁ . ₄ -aliphatic residue, a N^C^ aliphatic residue), a N(C^ aliphatic residue) ₂ , a NH-C(=0)-C ₁ ^ ₍ aliphatic residue, and a NH- S(=0) ₂ -C . ₄ -aliphatic residue, wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and a

residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C _1- -aliphatic residue and a 0-C _1-4 -aliphatic residue, and in each case optionally bridged via an unsubstituted C _1-4 aliphatic group,

preferably on the condition that at least one of R ⁷⁰³ , R ⁷⁰⁴ , R ⁷⁰⁵ and R ⁷⁰⁶ is≠ H, denotes a Ci_i ₀ -aliphatic residue, preferably a C^e-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, CF ₃ , CN, a C _-4 -aliphatic residue and C(=0)- OH,

wherein the Ci_4-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-Ci. ₄ -aliphatic residue, or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_ ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, a C3_ ₆ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the C _M cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_ ₄ aliphatic residue), an N(C _-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)- OH,

and wherein the C ₃ . ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C^e aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1Jt aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C ₁ _ ₄ -aliphatic residue and C(=0)-OH,

on the condition that if R ⁷⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom.

In a preferred embodiment of the compound according to general formula (2-I), the residue

R ⁷⁰¹ denotes a C _1-10 -aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci_ ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an 0-Ci_ ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, CF ₃ , CN, a d_ ₄ -aliphatic residue and C(=0)- OH,

wherein the C-|. ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-d. ₄ -aliphatic residue, or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d_ ₄ aliphatic residue), an N(Ci. ₄ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a d_ ₄ -aliphatic residue, C(=0)-OH, a Cs-ecycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the d^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-Ci. ₄ -aliphatic residue, and

wherein the C^cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d_ aliphatic residue), an N(d. ₄ aliphatic residue) ₂ , OH, =0, an 0-d_ ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-d_ ₄ aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH,

and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a d_ ₈ aliphatic group, preferably a C _-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d_ aliphatic residue), an N(C _lJt aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a d. ₄ -aliphatic residue and C(=0)-OH, or denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C ₁ . ₄ aliphatic residue), an N(Ci_ ₄ aliphatic residue) ₂ , OH, an 0-d. ₄ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C^ecycloal residue, a 3 to 6 membered heterocycloaliphatic residue, ^¾0 > _t ^' O _t ^¾Q > , benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-d. ₄ -aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(d_ ₄ aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an 0-d. ₄ aliphatic residue, OCF ₃ , 0-CH ₂ -OH, 0-CH ₂ -0-CH ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C ₁ _ ₄ aliphatic residue), an N(C^. ₄ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)- OH,

and wherein the aryl or the heteroaryl residue may in each case be optionally bridged via a C _1-8 aliphatic group, preferably a C^ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1- aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN and C(=0)-OH.

In a further preferred embodiment of the compound according to general formula (7-1), the residue R ⁷⁰¹ represents the partial structure (7-T1 )

_ _(CR 708a _R 708b _)m ^ _R 708c wherein

m7 denotes 0, 1 , 2, 3 or 4, preferably denotes 0, 1 , or 2,

R ^708a and R ^708b each independently of one another represent H, F, CI, Br, I, N0 ₂ , NH ₂ , a NH(C _1-4 aliphatic residue), an N(C _1-4 aliphatic residue) ₂ , OH, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 aliphatic residue or C(=0)-OH, or together denote =0,

preferably each independently of one another represent H, F, CI, Br, I, NH ₂ , a NH(C _1-4 aliphatic residue), a N(C _M aliphatic residue) ₂ , OH, O-C^ aliphatic residue or a C^ aliphatic residue,

more preferably each independently of one another represent H, F, CI, Br, I, an 0-C _1- aliphatic residue or a C _-4 aliphatic residue,

even more preferably each independently of one another represent H, F, an 0-C _1-4 aliphatic residue or a C^ ₄ aliphatic residue, and denotes a C^ aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(Ci. ₄ aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S C _1-4 aliphatic residue, CF ₃ , CN, a C- -aliphatic residue and C(=0)-OH, or denotes a C _3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, preferably when m2 is≠ 0, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C!. aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S C _1- aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, a C ₃ . ₆ cycloaliphatic residue and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1- -aliphatic residue, and wherein the C^ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NHiC^ aliphatic residue), an N(C^. ₄ aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF3, SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH, or denotes - preferably when m2 is = 0 - an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci. ₄ aliphatic residue), an N(Ci. aliphatic residue) ₂ , OH, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, a d. ₄ -aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a C3.6 cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, , benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an HfC^ aliphatic residue), an N(C!_ aliphatic residue) ₂ , OH, an 0-C _1-4 aliphatic residue, 0CF ₃ , SH, SCF ₃ , a S-C _1J( aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0- CH ₃ and C(=0)-0-C ₂ H ₅ , and

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(Ci _-4 aliphatic residue) ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1-4 -aliphatic residue and C(=0)- OH.

Preferably,

R ⁷⁰¹ represents the partial structure (7-T1 ),

wherein

m7 denotes 0, 1 , or 2,

R ^708a and R ^708b each independently of one another represent H, F, CI, Br, I, an 0-C _1-4 aliphatic residue or a C- aliphatic residue, preferably each independently of one another represent H, F, a 0-C _1-2 aliphatic residue or a C _1-2 aliphatic residue, and

denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , CF ₃ , a C _1- -aliphatic residue and C(=0)-OH, or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered

heterocycloaliphatic residue, in each case unsubstituted or mono- or

polysubstituted with at least one substituent selected from the group consisting of F, CI, ^" Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , a C^-aliphatic residue, C(=0)-OH, a C^e cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O- C- -aliphatic residue, and

wherein the C^ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , CF ₃ , a d. ₄ -aliphatic residue and C(=0)-OH,

or denotes - preferably when m7 is = 0 - an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a CM cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl or oxazolyl,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O- C^-aliphatic residue, and

wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O- C^ aliphatic residue, OCF ₃ , CF ₃ , CN, a C^-aliphatic residue, C(=0)-OH, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ ,

wherein the C ₃ . ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C1-4 aliphatic residue,

OCF3, CF ₃ , a C^-aliphatic residue and C(=0)-OH.

More preferably,

R ⁷⁰¹ represents the partial structure (7-T1 ),

wherein

m7 denotes 0, 1 , or 2,

R ^708a and R ^708b each independently of one another represent H, F, CI, Br, I, an 0-C _1- aliphatic residue or a Ci_4 aliphatic residue,

preferably each independently of one another represent H, F, a O-C^ aliphatic residue or a C _1-2 aliphatic residue, and denotes a C _1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes a C3_ ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an O-C^ aliphatic residue, CF ₃ , and a d. ₄ -aliphatic residue, wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes - preferably when m7 is = 0 - an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , CN, a C^-aliphatic residue, C(=0)-CH ₃ , C(=0)- C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , a Cs-β cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl,

wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C1.4 aliphatic residue, OCF ₃ , CF ₃ , CN, a C^-aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ , and

wherein the C ₃ _ ₆ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , CF ₃ , a C^-aliphatic residue and C(=0)-OH.

In a further preferred embodiment of the compound according to general formula (7-I), the residue R ⁷⁰¹ represents the partial structure (7-T1), wherein

m7 is 0, 1 or 2 and

R ^708a and R ^708b each independently of one another represent H, F, a 0-0 _1-4 aliphatic residue or a C _1-4 aliphatic residue; preferably H, F, CH ₃ or OCH ₃ ;

R ^708c denotes a aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, an unsubstituted 0-Ci_ ₄ aliphatic residue, CF ₃ , and an unsubstituted C _1-4 -aliphatic residue,

or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted 0-C _1-4 aliphatic residue, CF ₃ , and an unsubstituted C^-aliphatic residue,

or

wherein

m7 is 0,

R ^708a and R ^708b each independently of one another represent H, F, a O-C^ aliphatic residue or a C _1-4 aliphatic residue; preferably H, F, CH ₃ or OCH ₃ ; and

R ^708c denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue,

OCF ₃ , CF ₃ , CN, a C^-aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ , C(=0)-0-C ₂ H ₅ and phenyl,

wherein phenyl may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ .

Particularly preferred is a compound according to general formula (7-I) which has the following general formula (7-le):

(7-le).

In a preferred embodiment of the compound according to general formula (7-I), the residue

R ⁷⁰² represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C^-aliphatic residue, a S-C^-aliphatic residue, a O-C^-aliphatic residue, wherein the C^ aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted; a Cs-e-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a Ci_ ₄ aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted. Preferably,

R ⁷⁰² represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C _1-4 -aliphatic residue, a S-C^-aliphatic residue, a 0-C-|. ₄ -aliphatic residue,

wherein the C _ ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted O-C^-aliphatic residue,

a C ₃ _ ₆ -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C _1-4 -aliphatic residue and a 0-C _1-4 -aliphatic residue,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted O-C- -aliphatic residue,

and wherein the C ₃ . ₆ -cycloaliphatic residue or the 3 to 6 membered heterocycloaliphatic residue may in each case be optionally bridged via a Ci_4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, an unsubstituted C^-aliphatic residue and an unsubstituted O- C _1-4 -aliphatic residue.

More preferably,

R ⁷⁰² represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; a C^-aliphatic residue, a S-C _-4 -aliphatic residue, a 0-d. ₄ -aliphatic residue,

wherein the residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and an unsubstituted 0-Ci. ₄ -aliphatic residue,

cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, morpholinyl, or piperidinyl, preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, an unsubstituted C _1-4 -aliphatic residue and an unsubstituted O-C- -aliphatic residue,

and wherein cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, 4- methylpiperazinyl, morpholinyl or piperidinyl may in each case be optionally bridged via an C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, OH, an unsubstituted C _1-4 -aliphatic residue and an unsubstituted 0-C _lJ( -aliphatic residue.

Even more preferably,

R ⁷⁰² represents H; F; CI; Br; I; CN; CF ₃ ; N0 ₂ ; OCF ₃ ; SCF ₃ ; methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec-butyl; tert.-butyl; O-methyl; O-ethyl; 0-(CH ₂ ) ₂ -0-CH ₃ ; 0-(CH ₂ ) ₂ -OH; S-Methyl; S-Ethyl; cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

Still more preferably, R ⁷⁰² is selected from the group consisting of H; F; CI; CF ₃ ; CN; SCF ₃ ; OCF ₃ ; CH ₃ ; C ₂ H ₅ ; n-propyl; iso- propyl; t-butyl; cyclopropyl; 0-CH ₃ and 0-C ₂ H ₅ ;

In particular,

R ⁷⁰² is selected from the group consisting of H; F; CI; CF ₃ ; CH ₃ ; C ₂ H ₅ , iso-propyl; cyclopropyl; and O- CH ₃ ;

In a particular preferred embodiment of the compound according to general formula (7-1), the residue

,702 is≠H.

In a preferred embodiment of the compound according to general formula (7-1), the residues

_R 703 _R 704 _R 705 _{and R} 706 _egch j _ndependent | _{y of one ano} ther represent H; F; CI; Br; I; CN; CF ₃ ;

OCF ₃ ; SCF ₃ ; C(=0)H; C(=0)-OH; C(=0)-NH ₂ ; S(=0) ₂ -OH; N0 ₂ ; a d_ ₄ -aliphatic residue, a C(=0)-C _-4 aliphatic residue, a C(=0)-0-C ₁ . ₄ aliphatic residue, a C(=0)- NH-C _1J( aliphatic residue, a C(=0)-N(C _ ₄ aliphatic residue) ₂ , a O-C^-aliphatic residue, a residue, a S-Ci_ ₄ -aliphatic residue, a S(=0) ₂ -C ₁ . 4-aliphatic residue, a NH(C _1-4 aliphatic residue), a NKC^ aliphatic residue) ₂ , a NH- C(=0)-C ₁ . aliphatic residue, and a NH-S(=0) ₂ -C _1^t -aliphatic residue, wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and a 0-C _1-4 -aliphatic residue; a C _3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C _1-4 -aliphatic residue and a O-C^-aliphatic residue, and in each case optionally bridged via an unsubstituted C _-4 aliphatic group,

preferably on the condition that at least one of R ⁷⁰³ , R ⁷⁰ , R ⁷⁰⁵ and R ⁷⁰⁶ is≠ H.

Preferably,

_R 703 _R 704 _R 705 _{and R} 7°e _each independently of one another represent H; F; CI; Br; I; CN; CF ₃ ; OCF ₃ ;

SCF ₃ ; C(=0)H; C(=0)-OH; C(=0)-NH ₂ ; S(=0) ₂ -OH; N0 ₂ ; a C^-aliphatic residue, a

residue, a 0-C(=0)-C _1-4 -aliphatic residue, a S-C^-aliphatic residue, a S(=0) ₂ -C ₁ . 4-aliphatic residue, wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and a O-C^-aliphatic residue; a C^e-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C _1-4 -aliphatic residue and a 0-C _-4 -aliphatic residue, and in each case optionally bridged via an unsubstituted C^ aliphatic group,

preferably on the condition that at least one of R ⁷⁰³ , R ⁷⁰⁴ , R ⁷⁰⁵ and R ⁷⁰⁶ is≠ H. More preferably,

_R 703 _R 704 _R 705 _{AND R} 7oe _each j _ndependent | _{y of one anot} her represent H; F; CI; Br; I; CN; CF ₃ ; OCF ₃ ;

SCF ₃ ; C(=0)H; N0 ₂ ; a C _1-4 -aliphatic residue, a C(=0)-C ₁ . ₄ aliphatic residue, a

residue, wherein the C- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, and a 0-C _1-4 -aliphatic residue; a C^- cycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, =0, OH, a C^- aliphatic residue and a O-C^-aliphatic residue, and in each case optionally bridged via an unsubstituted aliphatic group,

preferably on the condition that at least one of R ⁷⁰³ , R ⁷⁰ , R ⁷⁰⁵ and R ⁷⁰⁶ is≠ H. In a further preferred embodiment of the present invention,

_R 703 _R 704 _R 705 _{GN(J R} 706 _{EGCH jndependent} | _{y Q} one another are selected from the group consisting of H;

F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; OCF ₃ ; SCF ₃ ; a (C=0)-C _1-4 aliphatic residue, a C _1-4 aliphatic residue, O-C^ aliphatic residue, a S- C^ aliphatic residue, wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of

F, CI, and 0-CH ₃ ;

preferably on the condition that at least one of R ⁷⁰³ , R ⁷⁰⁴ , R ⁷⁰⁵ and R ⁷⁰⁶ is≠ H. Preferably,

R ⁷⁰³ , R ⁷⁰⁴ , R ⁷⁰⁵ and R ⁷⁰⁶ each independently of one another are selected from the group consisting of H;

F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; OCF ₃ ; SCF ₃ ; methyl; ethyl; n-propyl; iso-propyl; n- butyl; sec-butyl; tert.-butyl; cyclopropyl; C(=0)-methyl; C(=0)-ethyl; (C=0)- isopropyl; (C=0)-t-butyl; O-methyl; O-ethyl; O-isopropyl; O-t-butyl; 0-(CH ₂ ) ₂ -0- CH ₃ ; S-Methyl; S-Ethyl;

preferably on the condition that at least one of R ⁷⁰³ , R ⁷⁰⁴ , R ⁷⁰⁵ and R ⁷⁰⁶ is≠ H.

In particular,

_R 703 _R ⁽ M _R 705 _anc j _R 706 _{gre eac} ^ j _nde p _enden tiy ₀ f one another are selected from the group consisting of H; F; CI; Br; I; N0 ₂ ; CF ₃ ; CN; (C=0)-methyl; (C=0)-ethyl; (C=0)- isopropyl; (C=0)-t-butyl; methyl; ethyl; isopropyl; t-butyl; O-methyl; O-Ethyl; O- isopropyl; O-t-butyl; OCF ₃ ; S-methyl; S-ethyl; and SCF ₃ ;

preferably on the condition that at least one of R ⁷⁰³ , R ⁷⁰⁴ , R ⁷⁰⁵ and R ⁷⁰⁶ is≠ H.

More particularly,

_R 703 _R 704 _R 705 _R 706 ^ j _ndependent | _{y Q} f one another selected from the group

consisting of H; F; CI; Br; CF ₃ ; CN; OCF ₃ and N0 ₂ ;

preferably on the condition that at least one of R ⁷⁰³ , R ⁷⁰⁴ , R ⁷⁰⁵ and R ⁷⁰⁶ is≠ H. Most preferred,

R ⁷⁰³ , R ⁷⁰⁴ and R ⁷⁰⁶ each independently of one another are selected from the group consisting of H and F; and

R ⁷⁰⁵ denotes F; Br; CF ₃ ; OCF ₃ ; CN; or N0 ₂ ;

In a particular preferred embodiment of the compound according to general formula (7-1)

at least one of the residues R ⁷⁰³ , R ⁷⁰⁴ , R ⁷⁰⁵ and R ⁷⁰⁶ is≠ H. In a preferred embodiment of the compound according to general formula (7-1), the residue

R ⁷⁰⁷ denotes a C _1-10 -aliphatic residue, preferably a C^e-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1J( aliphatic residue), an N(Ci. ₄ aliphatic residue) ₂ , OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, CF ₃ , CN, a C - -aliphatic residue, a C(=0)-0- C _1-4 -aliphatic residue, and C(=0)-OH,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue,

or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(d_4 aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C _1- -aliphatic residue, C(=0)-OH, a C(=0)-0-C _lJ( -aliphatic residue a C3_ ₆ cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C _1- -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, and

wherein the C^ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(Ci. ₄ aliphatic residue), an N(C!. ₄ aliphatic residue) ₂ , OH, =0, an 0-C _1- aliphatic residue, 0CF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)- OH,

and wherein the residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C^e aliphatic group, preferably a C _-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , NH ₂ , an NH(C _1-4 aliphatic residue), an N(C-|_ ₄ aliphatic residue) ₂ , OH, =0, an O-C^ aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, CF ₃ , CN, a C^-aliphatic residue and C(=0)-OH, on the condition that if R ²⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom. In a further preferred embodiment of the compound according to general formula (7-1), the residue R ⁷⁰⁷ denotes a C _-10 -aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, a C(=0)-0- Ci_ -aliphatic residue, CF ₃ , CN, and a C^-aliphatic residue

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C 4 aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , CN, a C^-aliphatic residue, a C ₃ . _e cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic residue,

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI,

Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the C^ cycloaliphatic residue and the 3 to 6 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an O-C^ aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, and a C _-4 - aliphatic residue,

and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a C^. ₈ aliphatic group, preferably a C _-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, N0 ₂ , OH, =0, an 0-Ci_4 aliphatic residue, a

C(=0)-0-C ₁ . ₄ -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^ aliphatic residue, CF ₃ , CN, and a C^- aliphatic residue.

on the condition that if R ⁷⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom.

Preferably,

R ⁷⁰⁷ denotes a C-|. ₈ -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one

substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C^-aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , and a C 4- aliphatic residue

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted 0-Ci. ₄ -aliphatic residue,

or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , SCF ₃ , a C(=0)-0- C^-aliphatic residue, a S-C1.4 aliphatic residue, CF ₃ , and a C- -aliphatic residue, wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a Ci _-8 aliphatic group, preferably a C1.4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1- aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _M aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , CN, and a C _1-4 -aliphatic residue.

on the condition that if R ⁷⁰⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom.

More preferably,

R ⁷⁰⁷ denotes a C^-aliphatic residue, preferably a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 -aliphatic residue, CF ₃ , a C(=0)-0-d. ₄ - aliphatic residue, and a C ₄ -aliphatic residue

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted O-C^-aliphatic residue,

or denotes a C3.i ₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-Ci _-4 aliphatic residue, OCF ₃ , SCF ₃ , a S-C^ aliphatic residue, a C(=0)-0-C _1- -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted 0-C ₁ . ₄ -aliphatic residue, and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue is bridged via a C _1-8 aliphatic group, preferably a C _1-4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , CN, and a C^-aliphatic residue.

Even more preferably,

R ⁷⁰⁷ denotes a C _1-8 -aliphatic residue, preferably a C^e-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _1-4 -aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-Ci. ₄ -aliphatic residue, a C(=0)-0-C _1-4 - aliphatic residue, CF ₃ , and a C^-aliphatic residue

wherein the C^-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, CF ₃ and an unsubstituted 0-C _1-4 -aliphatic residue, or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , SCF ₃ , a S-C _-4 aliphatic residue, a C(=0)-0-C ₁ . ₄ -aliphatic residue, CF ₃ , and a C _1-4 -aliphatic residue,

wherein the C _1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCF ₃ , CF ₃ and an unsubstituted O-C^-aliphatic residue, and wherein the C ₃ . ₁₀ -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue is in each case bridged via a unsubstituted C^e aliphatic group, preferably an unsubstituted C _1-4 aliphatic group.

Still more preferably,

R ⁷⁰⁷ denotes a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^-aliphatic residue, a C(=0)-0-C _lJr aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-C _1-4 -aliphatic residue, CF ₃ , and a C^- aliphatic residue

wherein the C^-aliphatic residue in each case is unsubstituted,

or denotes a C ₃ . ₁₀ -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^ aliphatic residue, OCF ₃ , SCF ₃ , a S-Ci_ ₄ aliphatic residue, a C(=0)-0-C ₁ . -aliphatic residue, CF ₃ , and a Ci_ -aliphatic residue,

wherein the d_ ₄ -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with OH or an unsubstituted 0-C _1-4 -aliphatic residue,

and wherein the C^o-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue is in each case bridged via a unsubstituted C _1-4 aliphatic group

In particular,

,707

R denotes a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an O-C^-aliphatic residue, a

aliphatic residue

wherein the residue in each case is unsubstituted.

Most preferred,

,707

R denotes a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CF ₃ , CI, OH, and O-methyl.

Preferred is also a compound according to general formula (7-I), wherein

R ⁷⁰¹ represents the partial structure (7-T1),

,708c

(7-T1), wherein

m7 is 0, 1 or 2 and

R ^708a and R ^708b each independently of one another represent H, F, a 0-C aliphatic residue or a

C _-4 aliphatic residue; preferably H, F, CH ₃ or OCH ₃ ;

R ^708c denotes a aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted O-C- aliphatic residue, CF ₃ , and an unsubstituted C _1-4 -aliphatic residue,

or denotes a C^o-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, an unsubstituted 0-C _1- aliphatic residue, CF ₃ , and an unsubstituted C^-aliphatic residue,

or

wherein

m7 is 0,

R ^708a and R ^708b each independently of one another represent H, F, a O-C^ aliphatic residue or a

C _1-4 aliphatic residue; preferably H, F, CH ₃ or OCH ₃ ; and

R ^708c denotes an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ , C(=0)-0-C ₂ H ₅ and phenyl,

wherein phenyl may be unsubstituted or mono- or polysubstituted, preferably unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, an O-C^ aliphatic residue, OCF ₃ , CF ₃ , CN, a C _1-4 -aliphatic residue, C(=0)-CH ₃ , C(=0)-C ₂ H ₅ , C(=0)-0-CH ₃ and C(=0)-0-C ₂ H ₅ , preferably with at least one substituent selected from the group consisting of F, CI, CH ₃ , 0-CH ₃ , CF ₃ and OCF ₃ ,

R ⁷⁰² is selected from the group consisting of H; F; CI; CF ₃ ; CH ₃ ; C ₂ H ₅ , iso-propyl; cyclopropyl; and O- CH ₃ ;

R ⁷⁰³ , R ⁷⁰⁴ , R ⁷⁰⁵ and R ⁷⁰⁶ are each independently of one another selected from the group

consisting of H; F; CI; Br; CF ₃ ; CN; OCF ₃ and N0 ₂ ;

preferably on the condition that at least one of R ²⁰³ , R ²⁰⁴ , R ²⁰⁵ and R ²⁰⁶ is≠ H,

R ⁷⁰⁷ denotes a C^-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, =0, an 0-C _ ₄ -aliphatic residue, a C(=0)-0-C ₁ ^-aliphatic residue, OCF ₃ , SH, SCF ₃ , a S-Ci. ₄ -aliphatic residue, CF ₃ , and a C^- aliphatic residue

wherein the C _1-4 -aliphatic residue in each case is unsubstituted.

Particularly preferred is also a compound according to general formula (7-I), wherein R ⁷⁰¹ represents aryl, preferably phenyl, or heteroaryl, preferably pyridyl or thienyl, in each case unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCH ₃ , OCF ₃ , CF ₃ , CN, and CH ₃ ,

preferably represents phenyl, unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, OCH ₃ , OCF ₃ , CF ₃ , CN, and CH ₃ ;

R ⁷⁰² is selected from the group consisting of H, F, CI, CF ₃ , CH ₃ , C ₂ H ₅ , iso-propyl, cyclopropyl, and O- CH ₃ ; preferably is selected from the group consisting of CH ₃ , C ₂ H ₅ , OCH ₃ and CF ₃ ;

R ⁷⁰³ , R ⁷⁰⁴ , R ⁷⁰⁵ and R ⁷⁰⁶ are each independently of one another selected from the group consisting of H, F, CI, Br, CF ₃ , CN, OCF ₃ and N0 ₂ ;

preferably on the condition that at least one of R ⁷⁰³ , R ⁷⁰⁴ , R ⁷⁰⁵ and R ⁷⁰⁶ is≠ H, more preferably on the condition that R ⁷⁰⁵ is≠ H;

R ⁷⁰⁷ denotes a saturated C _1-4 -aliphatic residue, unsubstituted or mono- or disubstituted with at least one substituent selected from the group consisting of F, CI, Br, I, OH, 0-CH ₃ , OCF ₃ , SCF ₃ , and CF ₃ .

Another aspect of the present invention further relates to at least one compound according to general formula (I) and also if appropriate of one or more pharmaceutically acceptable auxiliaries for the use in the preparation of a medicament for prophylaxis and/or treatment of disorders and/or diseases which are mediated, at least in part, by TSPO activity.

The selection of the physiologically acceptable auxiliaries and also the amounts thereof to be used depend on whether the pharmaceutical composition is to be applied orally, subcutaneously, parenterally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally, buccally, rectally or locally, for example to infections of the skin, the mucous membranes and of the eyes. Preparations in the form of tablets, dragees, capsules, granules, pellets, drops, juices and syrups are preferably suitable for oral application; solutions, suspensions, easily reconstitutable dry preparations and also sprays are preferably suitable for parenteral, topical and inhalative application. The substituted compounds according to the invention used in the pharmaceutical composition according to the invention in a repository, in a dissolved form or in a plaster, and further agents promoting skin penetration being added if appropriate, are suitable percutaneous application preparations. Orally or percutaneously applicable preparation forms can release the respective substituted compound according to the invention also in a delayed manner.

The pharmaceutical compositions according to the invention can be prepared with the aid of conventional means, devices, methods and process known in the art, such as are described for example in

..Remington's Pharmaceutical Sciences", A.R. Gennaro (Editor), 17 ^th edition, Mack Publishing Company, Easton, Pa, 1985, in particular in Part 8, Chapters 76 to 93. The corresponding description is introduced herewith by way of reference and forms part of the disclosure. The amount to be administered to the patient of the respective substituted compounds according to the invention of the above-indicated general formula (I) may vary and is for example dependent on the patient's weight or age and also on the type of application, the indication and the severity of the disorder. Conventionally, 0.001 to 100 mg/kg, preferably 0.05 to 75 mg/kg, particularly preferably 0.05 to 50 mg of at least one compound according to the invention are applied per kg of the patient's body weight. Preference is given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for the use in the preparation of a medicament for the prophylaxis and/or treatment of disorders and/or diseases selected from the group consisting of

(i) neurological and neurodegenerative disorders, including

ischaemic stroke, Alzheimer's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis, diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, amyotrophic lateral sclerosis, exictotoxic brain injury, traumatic brain injury, ischaemic brain damage, cerebrovascular disorders and cerebral ischemia;

(ii) psychiatric disorders, including

anxiety disorders, particularily panic disorders, post traumatic stress disorder, panic and adult separation disorder, social anxiety, major depression with adult separation anxiety disorder and bipolar disorder with adult separation anxiety disorder, dysthymia, angina pectoris, suicidality and schizophrenia;

(iii) brain tumours;

(iv) immunological disorders and inflammatory diseases, including

neuroinflammation and arthritis, encephalomyelitis and irritable bowel syndrome.

Particular preference is given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for use in the preparation of a medicament for the prophylaxis and/or treatment of neurological and neurodegenerative disorders, including Ischaemic stroke, Alzheimer's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis, diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, amyotrophic lateral sclerosis, exictotoxic brain injury, traumatic brain injury, ischaemic brain damage, cerebrovascular disorders and cerebral ischemia.

Particular preference is given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for use in the preparation of a medicament for the prophylaxis and/or treatment of psychiatric disorders, including anxiety disorders, particularily panic disorders, post traumatic stress disorder, panic and adult separation disorder, social anxiety, major depression with adult separation anxiety disorder and bipolar disorder with adult separation anxiety disorder, dysthymia, angina pectoris, suicidality and schizophrenia.

Particular preference is given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for use in the preparation of a medicament for the prophylaxis and/or treatment of brain tumours. Particular preference is given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for use in the preparation of a medicament for the prophylaxis and/or treatment of immunological disorders and inflammatory diseases, including neuro- inflammation and arthritis, encephalomyelitis and irritable bowel syndrome.

Another aspect of the present invention is a method of treatment and/or prophylaxis of disorders and/or diseases, which are mediated, at least in part, by TSPO activity, in a mammal, preferably of disorders and/or diseases selected from the group consisting of

(i) neurological and neurodegenerative disorders, including

ischaemic stroke, Alzheimer's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis, diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, amyotrophic lateral sclerosis, exictotoxic brain injury, traumatic brain injury, ischaemic brain damage, cerebrovascular disorders and cerebral ischemia;

(ii) psychiatric disorders, including

anxiety disorders, particularily panic disorders, post traumatic stress disorder, panic and adult separation disorder, social anxiety, major depression with adult separation anxiety disorder and bipolar disorder with adult separation anxiety disorder, dysthymia, angina pectoris, suicidality and schizophrenia;

(iii) brain tumours;

(iv) immunological disorders and inflammatory diseases, including

neuroinflammation and arthritis, encephalomyelitis and irritable bowel syndrome,

which comprises administering an effective amount of at least one compound of general formula (I) to the mammal.

The various, and in particular the preferred, embodiments of the first ascpet of the present invention apply in analogous manner -mutatis mutandis- to the other aspects of the present invention.

Pharmacological experiments

Evaluation of the in vitro affinity of test substances for the rat peripheral BZD receptor was performed according to Le Fur et al. (1983). Life Sci., 33: 449-457. For this purpose, rat heart membranes and [3HJPK 11195 (1-(2-chlorophenyl)-/\/-methyl-/\/-(1-methylpropyl)-3-isoqui nolinecarboxamide) were used in a radioligand binding test system.

In detail, membrane homogenates of heart (20 μg protein) are incubated for 15 min at 22°C with 0.2 nM [3H]PK 11195 in the absence or presence of the test compound in a buffer containing 50 mM Tris-HCI (pH 7.4) and 10 mM MgCI ₂ (96-well plate format). Compound addition is 100x solution in solvent.

Nonspecific binding is determined in the presence of 10 μΜ PK 11195. Following incubation, the samples are filtered rapidly under vacuum through glass fiber filters (GF/B, Packard) presoaked with 0.3% PEI and rinsed several times with ice-cold 50 mM Tris-HCI using a 96-sample cell harvester (Unifilter, Packard). The filters are dried, then counted for radioactivity in a scintillation counter (Topcount, Packard) using a scintillation cocktail (Microscint 0, Packard). The results are expressed as a percent inhibition of the control radioligand specific binding.

The standard reference compound is PK 11195, which is tested in each experiment concurrently with the test compounds.

For analysis, the specific ligand binding to the receptors is defined as the difference between the total binding and the nonspecific binding determined in the presence of an excess of unlabelled ligand. The results are expressed as a percent of control specific binding ((measured specific binding/control specific binding) x 100) obtained in the presence of the test compounds. The data are summarized in table 1.

Table 1

For the preparation of the test compounds, see referenced source.